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The frequency of S. aureus infection and subsequent biofilm formation associated with 
vascular catheterization has been increasing in recent years and often begins as a local 
colonization at the site of the catheter insertion. Antimicrobial enzymes and peptides, which are 
effective against a broad range of pathogens and low rates of resistance, have attracted attention 
as promising alternative candidates in treatment of infections caused by antibiotic resistant 
bacteria. The use of nanoparticles as carriers for enzymes, in addition to their size, charge, high 
surface area per volume etc. offers targeted delivery of enzymes to pathogenic bacteria. We 
proposed to use nanoparticles as surfaces for targeted delivery of antibacterial enzymes and as 
„surrogate‟ surface coatings on indwelling central venous catheters (CVCs) to inhibit bacterial 
colonization and subsequent biofilm formation.  
It was shown that nanoparticle charge can be used to enhance delivery and increase 
bactericidal activity of an antimicrobial enzyme, lysozyme. In the case of bacterial lysis assay 
with a Gram-positive bacterium Micrococcus lysodeikticus, activity of lysozyme conjugated to 
positively charged nanoparticles was approximately twice as high as that of free lysozyme. This 
was believed to occur through charge-directed targeting of enzyme-nanoparticle conjugates to 
negatively charged bacterial cell walls through enhanced electrostatic interactions. In a clinically 
more relevant model, we studied antimicrobial activity of lysostaphin against S. aureus for both 
lysostaphin-coated and lysostaphin-antibody coated nanoparticle conjugates at different enzyme: 
antibody: nanoparticle ratios. At the highest antibody loading, bacterial lysis rates for antibody-
lysostaphin-coated samples were significantly higher than for plain lysostaphin-coated samples 
and free enzyme due to multiple-ligand directed targeting of antibody molecules to bacterial cell 
walls (p<0.05).   
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We also performed in vitro experiments to evaluate the inhibition of bacterial colonies 
adhering to a surface. Bacterial infections by S. aureus strains are among the most common 
postoperative complications in surgical hernia repair with synthetic polymer meshes. Colony 
counting data from the broth count (model for bacteria in wound fluid) and wash count (model 
for colonized bacteria) for the enzyme-coated samples showed significantly decreased number of 
colony forming units (CFU) when compared to uncoated samples (p< 0.05). A pilot in vivo study 
showed a dose-dependent anti-S. aureus efficacy of lysostaphin-coated meshes in a rat model.  
Finally, we observed that that coating of nanoparticles overall did not significantly 
improve binding yield, leaching, durability and antibiofilm activity of enzymes adsorbed on 
catheter segments (p>0.05). Alternatives to coating catheter surfaces using covalent chemistry 
through functional groups on nanoparticles either directly or through appropriate crosslinkers 
could result in significantly higher enzyme loadings, better stability and long term durability for 
future applications. The approach developed here is universal and can potentially be used for 
treatment of other medical device-associated infections. Moreover, use of antibacterial enzyme-
NP conjugates can eventually be expanded for intravenous administration, which will further 
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My graduate research at the department of Bioengineering in Clemson focused on 
the specific application of Nanotechnology for targeted delivery of antibacterial enzymes 
and for enzyme-based coatings on medical devices and implants. Using different model 
studies, further discussed in various chapters of my dissertation, the goal of my research 
was to use nanotechnology to address specific issues and drawbacks involved in the 
delivery of antibacterial enzymes as infections and as coatings on implants to prevent 
bacterial colonization and biofilm formation. Chapter 2 of this dissertation presents a 
detailed literature review on the current problems associated with treatment of nosocomial 
infections with antibiotics specifically focusing on multidrug resistant S. aureus, enzymes 
and peptides as alternatives to antibiotics and its drawbacks and finally the need for 
enzyme immobilization using nanotechnology through various techniques.  
Chapter 3 lists the specific aims and goals of our research project by using model 
studies to test our hypothesis and fundamentally address specific issues involved in the 
application of enzymes for - a) targeted delivery using polymer nanoparticles (NPs) and b) 
as coatings on hernia repair polymer meshes and Central venous catheter segments.   
Our first model study in Chapter 4 aimed at comparing the influence of 
nanoparticle charge on antibacterial activity of enzyme-nanoparticle conjugates. 
Specifically, we covalently attached a model antibacterial enzyme hen egg lysozyme to 
two types of polystyrene latex nanoparticles: positively charged, containing aliphatic 
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amine surface groups, and negatively charged, containing sulfate and chloromethyl surface 
groups. We tested lysozyme activity against its substrate, Micrococcus lysodeikticus and 
compared antibacterial activity of free enzyme against enzyme conjugated to NPs. We 
further evaluated the method of enzyme purification and effect of PEG spacers on 
antibacterial activity of enzyme-NP conjugates 
In a clinically more relevant model (Chapter 5), we studied whether co-attachment 
of different ligands such as an antibody (against the pathogen) along with antibacterial 
enzymes to NPs enhances in vitro antimicrobial activity of the enzyme. We compared the 
anti S. aureus activity of lysostaphin adsorbed on the surface of PLA (poly (lactic acid)) 
nanoparticles to that of the free enzyme at different initial enzyme: NP molar ratios. A 
rabbit polyclonal S. aureus antibody was coadsorbed on PLA nanoparticles along with 
lysostaphin to evaluate the effect of delivery based on antibody-directed targeting.  
Bacterial infections by antibiotic-resistant S. aureus strains are known to be one of 
the most common postoperative complications in surgical hernia repair. In our third model 
study, we evaluated the in vitro antimicrobial susceptibility of S. aureus to lysostaphin-
coated hernia repair polymer meshes and study the effect of enzyme coating concentration 
on antimicrobial activity. In vivo antimicrobial efficacy of lysostaphin-coated meshes was 
further evaluated by our clinical collaborators at Carolinas Medical Center in a rat hernia 
repair model (Chapter 6).  
It is well known that bacteria can either colonize the implant surface or exist in a 
planktonic free floating form. Both these chapters (4 and 5) provided insight into taking 
advantage of special properties of NPs such as size, charge, surface area etc. to improve 
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functionality of enzyme-NP conjugates, specifically towards targeting to planktonic cell 
suspensions.  
Colonization is the first stage of device associated-infection. Bacteria in colonies 
(biofilms) present more danger than planktonic bacteria and are also less susceptible to 
treatment by antimicrobial agents. Although coating medical devices with plain 
antibacterial enzymes could work just as effectively, we hypothesized that coating catheter 
surfaces with nanoparticles initially may be advantageous due to larger surface area for 
effective enzyme coating, higher stability, durability and low enzyme leaching. Thus the 
goal of our final model study was the characterization and comparison of the in vitro 
performance for plain and NP coated catheter segments using antimicrobial and 
antibiofilm enzymes (Chapter 7).  Coating was achieved via adsorption of two model 
enzymes, DispersinB (antibiofilm) and lysostaphin (antimicrobial) on the surface of plain 
and poly ((lactic acid)) nanoparticle coated polyurethane catheter segments. A series of 
experiments evaluating enzyme binding efficiency, activity, leaching, cytotoxicity, 
antibiofilm efficacy and durability were performed to compare plain and NP coated 
catheter segments.  
Chapters 8 and 9 provide a conclusion to our studies and future recommendations 
to design more effective antibacterial surface coatings on devices and implants. By 
manipulating the available technology today, we do not just limit ideas only to 









Bacteria were one of first types of cell to evolve in nature. They have been 
described as a „prokaryotic‟ organism because their cells lack a membrane bound nucleus 
and their genetic material is typically a single circular chromosome located in the 
cytoplasm in an irregularly shaped body called the nucleoid [1]. Despite their small size, 
bacteria have an enormous range of metabolic capabilities, and a lot of them can be found 
in some of the extreme environments on earth. All of the various surface components of a 
bacterial cell are important in its ecology since they mediate contact of the bacterium with 
its environment. It must use its own surface components to assess the environment and 
respond ways that supports its own existence and survival in that environment. The 
surface properties of a bacterium are determined by the molecular composition of its 
membrane and cell wall. In most prokaryotes, the primary function of the cell wall is to 
protect the cell from internal turgor pressure caused by the much higher concentrations of 
proteins and other molecules inside the cell compared to its external environment.  
Most bacteria also contain some sort of a polysaccharide layer outside of the cell 
wall or outer membrane. In a general sense, this layer is called a capsule. A true capsule is 
a discrete detectable layer of polysaccharides deposited outside the cell wall. A type of 
capsule found in bacteria called a glycocalyx is a thin layer of polysaccharide fibers which 
is mostly observed on the surface of cells growing in nature. Capsules are known to 
protect bacteria from engulfment by phagocytes and from attack by antimicrobial agents 
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[2]. In nature, and in many medical conditions, colonies of bacteria live in a biofilm, 
primarily composed of an outer slimy layer.  
These films can range from a few micrometers to up to tens of centimeters in 
thickness. Bacteria living in biofilms display a complex arrangement of cells and 
extracellular components, forming secondary structures such as microcolonies, through 
which there are networks of channels to enable better diffusion of nutrients [3, 4]. Also, 
bacteria communicate with each other through an internal cell signaling process called 
Quorum sensing, thus regulating a host of cell metabolic activities, similar to a 
communication network. In natural environments, such as soil or the surfaces of plants, 
the majority of bacteria are bound to surfaces in biofilms [5]. Biofilms are also important 
for chronic bacterial infections and infections of implanted medical devices, as bacteria 
protected within these structures are much harder to kill than individual bacteria [6].  
 
Figure 2.1. A) Biofilm growing on a creek (http://toxics.usgs.gov) and B) S .aureus 




2.1.1. Bacterial cell wall 
The bacterial cell wall has been one of the important clinical targets for antibiotic 
agents since the first use of penicillin in World War II. Bacterial cell walls are made of 
peptidoglycan (also called murein), which is made from polysaccharide chains cross-
linked by unusual peptides containing D-amino acids [7]. Bacterial cell walls are different 
from the cell walls of plants and fungi which are made of cellulose and chitin, 
respectively[8]. Although the primary function of the cell wall is to provide a rigid 
exoskeleton for protection against both mechanical and osmotic lysis [9], it also serves as 
an attachment site for proteins that interact with the bacterial environment.  
Based on the structure of their cell wall, bacteria are classified into two types – a) 
Gram-positive and b) Gram-negative bacteria. The names originate from the reaction of 
cells to the Gram stain, a test long-employed for the classification of bacterial species. 
Gram-positive bacteria have a thick mesh-like cell wall made of peptidoglycan, which 
stain purple and Gram-negative bacteria have a thinner layer, which stain pink. Although
 
the vast majority of bacteria adhere to the color differentiation
 
of the Gram stain,
 
some 
bacteria do not; these are called Gram-variable bacteria [10].  
The cell wall of Gram-positive bacteria is a peptidoglycan macromolecule with 
attached accessory molecules such as teichoic acids, teichuronic acids, polyphosphates, or 
carbohydrates [9, 11]. Gram-positive bacteria have much thicker peptidoglycan layer than 
their Gram- negative counterparts and no external outer membrane. They lack a distinct 
periplasmic space, which is usually defined as the region between the cytoplasmic 
membrane and the outer membrane. The glycan strands of the cell wall consist of the 
repeating disaccharide N-acetylmuramic acid-(b1-4) - N-acetylglucosamine (MurNAc-
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GlcNAc) [12, 13]. Glycan strands vary in length and are estimated to contain 5 to 30 
subunits, depending on the bacterial species [14-16]. 
The muramic acid is a unique substance associated with bacterial cell walls and 
these chains are cross-linked by short polypetide chains consisting of both L- and D-
aminoacids. Wall peptides are cross-linked with other peptides that are attached to a 
neighboring glycan strand [17-20], thereby generating a three-dimensional molecular net- 
work that surrounds the cell and provides the desired exoskeletal function [21]. The 
teichoic acids are polyols consisting predominantly of glycerol, ribitol and mannitol, 
covalently linked to the peptidoglycan through phosphodiester bonds and can be 
substituted by sugars, aminosugars or D-alanine residues. These anionic polymers account 
for 10–60% (by weight) of the bacterial cell wall, with the relative amount depending on 




Figure 2.2. - Bacterial cell walls for Gram positive and Gram negative bacteria 
(figure modified from Cabeen et al; 2005 [24].  
Although they are structurally diverse[25, 26] ,the negative charge of these anionic 
polymers mainly originates from phosphate or carboxyl groups, and they may also 
elaborate acidic side chains containing glycerol, phosphate, organic acids (e.g. pyruvic and 
succinic acid), or sulphates. They play a very crucial role in the binding of divalent 
cations, balance of metal ions for membrane functionality, folding of extracellular 
metallo-proteins and formation of a barrier to prevent diffusion of nutrients and 
metabolites [23, 27-30]. In addition, the peptidoglycan is a well-known target for almost 
all clinically useful antibiotics that inhibit bacterial cell wall synthesis [31]. Being an 
essential and unique cell wall component of virtually all bacteria and not eukaryotic cells, 
it is an excellent target for recognition by the innate immune system of the host [31, 32]. 
The cell walls of Gram negative bacteria are composed of three layers, an inner 
bilayer phospholipid membrane, a thin peptidoglycan layer, and the outer bilayer 
membrane, composed of lipopolysaccharides [31, 32]. Along with the plasma membrane 
and the cell wall (outer membrane, peptidoglycan layer, and periplasm) constitute the 
Gram-negative envelope [33, 34].The envelope of E-coli and other Gram-negative bacteria 
contains two distinct lipid bilayers that are separated by the peptidoglycan-containing 
periplasmic space that represent the inner membrane (IM) and the outer membrane (OM) 
respectively [35, 36].  The inner membrane is composed of phospholipids in both its inner 
and outer leaflets as well as integral and peripheral membrane proteins. It carries out a 
variety of functions typically assigned to both the plasma membrane and specific 
organelles in higher organisms that includes cell signaling, biosynthesis, electron transport 
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and ATP synthesis [37] . The OM is a unique asymmetric lipid bilayer consisting of an 
inner face of phospholipids and an outer face of lipopolysaccharide (LPS). The outer 
membrane (OM) plays an important role in nutrient uptake but in addition provides the 
organism with a remarkable permeability barrier, conferring resistance to a variety of 
agents including antibiotics [38].  
2.1.2 Staphylococcus aureus 
Staphylococcus aureus is facultative anaerobic Gram-positive coccus which occurs 
singly, in pairs, and in irregular clusters. It is nonmotile, non-spore forming, catalase and 
coagulase positive bacteruim. The term Staphylococcus is derived from the Greek term 
staphyle, meaning "a bunch of grapes." It can colonize and infect both healthy, 
immunologically competent people in the community and hospitalized patients with 
decreased host defenses [39]. It‟s repertoire of virulence factors is extensive, with both 
structural and secreted products playing a role in the pathogenesis of infection. Up-
regulating the production of virulence factors enables it to persist in the blood stream, 
adhere and colonize the skin and mucosa, evade the host immune response, form 
protective biofilms through quorum sensing and also develop resistance against a wide 
range of antibiotics.  
S. aureus has an intrinsic ability to form biofilms on damaged tissue, prosthetic 
materials such as medical devices and heart valves, thereby making it much more difficult 
to treat than planktonic bacteria. The biofilm matrix is usually composed of biopolymers 
such as polysaccharides, proteins and lipids which build a firm consistency thus providing 
protection against the immune cells and penetration of antimicrobial agents [40]. It is also 
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known that cells living in biofilms display a complex arrangement of various extracellular 
components and form secondary structures such as microcolonies and small-colony 
variants (SCVs) that demonstrate almost complete resistance against conventional 
antibiotics [41].   
S. aureus biofilm formation involves two stages – initial adhesion of cells to a 
surface mediated by a number of surface proteins that serve as an anchor, followed by 
production of various extracellular factors that enable cell multiplication and maturation 
into a structured community. „Quorum Sensing‟ or intracellular signaling between cells 
via the accessory gene regulatory (agr) system has also been strongly implicated in the 
pathogenesis of biofilm-associated S. aureus infections [42]. The (agr) quorum-sensing 
system decreases the expression of several cell surface proteins and increases expression 
of many secreted virulence factors based on bacterial density [43]. It regulates the 
detachment of cells from the established biofilm and then allows them to colonize new 
sites or even enter the blood stream. The rates of infections caused by both community 
and hospital-acquired strains are increasing steadily and subsequent treatment of these 
infections is also becoming more difficult because of the increasing prevalence of 
multidrug-resistant strains [44]. 
2.2. Antibiotic resistance 
Antibiotics have traditionally been used in modern medicine as chemotherapeutic 
agents to treat infections thus becoming indispensable in the modern health care system. 
However the rates of multi-antibiotic resistance among bacteria that infect wounds are 
constantly on the rise and surgical site infections have become a substantial burden of 
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disease for patients and health services [45-48]. The US Centers for Diseases Control and 
Prevention (CDC) estimates that about 500,000 surgical site infections occur annually in 
the United States [48-51]. There are several factors contributing to surgical site infections 
namely the inoculum of bacteria introduced into the wound during the procedure, the 
unique virulence of contaminants, the microenvironment of each wound, and the integrity 
of the patients host defense mechanisms [48, 50].Consequently, rapid control of wound 
infections and monitoring of prophylactic and therapeutic strategies have recently been 
proposed [49, 51] . Antibiotic resistance in nosocomial infections is thus an ever-
increasing problem.  
Antibiotics have been shown to act in different ways, either by targeting the 
pathogen„s physiology directly or by disrupting the cellular structure of bacterial cells. 
There are 4 major modes of action: (1) interference with cell wall synthesis, (2) inhibition 
of protein synthesis, (3) interference with nucleic acid synthesis, and (4) inhibition of a 
metabolic pathway. Antibacterial drugs that work by inhibiting bacterial cell wall 
synthesis include the b-lactams, such as the penicillins, cephalosporins, and carbapenems 
[52, 53]. They inhibit synthesis of the bacterial cell wall by interfering with the enzymes 
required for the synthesis of the peptidoglycan layer [52]. Macrolides, aminoglycosides 
and tetracyclines produce their antibacterial effects by inhibiting protein synthesis by 
binding to different subunits of the Ribosome [52, 53]. Fluoroquinolones exert their 
antibacterial effects by disrupting DNA synthesis and causing lethal double-strand DNA 
breaks during DNA replication [54]. Antibacterial drugs such as folic acid analogues 
inhibit different metabolic pathways.  Disruption of the bacterial membrane is 
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characteristic of polymyxins that exert their inhibitory effects by increasing bacterial 
membrane permeability, causing leakage of bacterial contents [55].  
Several mechanisms of antimicrobial resistance occur in different bacterial genera. 
First, the organism may acquire genes encoding enzymes, such as β-lactamases, that 
destroy the antibacterial agent before it can have an effect.  Susceptible bacteria can 
acquire resistance to an antimicrobial agent via new mutations [56]. Such spontaneous 
mutations may cause resistance by altering the target protein to which the antibacterial 
agent binds by modifying or eliminating the binding site (e.g., change in penicillin-binding 
protein 2b in pneumococci, which results in penicillin resistance), upregulating the 
production of enzymes that inactivate the antimicrobial agent (e.g., erythromycin 
ribosomal methylase in staphylococci) and altering an outer membrane protein channel 
that the drug requires for cell entry or by upregulating pumps that expel the drug from the 
cell [56]. Therefore strains of bacteria carrying resistance conferring mutations are 
selected by continuous antibiotic use, which kills the susceptible strains but allows the 
newly resistant strains to survive and grow.  
Bacteria also develop resistance through the acquisition of new genetic material 
from other resistant organisms. Mutation and selection, together with mechanisms of 
genetic exchange, enable many bacterial species to adapt quickly to the introduction of 
antibacterial agents into their environment [57]. Resistance to multiple antibiotics is 
increasingly reported in a number of Gram-negative pathogens, especially the 
Enterobacteriaceae [58-61], E-coli [62, 63], Pseudomonas aeruginosa [64-66]etc. 
Multidrug resistance occurs as a result of accumulation of multiple mutations and/or 
resistance genes, though single mutations can also promote multidrug resistance 
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Also, drugs come with adverse effects and antibiotics are no exception. Common 
side-effects are gastrointestinal symptoms, skin rashes, and thrush. A common problem in 
clinical practice is in determining the required antibiotic to treat infection in a patient who 
has been labeled as being allergic to the antibiotic. In many cases, such patients are 
prescribed antibiotics that are less effective or more toxic, have a broader spectrum, or are 
more expensive than the drug of choice for their condition. The occurrence of overgrowth, 
or infection, as a direct result of antibiotic consumption is also less well understood by 
physicians. An antibiotic will inhibit, or kill, a whole range of bacteria, which creates 
space on mucosal and other surfaces for other organisms to proliferate [67]. These 
survivors might show various rates of acquired resistance,   are more difficult to treat and 
almost impossible to eradicate in some patients [68].  
2.2.1 Alternatives to antibiotics  
There is therefore an urgent need for the use of alternative approaches to 
antibiotics. Widespread application of an effective topical antimicrobial agent 
substantially reduces the microbial load on an open wound surface and reduces the risk of 
infection [69-71]). However the selection of topical antimicrobial therapy should be based 
on the agent's ability to inhibit the microorganisms recovered from wound cultures and 
monitoring of the nosocomial infections acquired in hospitals and medical centers. For e.g. 
several topical antimicrobials have also been used for topical burn therapy, including 
gentamicin sulfate (0.1% water-soluble cream), betadine (10% povidone-iodine ointment), 




Fig 2.3. Images of AQUACEL® Ag - ionic silver (Convatec, NJ, USA). This 
material provides an effective barrier to bacterial penetration to help reduce 
infection. AQUACEL® Ag is indicated for use on acute and chronic wounds 
including burns, surgical wounds, diabetic foot ulcers, pressure ulcers and leg 
ulcers. The power of ionic silver in AQUACEL® Ag kills a broad spectrum of 
wound pathogens in the dressing that can cause infection - including 
Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus (VRE), and other pathogens (Figure source : 
http://www.convatec.com).  
However, these compounds are no longer used extensively because significant 
resistance has developed and/or they have been shown to be toxic or ineffective at 
controlling localized burn wound infections [73]. Toxicity from silver is observed in the 
form of argyria or skin discoloration, usually when there is a large amount of silver ions 
are used in the wound dressing. However, a delayed wound healing response has also been 
observed in a clinical setting. It has been shown that exposure of human dermal fibroblasts 
and epidermal keratinocytes to silver sulfadiazine in vitro produced a significant 
reduction in cell proliferation and increased cytotoxicity [74, 75].  It has also been 
reported to inhibit collagen synthesis in human rheumatoid synovial cells in culture [76].   
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Novel vaccines were developed as they do not suffer the problem of resistance 
instead work to enhance the body's natural defenses. Nevertheless, it is possible that new 
strains may evolve that escape immunity induced by vaccines. Vaccines also do not 
guarantee complete protection from a disease. This may be due to a lowered immunity in 
general (diabetes, steroid use, HIV infection) or because the host's immune system does 
not have B-cells capable of generating antibodies to that antigen.  
Bacteriophage therapy has been recently studied as an emerging alternative to 
antibiotics [77]. Phages were found to possess several potential disadvantages when 
compared with antibiotics. Although they are specific for the target bacterium, which 
reduces the disruption to the natural flora of the host, the need for isolation of a phage 
specific to the target bacteria leads to the increased costs and development time. Also, 
phages that are injected into the bloodstream are immunogenic [78]. Some of them are 
cleared very quickly and, after a certain period, antibodies against the phages are produced 
by the body [78]. Funding for phage therapy research and clinical trials is also generally 
insufficient and difficult to obtain, since it is a lengthy and complex process to patent 
bacteriophage products. Phage therapy has been used publicly for many years; therefore, 
the technique itself would not be patentable. Additionally, it is unlikely that it would be 
possible to patent individual phage, and the wide range of phage targeting each species of 




2.3. Antimicrobial proteins and peptides 
Use of proteins and peptides as antimicrobial agents is inspired from nature and 
has recently attracted much attention as an antibiotic-free approach to treat bacterial 
infections [79-81]. Naturally occurring antimicrobial peptides and enzymes have are 
characterized by higher activity, broad antimicrobial spectrum, and the low rate of 
resistance to these agents by bacteria. They may be expressed constitutively or sometimes 
inducibly in response to certain specific pathogenic challenges [82].  
The current promising candidates of antibacterial enzymes are functionally 
classified as either hydrolases or oxidoreductases [83]. Hydrolases are bacteriolytic 
enzymes that function by degrading key structural components of the cell walls of 
bacteria. Peptidoglycan is the major structural component of bacterial cell walls. 
Degradation of bacterial cell walls results in lysis due to rupture of osmotic balance in the 
cell. These enzymes are further grouped into three different classes –1) N-
acetylhexosaminidases that catalyze the cleavage of the β (l-4)-glucosidic linkages in the 
carbohydrate backbone of the peptidoglycan, 2) N-acetylmuramyl-L-alanine amidases that 
catalyze the cleavage between the carbohydrate moiety and the peptide moiety of the 
peptidoglycan, and 3) Endopeptidases that hydrolyze the peptide crosslinks of the 
peptidoglycan [84]. Lysostaphin is an antibacterial enzyme which specifically cleaves 
cross-linked pentaglycine bridges in the peptidoglycan of S. aureus, thereby hydrolyzing 
the cell wall and lysing the bacteria. 
Oxidoreductases on the other hand do not possess any antimicrobial activity by 
themselves. However they exert their effect through the generation of reactive species that 
are known to be toxic to bacteria. Glucose Oxidase, Lactoperoxidase and 
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Myeloperoxidase are some well-studied oxidoreductase systems [83, 85, 86]. These 
enzymes (Peroxidases) are synthesized and secreted by ductal epithelial cells of the 
mammary gland and other exocrine glands. They also probably provide protection against 
microbial infection to the mucosal surfaces of eye, nose, mouth, trachiobronchial tree and 
intestinal tract [87]. Both salivary peroxidase and myeloperoxidase, the two peroxidase 
enzymes in human mixed saliva, have been purified but only for research purposes. Large-
scale purification from human saliva or from human polymorphonuclear leukocytes is 
difficult and far too expensive for commercial purposes. Therefore, for commercial 
purposes bovine lactoperoxidase (purified from milk or colostrum) has been used because 
this enzyme is structurally and catalytically very close to human salivary peroxidase [87]. 
The lactoperoxidase system has been incorporated into commercial products such as tooth 






 [87]. It is also well 
understood that bacteriolytic enzymes usually offer protection against only a few bacteria, 
owing to their specificity. The oxidoredctuase systems may affect a broader spectrum of 
microorganisms but suffer from the drawback of being dependent on the availability of 
substrates for the generation of antimicrobial reaction products and toxicity towards 
eukaryotic cells.  
2.3.1 Antimicrobial peptides (AMPs)  
These are a group of short 10–40-residue polypeptides that are part of the innate 
immune system in many organisms including bacteria, insects, plants, and vertebrates[88]. 
In mammals, these peptides are present mainly in phagocytic cells and in mucosal 
epithelial cells.  In addition to their antimicrobial role, antimicrobial peptides (AMPs) also 
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serve as important molecules involved in inflammation, immune activation, and wound 
healing [89-91].  
In humans, three distinct groups of antimicrobial peptides are usually 
distinguished: defensins, cathelicidins, and histatins [92, 93]. Histatins will not be 
considered here because their primary function is antifungal, rather than antibacterial. A 
characteristic feature of defensins (molecular weight 3-5 kDa) is the presence of six 
cysteine residues forming three intramolecular disulfide bridges. Defensins are further 
subdivided into - and -defensins based on the distribution of the cysteines and linkages 
of disulfide bridges.  Cathelicidins are a family of proteins containing an N-terminal 
cathelin domain and a C-terminal cationic antimicrobial domain that becomes active after 
cleavage [94]. Only one human cathelicidin is known. It is a cationic 18 kDa protein 
precursor, hCAP18. Its mature antibacterial peptide named LL-37 is liberated through 
cleavage by elastase and proteinase 3 [95]. LL-37 has a broad-spectrum antimicrobial 
activity against a variety of Gram-positive and Gram-negative bacterial, fungal, and viral 
pathogens.  
Amphipathicity (presence of both hydrophilic and hydrophobic groups) and net 
charge are characteristics conserved among many antimicrobial peptides [88]. All 
antimicrobial peptides bear a large positive charge, which results in their preferential 
targeting to bacteria, rather than to eukaryotic cells. It is generally understood that the 
bactericidal activity of antimicrobial peptides is due to permeation of bacterial cell 
membranes [88, 96]. It is also likely that antimicrobial enzymes and peptides may use 
more than one mechanism of action, such as destabilization of the cell membrane 
combined with inhibition of one or more intracellular targets [97]. This “multitarget” 
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mechanism hypothesizes that highly charged cationic peptides and enzymes can bind to 
anionic molecules within the cytoplasm, such as nucleic acids or enzymes with ionic 
surfaces, thus interfering with processes in which these molecules are involved. 
2.3.2 Synergy  
Interactions between antimicrobial enzymes and peptides may be synergistic, 
additive, or antagonistic in nature. Because of their different modes of action, 
antimicrobial enzymes and peptides may act cooperatively by simultaneously attacking 
essential structures in microorganisms [98]. Synergy among individual peptides, was first 
observed with frog peptides, including members of the dermaseptin family [99] and the a-
helical peptides magainin and PGLa [100], and between b-defensins and the cationic 
protein BPI [101].  
The synthetic peptide LL-37 demonstrated antibacterial activity against a number 
of Gram-negative and Gram-positive organisms including P. aeruginosa and was 
synergistic with lactoferrin and lysozyme [102]. A synergistic antibacterial effect between 
LL-37, β-defensins, and lysozyme was initially described by Nagaoka et al. [103]and later 
comprehensively investigated by Chen et al [104]. They observed that the antibacterial 
agents- hBDs (human beta defensins), LL-37 and lysozyme exhibit antimicrobial activities 
synergistically against invading microorganisms, in particular S. aureus that frequently 
colonizes the skin [104]. The synergistic effect found was strong enough to speculate that 
defensins may not be able to act as antibacterial molecules by themselves, but only in 
synergism with cathelicidins [103].  In another study, synergism in various combinations 
of six antimicrobial factors, including lysozyme, lactoferrin, LL-37, HBD-1, HBD-2, and 
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secretory leukocyte protease inhibitor (SLPI), had been evaluated by Welsh and co-
authors [105]. In this work, synergy of lysozyme with LL-37 has been confirmed, while 
no synergy has been observed in the cases of lysozyme combined with either HBD-1 or 
HBD-2.  
Thus synergistic interactions appear to be important evolutionary survival 
mechanisms that can be cleverly manipulated in the design of antibacterial combinations. 
Combining multi-targeting functions through different peptides and proteins 
simultaneously ensures their antimicrobial action to a wide range of microorganisms. Due 
to widespread antibiotic resistance, such multiple combinations, similar to that of an 
antibiotic cocktail, are often required to overcome infectious diseases. Implementing such 
synergistic principles into the design of next generation therapeutics could prove to be an 
important determinant in the effectiveness of using an antibiotic-free approach.  
2.3.3 Antibiofilm activity  
The biofilm matrix is composed of an assortment of cells and various extracellular 
polymers of different polysaccharides such as glucose, dextrans, cellulose, alginate etc. 
and also of some glycoproteins [40]. Antimicrobial enzymes have been used in the 
inhibition of biofilm formation. However due to the heterogeneity of these 
polysaccharides, a combination of enzymes is necessary to achieve a synergistic effect for 
biofilm inhibition.  For instance, Pectinex UltraSP (a mixture of enzymes containing 
cellulose, pectinase etc.) has been used for enzymatic degradation of S. aureus, P. 
aeruginosa, P. fluorescens and S. epidermis biofilms with S. aureus being the most 
sensitive [106].  
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Some of these polysaccharide-hydrolyzing enzymes are only known for dispersion 
and inhibition of biofilms but do not have a significant bactericidal activity. For example 
DispersinB (patented by Kane Biotech Inc.), a naturally occurring N-
acetylglucosaminidase isolated from A. actinomycetemcomitan is a highly active and 
stable glycoside hydrolase that specifically glycosidic linkages of poly-b-1, 6-N-
acetylglucosamine in polysaccharide adhesins of bacteria needed for biofilm formation 
[107, 108]. As DispersinB can only inhibit or disperse bacterial biofilms without affecting 
their growth, it would be necessary to combine it with another antimicrobial in order to 
inhibit the growth and proliferation of biofilm-embedded bacteria [107, 109]. When used 
in combination with glucose oxidase; it increased the sensitivity of S. epidermidis biofilm 
to glucose oxidase [110]. Johansen et al also similarly showed that combining 
oxidoreductases such as glucose oxidase and lactoperoxidase with polysaccharide-
hydrolyzing enzymes resulted in bactericidal activity as well as removal of the biofilm 
thus citing another example of a synergistic effect [106]. Apart from the 
exopolysaccharide layer, extracellular DNA has also been as a target used to inhibit 
biofilm formation. For e.g Bovine DNase1 was shown to suppress P. aeruginosa, 
Streptococcus intermedius and S. mutans biofilm formation [111]. The antibiofilm activity 
of these DNases involves degradation of extracellular DNA, which is an essential 









Table 2.1. below shows list of some of the antibacterial peptides and proteins 
2.3.4 Challenges associated with application of antibacterial proteins and peptides 
Overall great enthusiasm exists regarding the prospect of developing antimicrobial 
proteins and peptides as a new generation of „antibacterial agents‟ for treatment of 
implant-associated infections. In spite of this, use of enzymes and peptides in a clinical 
setting is associated with several potential drawbacks, which includes 1) high 
 




Proposed antibacterial mechanism 
 
References 
Lysozyme Human, Chicken Enzymatic lysis of peptidoglycan layer; Non 
enzymatic mode of action 
 
[112, 113] 
Lactoferrin Human, Bovine  
Sequestering iron essential for microbial respiration ; 






α and β defensins 
Mammals; 
analogues in 
insects and fungi 





LL-37 Human  
Membrane permeabilization 










Membrane permeabilization; binds to lipid 2 of 





Magainin Frog Membrane permeabilization [124, 125] 
Protegrin Human, Porcine 












manufacturing cost, especially of peptides, 2) short half life in vivo, 3) loss of activity in 
physiological conditions (especially at high ionic strength, which may interfere with their 
charge-directed targeting and mechanism of action), 4) unwanted systemic reactions 
(aggregation, immunoreactivity), 5) interference with normal bacterial flora and even 6) 
site-specific delivery that may arise when attempts are made to use them for targeted 
delivery as antibacterial agents. It is also known that small molecules (lesser than 70kDa) 
such as antimicrobial enzymes and peptides have a relatively short half-life in blood after 
intravenous administration. Their rapid clearance from circulation may reduce its efficacy 
as an antimicrobial. Also, some of the enzymes such as lysostaphin and DispersinB are 
derived from bacterial species and could potentially show immunogenicity in humans 
which further stimulates its clearance from the blood stream. This is mainly due to the 
induction of a specific humoral response [129, 130]. Antibodies from the host might 
neutralize these enzymes and compromise the efficacy of the drug and there could also be 
other effects related to cross-reactivity with other autologous proteins. Thus, their short 
circulating half-life cannot be effectively countered by increasing the amount or frequency 
of dosage. There are also a number of MMPs (Matrix Metalloproteinases), Serine 
proteases etc. that could also result in protein degradation through hydrolysis. More 
expensive strategies such as synthesis of recombinant protein that is resistant to 
proteolytic degradation have been reported [131].  
Several research-related issues also must be resolved for better understanding of 
the fundamental aspects of the processes associated with clinical applications- 1) 
Development of standardized techniques to assess the activity of enzymes and peptides 2) 
Targeting of agents to the site of action. 3) Addressing toxicity in more detail, for e.g. the 
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positive charge of AMPs may result in their strong interactions with anionic components 
of both bacterial and host cells. 4) Understanding of the role and expression of 
antimicrobial enzymes and peptides in both health and disease. Focusing on these issues is 
expected to lay the foundation for the future applications of enzymes and peptides as 
highly effective antibacterial agents for treatment of device-related infections.  
2.4. Enzyme immobilization 
Immobilization of enzymes on surfaces is of great importance for a wide range of 
biomedical applications because of their recyclability, decrease in systemic toxicity, 
carrier specificity and improvement in enzyme stability [132]. Enzymes are highly 
specific and efficient biocatalysts with a wide range of biotechnological and biomedical 
applications [133, 134]. There are however quite of a few issues that need to be addressed 
towards their application for treatment of bacterial infections. These include substrate and/ 
or site specificity, systemic toxicity and loss of enzymatic activity in vivo due to low 
stability.  In order to overcome these problems, numerous efforts have been devoted to the 
development of several immobilization procedures. Presently, immobilized 
proteins/enzymes are used routinely in the medical field, such as in the diagnosis and 
treatment of various diseases. For example, immobilized antibodies, receptors, or enzymes 
are used in biosensors and ELISA for the detection of various bioactive substances in the 
diagnosis of disease states; antibody directed drug delivery using colloidal systems [135-
137]. 
Immobilization can be defined as the attachment of molecules to a surface 
resulting in reduction or loss of mobility. In fact sometimes, immobilization may lead to 
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partial or complete loss of protein activity, due to random orientation and structural 
deformation [138]. There is a multipoint attachment between enzyme molecules and the 
surface that reduces unfolding, and hence improves stability [139]. In order to retain 
biological activity, enzymes should preferably be attached onto surfaces without 
significantly affecting their conformation and function. 
Generally, the choice of a suitable immobilization strategy is determined by the 
physicochemical and chemical properties of both surface and enzyme. The stability of an 
immobilized enzyme is dictated by many factors such as the number of bonds formed 
between the enzyme and carrier, the nature of the bonds (i.e. covalent, non-covalent or 
different types of covalent or non-covalent bonds), the degree of confinement of enzyme 
molecules in/on the carrier, the microenvironment of the enzyme and carrier, and the 
immobilization conditions [138]. For e.g. nonporous materials, to which enzymes are 
attached to the surfaces, are subject to minimum diffusion limitation while enzyme 
loading per unit mass of support is usually low. On the other hand, porous materials can 
afford high enzyme loading, but suffer a much greater diffusional limitation of substrate. 
Many surface immobilization techniques have been developed in the past years, 
which are mainly based on the following three mechanisms: physical, covalent, and 
bioaffinity immobilization [138]. It is unlikely that one immobilization technique will be 
considered optimal for all proteins. Also, the most suitable strategy for protein 
immobilization is also particularly dependent upon the biomedical application. Hence, 
several unsolved challenges are involved in immobilization techniques. Correspondingly, 
many methods have been developed to improve the enzyme stability during 
immobilization. Engineering the microenvironment of the enzyme molecules has been 
26 
 
increasingly used to improve enzyme stability. For e.g. in the case of covalent enzyme 
immobilization, alteration of microenvironment can be easily achieved by quenching the 
remaining excess active functionalities using blocking agents [140], which can be simply 
classified into two groups: small molecules (e.g. amino acids or other amines), and 
macromolecules (e.g. bovine serum albumin, gelatin, polyethyleneimine (PEI) [141] , and 
polyethylene glycol (PEG)). These blocking agents (or quenching agents) can easily react 
with the active functionalities, such as epoxy rings or aldehyde groups, of the commonly 
used carriers without the use of additional activating chemistry. 
Other methods of immobilization include entrapment via inclusion of an enzyme in 
a polymer network (gel lattice) such as an organic polymer or a silica sol-gel, or a 
membrane device such as a hollow fiber or a microcapsule. Immobilization in silica sol 
gels prepared by hydrolytic polymerization of tetraethoxysilane, in the presence of the 
enzyme [142] and has been used for the immobilization of a wide variety of enzymes 
[143]. Also, it has been shown that cross-linking of dissolved enzymes via reaction of 
surface NH2 groups with a bifunctional chemical cross-linker, such as glutaraldehyde, 
results in insoluble cross-linked enzymes with retention of catalytic activity [144]. 
However, this method of producing cross-linked enzymes had several drawbacks, such as 
low activity retention, poor reproducibility, low mechanical stability, and difficulties in 
handling the immobilized enzyme. Some methods of immobilization are described below. 
2.4.1. Physical adsorption 
The type of intermolecular forces that take part in the adsorption process will 
depend on the particular protein and surface involved. Protein adsorption on surfaces is 
predominantly governed by electrostatic, hydrophobic interactions and to certain extent 
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even hydrogen bonding. The resulting layer is likely to be heterogeneous and randomly 
oriented, since each protein molecule can form many contacts in different orientations for 
minimizing repulsive interactions with the substrate and previously adsorbed proteins 
[145]. 
The arrival of protein at the interface is assumed to be driven solely by diffusion 
processes, which are dependent on bulk concentration and diffusion coefficient [145]. The 
particular surface chemistry, intermolecular forces between adsorbed molecules, solvent–
solvent interactions, topology and morphology of the protein-adsorbent interface also 
further dictates the adsorption kinetics. Protein adsorption process includes the 
redistribution of charged groups in the interfacial layer, hydrophobic interactions between 
protein and material‟s surface, and structural rearrangements of protein molecules [145]. 
Drawbacks of the adsorption are random orientation resulting in significant loss of 
activity and weak attachment followed by subsequent protein desorption from the surface.  
The structure of a protein is closely related to its function therefore unspecific protein 
adsorption and surface-induced conformational changes are important issues in 
biocompatibility of materials [146] 
2.4.2. Covalent Immobilization 
This method confers the immobilized enzyme with greater stability against 
environmental changes such as pH and temperature, as well as higher selectivity toward 
the substrates. However, the coupling protocols could involve complicated synthetic 
procedures, which are often carried out under harsh experimental conditions, and with use 
of toxic and expensive reagents. Furthermore, functional groups of the enzyme are used to 
28 
 
link the solid supports, resulting in a significant loss in enzymatic activity [147]. Covalent 
bonds are mostly formed between side-chain-exposed functional groups of proteins with 
suitably modified supports, resulting in an irreversible binding and producing a high 
surface coverage [148]. The functional groups on the support are generated by chemical 
treatment, and several pretreated surfaces are already commercially available. 
Covalent attachment is permanent, leaving no unbound material after clean-up. It 
may prevent elution of bound protein during storage, thus increasing shelf life. Covalent 
coupling on surfaces enables a uniform coating procedure [149, 150]. As a consequence of 
having reactive groups over the entire surface of the material, it is possible to completely 
cover the surface with protein. Protein coverage is also more easily controlled by covalent 
coupling, especially when the desired quantity of adsorbed protein is low. Achieving the 
correct spatial orientation for the bound protein can be difficult via physical adsorption. 
Covalent attachment, on the other hand, can orient the molecule properly, if the correct 
coupling chemistry is chosen, improving the activity of the bound proteins and resulting in 
lower reagent consumption [149, 150]. 
Because active enzymes necessarily have very flexible conformation, a spacer 
between the enzyme and the carrier surface is often used to improve the enzyme activity 
expression[151]. The obtained immobilized enzymes with spacers could have higher 
activity due to the favorable environment created by the hydrophilic spacer. Most 
probably, the presence of the spacer is able to endow the enzyme more conformational 
flexibility, which is usually a prerequisite for higher activity. Controlled modification of 
the enzyme molecules with the use of a bi-functional cross-linker have also been recently 
used to adjust the number of bonds and the spacer formed between the carrier and enzyme 
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.To preserve the activity of biomolecules upon immobilization, several techniques have 
been directed towards site-specific covalent immobilization [152, 153]. For antibodies, the 
carbohydrate moieties located in the Fc region were targeted to form aldehyde groups, 
using periodate for site-specific coupling to solid supports [154, 155]. 
2.4.3. Bioaffinity Immobilization 
Biochemical affinity reactions are also used for immobilization of proteins, 
providing an important advantage over other surface immobilization techniques. 
Moreover, not only oriented and homogeneous attachment is obtained, but it is also 
possible to detach proteins and make repeated use of the same surface. An example is 
described below. 
Avidin-Biotin interaction 





) and allowing the use of harsh conditions during biochemical assays [156]. The 
specificity of the interaction permits uniformly oriented protein immobilization [157]. 
Avidin is a tetrameric glycoprotein soluble in aqueous solutions and stable over wide pH 
and temperature ranges. It can bind up to four molecules of biotin. This bond formation is 
very rapid and unaffected by pH, temperature, organic solvents, enzymatic proteolysis, 
and other denaturing agents [157]. 
Streptavidin is a closely related tetrameric protein, with similar affinity to biotin, 
but differing in other aspects, such as molecular weight, amino acid composition, and pI. 
The properties of both avidin and streptavidin have been improved using chemical and 
recombinant methods providing enhanced stability and/or controlled biotin binding [157]. 
Biotin or vitamin H is a naturally occurring vitamin found in all living cells. Only the 
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bicyclic ring is required to be intact for the interaction with avidin; the carboxyl group on 
the valeric acid side chain is not involved and can be modified to generate biotinylation 
reagents used for conjugation with proteins [158]. Since biotin is a small molecule, its 
conjugation to macromolecules does not affect conformation, size, or functionality [158]. 
Biotinylation reagents can be classified depending on their reactivity toward different 
functional groups. The NHS ester of biotin is the most commonly used biotinylation 
reagent to target amine groups [159]. 
Both biotin and avidin/streptavidin may be attached to a variety of substrates. 
Direct immobilization of avidin occurs either via adsorption or via covalent coupling. It 
has been reported that covalent attachment of avidin onto carboxyl-derivatized polymers 
produces a higher coating density than immobilization via a biotinylated interlayer [160]. 
However, coupling via carbodiimide chemistry may affect its binding activity. A typical 
multilayer is composed by biotin directly immobilized and avidin creating a secondary 
layer for binding biotinylated molecules. This approach is generally preferred due to the 
higher organization (biotin/avidin/biotin) obtained in comparison to that of the direct 




Figure 2.4. Schematic of the Streptavidin-biotin system: Binding of biomolecules 
to the particle surface: (Source: http://www.microparticles.de/news_2005.html- 
accessed - 20/03/2011). 
2.4.4. Surface modification 
Spontaneous adsorption of proteins from biological fluids onto synthetic materials 
such as biomaterials and biomedical devices may induce undesirable reactions of the body 
to the foreign materials, such as immune responses, blood coagulation, or bacterial 
adhesion [162, 163]. Due to the diversity of the interactions between proteins and 
surfaces, a preferred strategy for blocking the adsorption of proteins is to immobilize 
polymers in the form of well-solvated brushes (e.g., poly (ethylene glycol), PEG) on the 
surface. 
Pegylation of a surface can be achieved by adsorbing PEG-containing block 
copolymers such as polyethylene oxide/polypropylene oxide [164] or poly(d,l-lactide)/ 
polyethylene oxide [160] on the surface, surface grafting using established strategies 
[165]depositing PEG-like coatings using a radiofrequency glow discharge technique [166] 
or forming self-assembled monolayers. The polymer layer shields the surface, introducing 
a high activation barrier for the proteins to adsorb. Poly (ethylene glycol) (PEG) has been 
shown to successfully confer protein resistance to a variety of surfaces [167, 168]. Both 
PEG chain length and surface coverage have been demonstrated to play a key role in 
imparting protein resistance, with PEG chains of typically 1-10 kDa molecular weight 
providing protein resistance. The protein resistance by PEG chains has been associated 




Attachment via PEG spacers also minimizes lateral interactions of immobilized 
protein with the surface [169, 170]. The spacer groups are thought to permit a degree of 
freedom to the reagent moiety separating it from the particle surface, thereby lending 
enhanced specificity [167]. In particular, nanoparticles whose surfaces were modified by 
the incorporation of poly(ethylene glycol) (PEG) during nanoparticle formulation either 
through covalent attachment of PEG to surface functional groups or through physical 
adsorption of PEG to the surface, have show a decreased uptake by phagocytic cells and 
an increased circulation time to effectively target diseased cells [171, 172]. PEG 
molecules on the surface of a polymeric nanoparticle can reduce the adsorption of 
opsonins and other serum proteins [172]. PEGylated polycyanoacrylate particles 
transferred more effectively across the blood brain barrier than with poloxamine coating 
[173].PEG density and configuration were shown to be important for this [174]. 
Additives such as polyethylene glycol (PEG), polyvinyl alcohol and albumin, can 
have a stabilizing effect even on sol-gel entrapped enzymes. For example, Zanin and co-
workers [175] compared three different methods – physical binding, covalent attachment 
and gel entrapment, in the presence and absence of PEG 1450 – for the immobilization of 
Candida rugosa lipase. Immobilization yields varied from 3 to 32%, the most active 
biocatalyst resulting from the encapsulation in the presence of PEG. 
2.5. Nanotechnology for enzyme immoblization 
Nanotechnology also seems to be as a promising alternative to overcome the 
problems of the administration of peptides and proteins and also stabilizing these 
biomolecules before targeted delivery. Various nanostructures, generally providing a large 
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surface area for the immobilization of enzyme molecules, have been actively developed 
for enzyme stabilization. The coupling of biomolecules and materials at the nanoscale has 
the potential to revolutionize many fields of science and technology potentially having a 
very significant impact on biomedical technology. Both nanomaterials and biomolecules 
lie in the same nanometer length scale and can thus complement each other in hybrid 
systems. Protein based nanostructures are expected to offer some additional advantages 
and play a key role in the development of multifunctional materials and devices for 
nanotechnological applications. [176-179]. 
Many methods have been developed to incorporate enzymes into nanostructures. 
Surface attachment was employed in many of the earlier studies and is often the method of 
choice [180-182]. Another way to develop nanoscale biocatalysts is to entrap enzymes 
within nanopores. Mesoporous silica gels have been used to host enzymes through 
physical adsorption [183] or chemical binding. Using carefully designed synthetic routes, 
enzymes were also entrapped within the cores of discrete polymeric articles. More 
sophisticated structures, such as porous materials hosting enzyme-carrying nanoparticles 
and cross-linked enzyme aggregates [185], have been developed by applying enzyme 
modification and fabrication procedures. Thus the functionalization and modification of 
nanomaterials using enzymes have led towards research and development for biomedical 
applications. 
However there are drawbacks to the handling of nanomaterials, which presents 
certain health and environmental concerns. Carbon nanotubes, which exist in powder form 
when in a pure state, share these concerns when used as enzyme supports due to toxicity 
[180-182]. Some of these problems can be overcome by using one-dimensional 
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nanomaterials, such as polymeric nanofibers [186]. The surface area: volume ratio of 
nanofibers is also high, representing two-thirds that of nanoparticles of the same diameter 
when considering equivalent amounts of material. Nanofibers, however, have the benefit 
of being much easier to produce and handle. They can be applied in the form of coils, 
sheets or dispersed fibers and can also be attached to the surface of other materials or 
blended with them, thus offering very flexible design of reactors [186]. 
In the case of surface attachment, smaller particles can provide a larger surface 
area for the attachment of enzymes, leading to higher enzyme loading per unit mass of 
particles [187]. A growing interest has been shown in using nanoparticles as carriers for 
enzyme immobilization [187-190]. The effective enzyme loading on nanoparticles could 
be achieved up to 10% wt due to a large surface area per unit mass of nanoparticles [188]. 
 
Figure 2.5. Nanotechnology for enzyme immobilization (a) Nanoparticles with 
surface-attached enzymes. (b) Nanofibers carrying enzymes. (c) Nanoporous 
matrix with entrapped enzymes. (d) Carbon nanotube–enzyme hybrid materials – 




The use of nanoparticles as enzyme supports was first reported in the late 1980s 
[192, 193].  Therefore, nanoparticles may appear as alternative carriers considering the 
design of more sophisticated systems including multifunctional types of device. 
Nanoparticles are of great scientific interest as they are effectively a bridge between bulk 
materials and atomic or molecular structures. Size-dependent properties are observed in 
case of nanoparticles when compared to the bulk material. Since they have a very high 
surface area to volume ratio it provides a tremendous driving force for diffusion, 
especially at elevated temperatures. 
Advantages of using nanoparticles over other „nanomaterials‟ and formulations are 
that they (e.g. polymer nanopaticles) are cheaper materials than lipids (e.g liposomes), and 
that polymers offer wider chemical engineering solutions. In addition, the stability of 
polymer particles can be much better controlled than the stability of liposomes upon slight 
modifications of the formulation. Intrinsic properties of nanoparticles, such as size, 
surface charge density, surface chemistry etc can also be used to add functionality to their 
conjugates with biomolecules. 
For example, drugs, proteins and peptides can be incorporated into nanospheres 
that are composed of a biodegradable polymer, and this allows for the timed release of the 
drug as the nanospheres degrade [194] The circumstances that cause the particle to 
degrade can be adjusted by varying the nature of the chemical bonding within the particle. 
For example, when acid-labile bonds are used, the particles degrade in acidic 
microenvironments, such as would exist in tumour cells or around a site of inflammation 
[195], and so this approach allows site-specific delivery. In other recent studies, polymeric 
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nanoparticles were labeled on their outer surfaces with a viral peptide sequence that 
promotes the permeation of substances through cell membranes [196]. These peptide-
derivatized nanoparticles passed through cell membranes, and were incorporated into 
living cells at much higher levels than nanoparticles without the surface-bound peptide. 
Similarly Gold nanoparticles (20 nm) modified with shells of bovine serum 
albumin (BSA) were conjugated to various cellular targeting peptides to provide 
functional nanoparticles that penetrate the biological membrane and target the nuclei [197, 
198]. Hybrids of silver nanoparticles with amphiphilic macromolecules exhibit 
antimicrobial properties and are used to treat bacterial infections [198]. Covalent coupling 
of proteins to metal nanoparticles is performed using appropriate capping agents such as 
citrate and thiol groups. This method has been applied in coating of colloidal gold with 
thiol containing proteins such as immunoglobulins and serine albumins which have 
cysteine residues that are accessible for coupling [199]. 
2.6.1. Polymer nanoparticles 
The term `polymer colloid' refers to a suspension or dispersion of polymeric 
microspheres having a diameter in the order of sub-micron to several microns. The 
dispersion medium is generally water. A dispersion whose medium is not water is referred 
to as a nonaqueous dispersion. `Latex' originally means a dispersion of microspheres from 
natural rubber. The stability of the polymer latex itself is decided by the contribution of 
three factors: electrostatic repulsive forces, van der Waals' attractive forces and steric 
repulsive forces among the particles [200]. 
Polymer colloids have a low viscosity and high fluidity compared to solutions 
containing the same amount of solid. The viscosity of polymer colloids is a universal 
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function of apparent volume fraction of the microspheres. The apparent volume fraction of 
microspheres can be changed by environmental conditions such as pH and temperature for 
some polymer colloids [201]. In dispersion, the microspheres can move macroscopically 
through the medium by gravity, electric field, etc and microscopically via Brownian 
motion. These movements keep a fresh interface between the microspheres and the 
medium. Particles having soft layers on the surface allow water to penetrate the layer and 
meet less resistance when they move through water [202]. Polymer particle dispersions are 
an alternative to be able to offer a large surface and they can be used as the carrier if easily 
recovered from the medium.  
Polymer latexes, usually with antibodies or antigens attached to their surfaces, can 
be used in the diagnostic tests. There are many factors that dictate the use of latex particles 
than the use of any other solid support for agglutination reactions. These include 
monodispersity (for detection of agglutination using light scattering techniques), colloidal 
stability and hydrophobicity of the particles. Biological molecules adsorb strongly to 
hydrophobic surfaces and this can be controlled by time, temperature, pH and protein 
concentration [149]. An antibody is an asymmetric molecule and its antigen-binding 
fragment (Fab) is located in two arms of Y-shaped molecules. Antibodies must be 
immobilized in a manner in which the Fab fragment does not have any steric hindrance and 
can bind to the directed antigen. When an antibody is immobilized in the opposite 
orientation, it causes not only lowering of reactivity but also nonspecific agglutination, 
since the fragment Fc of an antibody adsorbs to certain proteins [149]. Furthermore, 
surface activity could be enhanced if the antibodies are covalently coupled, by reducing 
the rearrangement of the protein molecules during and after adsorption [203-205]. Specific 
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covalency between protein and functionalized latex is achieved by treatment of protein–
latex system with surfactants under appropriate conditions able to remove all the 
physically adsorbed protein from the particle surface [150]. 
2.6.2. Protein-nanoparticle conjugates 
In recent years, much attention has been paid to the use of enzymes conjugated to 
polymer colloids in biomedical applications [206-208]. Such colloids are easy to produce 
and can be prepared with a high degree of monodispersity [209-211]. Colloidal 
nanoparticles provide an almost ideal remedy to the issues encountered in the optimization 
of immobilized enzymes: minimum diffusional limitation, maximum surface area per unit 
mass, and high enzyme loading [187]. The attachment of molecules to latex particles can 
be achieved through physical adsorption or covalent coupling. 
Polymer engineering has facilitated the synthesis of latex particles with surface 
reactive groups such as carboxylate, aldehyde, chloromethyl, and hydroxyl groups to 
enable covalent coupling of protein molecules to the particles[166, 212, 213]  Some of 
these groups must be activated prior to protein immobilization. A number of special 
linkers can be used to convert one surface functional group on a microsphere to another. 
For example, amino microspheres can be converted to carboxylic particles by reacting 
with succinic anhydride [214]. Carboxylic particles can be converted to amino 





Fig 2.6. Commonly used covalent coupling procedures for peptides and proteins 
to the surface of nanoparticles with reactive surface groups. 
There are also major drawbacks of any immobilization protocol based on the use 
of highly reactive and unstable intermediates. The balance between covalent coupling and 
unproductive side reactions depends to some extent on the activation reaction conditions. 
The ionic composition of the reaction, the pH, and the buffer type can greatly enhance or 
inhibit the total binding of protein to particles. Sufficient amounts of functional groups 
should be present to provide adequate coupling of the protein. The covalent attachment of 
the IgG molecule to carboxylated particles improves the immunoreactivity of antibodies 
when compared with physical adsorption and also maintaining its immunoreactivity after 
long periods of storage [150]. 
2.6.3. Stabilization using blocking agents and surfactants 
There also other techniques in order to improve stability and reduce non specificity 
of the protein-nanoparticle conjugates. The colloidal suspension can be treated with either 
a second protein or a surfactant that can act as a stabilizer by covering all the unoccupied 
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parts of the surface and thereby reducing non specificity [216]. Bovine serum albumin 
(BSA), a globular protein has been commonly used to improve the colloidal stability of 
protein coated microspheres. The BSA molecule is a highly-charged protein at 
physiological pH. It helps in the electrostatic stabilization of the protein-nanoparticle 
conjugate [217, 218]. Moreover, BSA is easily obtainable in significant amounts, which is 
why it is commercially available at reasonably low prices. 
There are two different methods for preparing latex–antibody complexes with 
coadsorbed BSA: (1) sequential adsorption where in a first step the antibody adsorption is 
carried out and after centrifugation the conjugate is resuspended in a solution of BSA at 
constant concentration [219]; (2) competitive adsorption whereby the adsorption of both 
proteins (including BSA) occurs in a single step [217, 218]. For competitive adsorption, 
the method becomes more complicated because of the two types of proteins in the 
dispersion medium. Peula et al. observed that the colloidal stabilization of IgG-covered 
particles appears when the coverage of co-adsorbed BSA is high and at pH 7 and 9, and is 
not stable at pH 5 (pI of albumin) [217]. It was also indicated from the same study that it 
is necessary to find the adequate equilibrium between the amount of IgG that produces a 
good immunological response and the amount of BSA responsible for the colloidal 
stability. These ways of stabilizing antibody–latex particles may have some disadvantages, 
e.g., only antibody–latex complexes with low antibody coverage can be stabilized or co-
adsorption with inactive proteins may involve partial or complete displacement of the 
preadsorbed molecules of antibody. 
The use of surfactants (e.g. Tween) as stabilizer molecules can also have also have 
desired effects on nonspecific agglutination. They mainly stabilize protein-coated particles 
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by means of steric forces, although electrostatic repulsions can also be generated by ionic 
surfactants. The surfactant concentration requires careful optimization because excess 
surfactant could also inhibit interaction with the desired antigen/substrate. However, this 
strategy to preserve the colloidal stability of particles presents some disadvantages, since 
such molecules can also desorb the previously adsorbed protein [220]. 
2.7. Enzyme-nanoparticle conjugates as antibacterials – Targeted delivery 
The stratum corneum layer of the epidermis is a strict barrier allowing limited 
penetration of particulate materials. This aspect has potential to serve as a novel route for 
drug delivery and has attracted enormous pharmaceutical research interests [221]. While 
intact skin is known to act as a barrier to nanoparticles, skin wounds may give rise to 
easier translocations. Dressings and bandages embedded or coated with antibacterial 
protein-nanoparticle conjugates could be potentially used for prevention of sepsis of 
severe skin wounds like burns. Close contact may allow nanoparticle-conjugates to 
penetrate through compromised skin barrier and gain access to the dermal capillaries. 
Recently Solid lipid nanoparticles (SLN) are gaining increasing importance as 
pharmaceutical formulations [222, 223]. Due to their small particle size, chemistry and 
consequent high surface area, they possess strong adhesive properties. Incorporation of 
antibacterials into the solid lipid matrix offers protection against chemical degradation of 
the active compound, as well as allowing either immediate or sustained release, depending 
upon the application [224]. Sustained release is important with antibacterials that are 
irritating at high concentrations or when a supply to the skin over a prolonged period of 
time is desired, whereas immediate release can be useful to improve penetration. 
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Antibacterial activity of nisin-loaded polylactide nanoparticles against 
Lactobacillus delbrueckeii has also been evaluated [225]. In most of these cases, the role 
of nanoparticles was to provide a sustained release of the loaded drug; however, targeted 
delivery of antibiotics to infected macrophages and to liver has been utilized using 
nanoparticles and liposomes [226]
 
. The above targeting was made possible because of the 
increased uptake of polymeric nanoparticles by reticuloendothelial system. 
More recently, specific targeted delivery of polymeric nanoparticles either 
unloaded or loaded by an antimicrobial drug, to bacteria had been studied. The 
antimicrobial effect of insoluble cross-linked quaternary ammonium polyethylenimine 
(PEI) nanoparticles incorporated at 1% w/w in a resin composite was assayed and resulted 
in complete inhibition of  growth S. aureus, S. epidermidis, P. aeruginosa, E. faecalis, and 
E. coli (p < 0.0001) [227]. Mannosylated or galactosylated polystyrene latex nanoparticles 
were shown to result in agglutination of mutant strains of E. Coli overexpressing mannose 
and galactose surface receptors, respectively [228, 229].  These studies have been thus far 
restricted to model E. coli mutants; however, the authors envision development of 
nanoparticles coated by oligosaccharides that will specifically recognize desired bacterial 
strains and kill them by sticking to bacterial cell walls and causing bacterial agglutination. 
Effect of antibody-directed targeting to Gram-positive Listeria Monocytogenes has 
recently been studied by the same group for lysozyme attached to polystyrene latex 
nanoparticles simultaneously with anti- L. Monocytogenes antibody [230]. The authors 
observed significantly (p<0.05) higher antibacterial activity for nanoparticle conjugates 
containing both lysozyme and the antibody, than for free lysozyme and enzyme-
nanoparticle conjugates in the absence of the antibody at higher concentrations. 
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2.8. Enzymes as antibacterial coatings on medical devices and implants 
Bacterial adherence to an implant is a known precursor to prosthetic infection 
[231, 232]. Antimicrobial coating of medical devices/implants has recently emerged as a 
potentially effective method for preventing infections [233-236]. Several attempts have 
been undertaken to immobilize enzymes and peptides on biomedical devices and implants 
to prevent device-related infections. For a catheter surface, the coating may be retained by 
either physical adsorption or covalent attachment of the enzyme.  
Wilcox et.al immobilized synthetic antimicrobial peptide melimin on contact 
lenses by physical adsorption, and observed significantly decreased bacterial colonization 
[237]. In another embodiment, antimicrobial protein lactoferrin was also adsorbed on 
contact lenses by the same group of authors and was also found to prevent bacterial 
colonization [238]. Balaban et.al found that adsorbed dermaseptin to Dacron vascular 
grafts showed resistant to bacterial infection and demonstrated in vivo efficacy in a rat 
model [239].  Langer et al covalently attached a hybrid synthetic AMP, Cecropin-Melittin, 
to model surfaces in a highly ordered manner, and reported enhanced antibacterial activity 
in comparison to physically adsorbed and randomly immobilized peptides. Shah et.al 
performed demonstrated significant antimicrobial activity against S. aureus for 
intravenous catheters coated by physically adsorbed lysostaphin, and observed high 
efficacy [240]. DispersinB, a naturally occurring enzyme in bacteria, Actinobacillus 
actinomycetemcomitans, coated on polymer well plates, rods and catheters has been 
shown to prevent the formation of Staphylococcus epidermis biofilms [241].   
Despite such growing interest, a combination of enzymes coated on implant 
surfaces to prevent bacterial colonization and subsequent biofilm formation has not been 
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studied. DispersinB, is an enzyme that is specifically active against Staph species, 
however when used alone it can only inhibit and disperse biofilms, but not in killing of the 
bacteria, which could still persist in the blood-stream to cause infection. So, it would be 
necessary to combine enzymes such as DispersinB (antibiofilm) with antimicrobial 
enzymes and peptides such as lysozyme, lysostaphin, LL-37 etc. to not only prevent 
colonization but also lyse bacteria embedded in biofilms.  The application of enzymes and 
peptides has been shown to work synergistically against a broad spectrum of bacteria from 
various studies [102-104].  But a systematic study on combination of different enzymes 
and/or peptides coated on surfaces at different coating concentrations working 
synergistically has not been performed. Also, aspects of enzyme leaching, cytotoxicity and 
long term durability on devices for antimicrobial applications have not been studied in 
detail. With this in mind, the final goal of our project aimed to address through 
nanotechnology, all issues involved in coating of enzymes (alone or in combination) on 












SPECIFIC AIMS AND SIGNIFICANCE 
3.1. Clinical significance  
Central venous catheters are commonly used modality in hospitals and clinics for 
administration of fluids, chemotherapeutic agents, central venous pressure monitoring, 
extracorporeal treatment regimen etc. thus serving a vital role as both a therapeutic and 
diagnostic tool for monitoring of health in critically ill patients. Nearly 5 million CVCs are 
inserted annually [242].  However, central venous catheterizations are associated with 
nearly 90% of nosocomial infections and are responsible for nearly 400,000 cases per year 
in the United States [242]. Although the incidence of local or bloodstream infections 
(BSIs) associated with peripheral venous catheters is usually low, serious infectious 
complications produce considerable annual morbidity because of the frequency with 
which such catheters are used. The magnitude of the potential for CVCs to cause 
morbidity and mortality resulting from infectious complications has been estimated in 
several studies [243]. The attributable cost per infection is estimated to be ~ $45000 [244] 
and the annual cost of patient treatment with CVC-associated BSIs has gone up to $2.3 
billion [245].  
Finding an effective treatment is also difficult as S. aureus has the ability to form 
biofilms on devices, which makes it even more impenetrable for antimicrobial agents. The 
antibiotic concentrations required to kill bacteria in the biofilm is a thousandfold higher 
than that needed to kill the planktonic cells of the same species [246]. Recent prophylactic 
strategies have included precoating devices with different antibiotics [247], however the 
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occurrence of a number of multi-drug resistant strains as spurred the need for alternatives 
to antibiotic treatment. [248].  
Use of enzymes and peptides as antimicrobial coatings on surfaces has prevented 
device-associated infections [79-81]. The use of nanoparticles (NPs) as surfaces for 
enzyme immobilization offers several important advantages over the use of purely enzyme 
based coatings.  Inherent physiochemical properties of NPs. can be used to improve 
activity of the enzymes immobilized on them [249]. Although coating medical devices and 
implants with plain antimicrobial enzymes could work just as effectively, coating catheter 
surfaces with enzyme-NP conjugates may be advantageous due to larger surface area for 
effective enzyme coating, higher stability, durability and lower enzyme leaching. However 
it is important to characterize enzyme-NP conjugates by studying individually whether 
aspects of nanoparticle size, surface charge density etc. could help improve efficacy of 
enzymes for antibacterial applications.  
Our studies involve simple models for studying efficacy of enzyme-NP conjugates 
to planktonic bacteria or cell suspensions, simultaneously against that of free enzymes. 
Also, these studies will help optimize and standardize a protocol that can be used for the 
preparation and synthesis of enzyme-NP conjugates for multiple enzymes for different 
applications.  For e.g. by studying the binding yields of enzymes at different NP: enzyme 
ratios, we can understand the binding affinities for each of the enzymes to the surface of 
nanoparticles. Specific antibacterial activity assays can quickly be used to measure the 
activity of conjugated enzymes to NPs. Here it is important to clarify the difference in 
using the terms „activity‟ and efficacy of enzyme-NP conjugates. Activity of the enzyme 
refers to a specific assay that characterizes the catalytic function of the enzyme against its 
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substrate. Efficacy of enzyme-NP conjugates refers specifically to the targeting and 
antibacterial activity of the conjugates against bacterial cell suspensions.  
High antibacterial efficacy of the conjugates against planktonic cells does not 
imply high efficacy against the same bacteria in colonies, as different factors may control 
activities in these cases. Therefore, it is necessary to perform in vitro experiments in order 
to evaluate the inhibition and disruption of bacteria grown on a surface.  Various 
combinations of enzymes have been studied for the disruption and destruction of bacterial 
biofilms [106]. This requires a minimum of two enzymes, one enzyme for disruption of 
the biofilm matrix and a second enzyme with bactericidal activity. Conjugation of these 
enzymes to the surface of the same catheter could address the problems associated with 
this application. We chose to attach enzymes to the surfaces of PLA nanoparticles, 
characterize enzyme-NP conjugates and coat catheter segments at different concentrations, 
simultaneously coating catheters with free enzymes and then evaluating the inhibition of 
S. aureus biofilms. Thus adsorption of two enzymes to the same surface could result in a 
synergistic effect that could cause inhibition and lysis of the biofilm-infected device and 
subsequently avoid the need for surgical removal of the infected device.  
Since our system will function as a blood contacting device in vivo, the sample 
coated catheters will encounter various blood plasma proteins [235]. If binding yield and 
activity of enzyme-NP conjugates coated on catheters is significantly lower than free 
enzyme coatings or enzyme leaching from the surface of the NPs is a problem, then an 
alternative strategy will be precoating the catheter segments with NPs before enzyme 
adsorption . Then, the goal of our final study will be comparison of in vitro performance 
for plain and NP coated catheter segments coated by antimicrobial enzymes.  
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3.2. Specific aims  
Specific aim I. Effect of charge-directed targeting on antibacterial activity using 
enzyme-nanoparticle conjugates of lysozyme to Micrococcus lysodeikticus 
Hypothesis: Use of antimicrobial enzymes attached to nanoparticles is of special 
interest alternative to antibiotics to treat microbial infections.  Special properties of the 
carrier can be used to improve targeting and activity of the conjugated enzyme. Here, we 
decided to show in a model system that nanoparticle charge can be used to enhance 
delivery of lysozyme to the cells of its natural substrate, Micrococcus lysodeikticus and 
significantly improve its lytic activity. Hen egg lysozyme was covalently attached to two 
types of polystyrene latex nanoparticles: positively charged, containing aliphatic amine 
surface groups, and negatively charged, containing sulfate and chloromethyl surface 
groups. Covalent conjugation of lysozyme to each of these groups was achieved either by 
direct conjugation or by using PEG spacers. Our study aimed at comparing the lytic 
activity of these enzyme-nanoparticle conjugates with that of free enzyme using either 
bacterial or low molecular weight substrates. The effect of attaching PEG spacers and 
method of enzyme purification from nanoparticles (through dialysis and centrifugation) on 
enzyme activity was also studied [250].  
Specific aim II. Effect of antibody-directed targeting on antibacterial activity using 
enzyme-nanoparticle conjugates of lysostaphin to Staphylococcus aureus 
Hypothesis: Our previous study clearly illustrated that physiochemical properties 
of nanoparticles can be used to help improve targeting of enzymes to bacterial cells. 
Lysozyme shows little or no antibacterial activity by itself against S .aureus [251]. 
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However, lysostaphin is an antibacterial enzyme which specifically cleaves cross-linked 
pentaglycine bridges in the peptidoglycan of S. aureus, thereby hydrolyzing the cell wall 
and lysing the bacteria [252]. We decided to study and compare the antimicrobial activity 
of lysostaphin adsorbed on the surface of PLA (poly (lactic acid)) nanoparticles and 
compare the activity of immobilized lysostaphin to that of the free enzyme. Enhanced 
antimicrobial efficacy against Gram-positive Listeria monocytogenes has been previously 
demonstrated for lysozyme co-immobilized with anti- L. monocytogenes antibody on 
polystyrene latex NPs for applications in storage and food packaging [230]. However, a 
systematic study of activity of targeted enzyme-NP conjugates with different enzyme and 
antibody loadings against clinically relevant pathogens has not been performed previously. 
With this in mind, the goal of the present work was a detailed study of antimicrobial 
activity of targeted (lysostaphin-antibody-NPs) and untargeted (lysostaphin-NPs) 
conjugates against S. aureus at different enzyme and antibody ratios.  
Specific aim III. Evaluation of antimicrobial activity of lysostaphin coated hernia repair 
meshes  
Hypothesis: The goal of the earlier proposed work was to initially show a proof of 
concept where we could achieve enhanced antibacterial efficacy through targeted delivery 
of enzymes using polymer nanoparticles to cell suspensions (model for planktonic or free 
floating bacteria) in vitro (Specific aim I and II). Bacteria can either colonize the implant 
surface or exist in a planktonic free floating form. Hence we had initially proposed to use 
enzymes and enzyme-NP conjugates as surface coatings for indwelling medical devices 
and implants to inhibit bacterial adhesion and subsequent colonization. But as mentioned 
earlier, high activity of enzymes of conjugates enzymes to bacterial cell suspensions does 
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not imply high activity against colonized bacteria, as different factors may control 
activities in these cases.  
Therefore, it was necessary to perform in vitro experiments in order to evaluate the 
inhibition bacteria adhering to a surface and then expand these studies to test and compare 
the antimicrobial activity and antibiofilm activity of devices coated by enzymes and 
enzyme-NP conjugates. However, the studies required to characterize and evaluate 
enzymes and enzyme-NP conjugates coated on implant surfaces are slightly different 
compared to studies characterizing enzymes conjugated to nanoparticles. Therefore, 
before embarking on this study, we decided to study and characterize antimicrobial 
activity of enzyme adsorption to implants and also evaluate inhibition of bacterial 
colonization.  
The objective of this study was to evaluate the in vitro antimicrobial antimicrobial 
susceptibility of S. aureus to lysostaphin-coated hernia repair polymer meshes and study 
the effect of enzyme coating concentration on antimicrobial activity. A pilot in vivo study 
was also performed by our collaborators at Carolinas Medical Center to study dose-
dependence on antimicrobial activity of lysostaphin-coated meshes using in a rat hernia 
repair model.  
Specific aim IV. Application of enzymes as antibacterial coatings on plain and 
nanoparticle coated catheter segments 
  Hypothesis: We had initially proposed to study and characterize the in vitro 
antimicrobial and antibiofilm efficacy of Central venous catheters segments coated with 
enzyme-NP conjugates and free enzymes. Different coating concentrations were estimated 
in order to optimize the bound weight of enzyme-NP per specific surface area to the bound 
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concentration of plain enzyme for the catheter segment from the same batch. Synthesis of 
enzyme-NP conjugates were done via coadsorption of two model enzymes, DispersinB 
(antibiofilm) and lysostaphin (antimicrobial) on the surface of Poly ((lactic 
acid))nanoparticles. However, we were not able to achieve higher loading via adsorption 
of enzyme-NP conjugates on the surface of 1 cm catheter segments compared to plain 
enzyme adsorption. We hypothesized that coating by enzymes interfered with nanoparticle 
attachment and lead to reduced adsorption.  
We therefore proposed an alternative strategy, which involved: a) Initial coating of 
the catheter segments by nanoparticles and b) Coating of a series of different initial 
enzyme concentrations (same set) on the surface of both plain and NP coated catheter 
segments. Through this method, we also did not had to optimize enzyme adsorption 
protocols for NPs separately, achieve high monolayer coatings individually and overall 
economically it was a more feasible option.   
We performed a series of experiments to study and characterize enzyme adsorption 
to plain and Poly ((lactic acid))nanoparticles coated Polyurethane catheter segments. PLA 
nanoparticle coating on Polyurethane catheter segments were achieved via adsorption and 
surface area for plain and NP coated catheter segments was characterized using BET 
surface are analysis and SEM imaging. The enzymes used for adsorption were the same 
set of enzymes used for characterization earlier, lysostaphin (antimicrobial and 
antibiofilm) and DispersinB (antibiofilm). Binding yield of lysostaphin and DispersinB to 
plain and NP coated segments either alone or coadsorption (in the presence of the other) 
was studied for a series of different coating concentrations through BCA and fluorescence 
analysis. Adsorbed lysostaphin and DispersinB activity on catheter segments was done 
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through turbidimetric assay (antibacterial activity) and colorimetric assay respectively. 
Enzyme leaching studies were performed using 2% BSA in phosphate buffered saline 
(PBS) as a model system. Cytotoxicity of the catheter segments were evaluated using 
MTS assay with 3T3 Mouse fibroblasts as a cell model for wound healing. Antibiofilm 
efficacy of the coated catheter segments was evaluated using a methylene blue staining 
method to quantify the amount of biomass (biofilm) adhered to the surface of the catheter. 
Finally we studied long term durability testing of the coated catheter segments to evaluate 
its shelf life stability (equivalent of 4 months) for both lysostaphin and DispersinB 
adsorbed on plain and NP coated segments. Activity of enzymes was monitored similarly 
using a turbidity assay (lysosyaphin) and colorimetric assay (DispersinB) as described 
previously.  
We expect to prevent bacterial colonization and eventual biofilm formation 
through surface coating of the catheters with enzyme-nanoparticle conjugates and plain 
enzymes but not expected to treat S. aureus associated-blood stream infections. Long term 
durability of NP coated catheters is expected due to enhanced stability of adsorbed 
enzyme compared to free enzyme at same coating concentrations.  The approach to be 
developed here is universal: it can potentially be used for treatment of other medical 








CHARGE-DIRECTED TARGETING OF ANTIMICROBIAL ENZYME-
NANOPARTICLE CONJUGATES 
4.1. Introduction 
Antibiotics once were regarded as a universal antimicrobial weapon. However, 
many bacteria have developed antibiotic-resistant strains, and the number of such resistant 
species is growing quickly [253]. Alternative approaches to treat bacterial infections are 
urgently needed in healthcare facilities worldwide. Use of enzymes as antimicrobial 
agents is nature-inspired and has recently attracted much attention as an antibiotic-free 
approach to treat bacterial infections [254]. The use of antimicrobial enzymes covalently 
attached to nanoparticles is of special interest because of enhanced stability of protein-
nanoparticle conjugates and the possibility of targeted delivery. 
In recent years, much attention has been paid to the use of proteins conjugated to 
polymer colloids in biomedical applications [206-208, 255, 256] . Such colloids are easy 
to produce and can be prepared with a high degree of monodispersity [210, 211, 257, 258]. 
Colloidal nanoparticles provide an almost ideal remedy to the usually contradictory issues 
encountered in the optimization of immobilized enzymes: minimum diffusional limitation, 
maximum surface area per unit mass, and high enzyme loading [187]. Different properties 
of nanoparticles, such as size, surface charge density or density of the surface reactive 
groups can also be used to add functionality to their conjugates with biomolecules. In spite 
of tremendous interest in potential applications of protein-nanoparticle conjugates, 
systematic studies of the effect of the properties of nanoparticles on the function of the 
attached proteins have rarely been conducted.  
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Here, we study the effect of nanoparticle charge on bactericidal activity of an 
antimicrobial enzyme, lysozyme. Hen egg white lysozyme (HEWL) belongs to a 
subfamily of c-type lysozymes (chicken or conventional). HEWL has molecular weight of 
14.3 kDa and consists of 129 amino acid residues. Among these, 17 are positively charged 
(6 lysines containing free amine groups and 11 arginins) and 9 are negatively charged (2 
glutamate and 7 asparatate residues). HEWL natural substrate is peptidoglycan murein, the 
major component of the bacterial cell wall. Hydrolysis of murein results in bacterial cell 
lysis [259]. Gram-positive bacteria are generally more sensitive to lysozyme than Gram-
negative bacteria because the latter possess a protective lipopolysaccharide outer 
membrane that prevents access of lysozyme to its substrate, murein.  
In this study, we covalently attached hen egg lysozyme to two types of polystyrene 
latex nanoparticles: positively charged, containing aliphatic amine surface groups, and 
negatively charged, containing sulfate and chloromethyl surface groups. Covalent 
coupling to each of these groups was achieved either by direct conjugation or by using 
polyethyleneglycol (PEG) spacers. Our study aimed at comparing the activity of these 
protein-nanoparticle conjugates with that of free enzyme using either bacterial or low 
molecular weight substrates.  
4.2. Materials and methods 
4.2.1. Materials 
Hen egg lysozyme and lyophilized Micrococcus lysodeikticus were purchased from 
Sigma Aldrich (St. Lous, MO). Bis-butyraldehyde PEG cross-linker and NH2-PEG-COOH 
55 
 
cross-linker were purchased from Nektar Therapeutics, Inc. (San Carlos, CA). All other 
chemicals were purchased from Sigma Aldrich. 
Protein concentrations for binding efficiency studies were determined using BCA 
and Micro BCA assay kits purchased from Pierce Biotechnology (Rockford, IL). 
Colorimetric and turbidometric activity assays were performed using a Synergy 
microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). Spectrum/Por Biotech 
Cellulose ester membranes with 5 kDa and 100 kDa (MCWO) from Spectrum laboratories 
Inc. (Rancho Dominguez, CA) were used for dialysis.  
Protein-nanoparticle conjugates were characterized by zeta potential measurements 
using a ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY).  The samples 
containing protein-nanoparticle conjugates were diluted 1:100 in 6 mM potassium 
phosphate buffer to obtain the appropriate particle concentration. Data presented are the 
average of the measurements of three sample replicates each reproduced four times. The 
protein-nanoparticle conjugates were characterized using Dimension III Atomic Force 
Microscope (AFM) with Nanoscope 4 controller (Vecco Instruments, Santa Barbara, CA). 
AFM experiments were conducted in tapping mode in ambient conditions using 
rectangular cantilevers backside-coated with aluminum with a spring constant of ~40 N/m 
(Mikromasch Inc., Chapel Hill, NC). For sample preparation, a silicon substrate surface 
was sonicated in reagent-grade ethanol and then rinsed copiously with HPLC-grade water. 
A 10-15 L drop of nanoparticle suspension was placed on the substrate surface, 




4.2.2.1. Preparation of protein-nanoparticle conjugates.  
The polystyrene nanoparticles used in all experiments were purchased from 
IDC.(Interfacial dynamics Corporation, Eugene, OR) and contained monodisperse 
particles with a diameter close to 20 nm. Positively-charged nanoparticles surface-
modified with aliphatic amine groups and negatively-charged nanoparticles surface-
modified with chloromethyl and sulfate groups were used in this study.  
 
The properties of the nanoparticles, as provided by the manufacturer, are highlighted in 
Table 4.1. above.  
Polystyrene nanoparticles are supplied as a stable suspension in solution 
containing a proprietary surfactant. To remove the surfactant, this suspension was purified 
by dialysis using a membrane with the 5 kDa molecular weight cutoff. Approximately 1 
mL of the suspension was diluted two-fold by 2 mM MES buffer and loaded into the 
dialysis tubing. The tubing was then clamped on both ends using dialysis membrane 
















































































performed overnight at room temperature; the entire dialysate was stirred continuously 
and changed after 2-4 hours, 6-8 hours and 10-14 hours.  Sample recovery was done by 
removing it from the tubing with a micropipette. The volume of dialysate did not change 
significantly after dialysis. Dialyzed sample was then sonicated for 30 min to destroy 
aggregates. 
4.2.2.2. Protein conjugation to aminated nanoparticles 
 In the case of direct conjugation of lysozyme to the amine-modified nanoparticles 
(Figure 4.1.A), dialyzed nanoparticles were again diluted two-fold in 2 mM MES buffer 
(pH=5.0) to the final concentration of ~7.8·10
14
 particles per mL. An 8 wt. % solution of 
glutaralehyde in 2 mM MES buffer was then added to the diluted nanoparticle suspension 
to achieve a final glutaraldehyde concentration of 1 wt. %. A 100 mM solution of sodium 
cyanoborohydride, Na[BH3(CN)] (Caution: foul odor; should be used in a chemical hood 
only), in 2 mM MES was added to the sample immediately after glutaraldehyde. Final 
concentration of sodium cyanoborohydride in the suspension was 10 mM. The amine 
groups on the surface of the particles react with the aldehyde moieties to form Schiff‟s 
base intermediates, which are then selectively reduced by sodium cyanoborohydride.  
After 7 h incubation at room temperature, the unreacted glutaraldehyde and 
Na[BH3(CN)] were separated by dialysis using a procedure similar to that described 
above. A cellulose ester membrane with a molecular weight cutoff of 5 kDa was used for 
dialysis. Six lysozyme solutions with concentrations of 2.94, 29.4, 73.6, 147.2, 220.8 and 
294.4 g/mL were prepared in 2 mM MES buffer at pH 5.0 from a 5 mg/mL lysozyme 
stock solution. These concentrations were chosen so that to achieve initial lysozyme-to-
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nanoparticle ratios of 1:1, 10:1, 25:1, 50:1, 75:1, and 100:1 enzyme molecules per 
nanoparticle, respectively.  
100 L of purified nanoparticle suspension (~6.2·10
13
 nanoparticles) was added to 
0.5 mL of each of the protein solutions. The mixtures were incubated overnight at room 
temperature with gentle stirring.  The protein-nanoparticle mixture was then treated with 
0.1% Tween 20 for 2 h to remove any physically adsorbed enzyme. The unbound protein 
along with the excess Tween 20 was then separated by either centrifugation or dialysis. In 
the case of centrifugation, the suspensions were centrifuged at 13,000 g for 75 minutes. 
The pellet was resuspended in 2mM MES buffer and centrifuged again. The supernatant 
was collected in both steps to quantify the unbound protein. Separation by dialysis was 
done similarly to dialysis of free nanoparticles described above. A cellulose ester 
membrane with a MWCO of 100 kDa was used for dialysis to separate any unbound 
lysozyme (molecular weight 14.3 kDa).  
Bis-butyraldehyde PEG spacers (O=CH-CH2-CH2-CH2-(PEG)n-CH2-CH2-CH2-
CH=O, MW 3,700) were also used for conjugation of lysozyme to aliphatic amine 
particles (Figure 4.1.B). Since attachment via PEG spacers minimizes interactions of 
immobilized protein with the support [170, 260], lysozyme conjugated to nanoparticles via 
PEG spacers was expected to show higher enzymatic activity. The conjugation protocol, 
enzyme and nanoparticle concentrations, and purification methods were similar to those 
described above for the glutaraldehyde-based attachment. Final concentration of bis-
butyraldehyde PEG spacers was 25 mg/mL in all experiments. It should be noted that the 
use of butyraldehyde chemistry enables protein conjugation specifically via its N-terminus 
if the reaction is performed at pH 5.0 [261]. 
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4.2.2.3. Protein conjugation to chloromethylated nanoparticles 
 Direct coupling of lysozyme to chlomethylated latex nanoparticles occurs via the 
reaction of the latex CH2Cl- groups with the amine groups of lysozyme to give a 
secondary amine (Figure 4.1.C). Conjugation in 2 mM MES buffer (pH = 5.0) was 
performed overnight at room temperature. Six lysozyme solutions with the concentrations 
of 8.82, 88.2, 220.5, 441, 661.5 and 882 g/mL were prepared in 2 mM MES buffer at pH 
5.0 from a 5 mg/mL lysozyme stock solution. The dialyzed chloromethylated particles 
suspension was diluted two-fold in 2 mM MES buffer, and 80 L of this suspension 
(~1.9·10
14
 particles) was added to 0.5 mL of each of the protein solutions. Lysozyme 
concentrations were chosen to achieve initial lysozyme-to-nanoparticle ratios of 1:1, 10:1, 
25:1, 50:1, 75:1, and 100:1 protein molecules per nanoparticle, respectively. To remove 
any physically adsorbed lysozyme, samples were treated with 0.1% Tween 20, and the 
protein-nanoparticle conjugates were separated by either centrifugation or dialysis.  
For conjugation via a spacer, a bifunctional NH2-(PEG)n-COOH (MW 3,400) spacer 
was employed. Dialyzed nanoparticle suspension was mixed with the spacer solution in 




; and final 
concentration of the NH2-(PEG)n-COOH spacer was 5 mg/mL. The nanoparticle/spacer 
mixture was incubated overnight at room temperature with gentle stirring. The amine 
group of the spacer reacts with the chloromethyl group on the nanoparticles (Figure 4D). 
The excess spacer was then separated by dialysis using 5 kDa MWCO membrane. 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) chemistry 
(Hermanson. 1996) was used to conjugate lysozyme to the PEGylated nanoparticles. First, 
25 mg/mL EDAC solution in 2 mM MES buffer was added to the dialysed nanoparticles 
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suspension (final EDAC concentration was 5 mg/mL). After 10 min incubation, 
nanoparticles with activated carboxyl groups were added to lysozyme solutions. 
Lysozyme and nanoparticle concentrations were the same as used for direct attachment to 
chloromethylated particles. After treatment with Tween 20, unbound lysozyme, as well as 
excessive reagents and reaction products, were separated by either centrifugation or 
dialysis with a 100 kDa MWCO membrane. 
 
Figure 4.1. Schematic of protein conjugation to nanoparticles. (A) Direct 
conjugation to aminated nanoparticles. (B) Conjugation to aminated nanoparticles 
via bis-butyraldehyde PEG spacer. (C) Direct conjugation to chloromethylated 
nanoparticles. (D) Conjugation to chloromethylated nanoparticles via NH2-PEG-
COOH spacer.  
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4.2.2.4. Binding yield study 
The number of bound lysozyme molecules per nanoparticle was determined as follows. 
Samples with initial lysozyme concentrations corresponding to 1, 10, 25, 50, 75, and 100 
molecules per nanoparticle were prepared. After the conjugation step, samples were 
treated with Tween 20 to remove any non-covalently adsorbed protein and centrifuged at 
13,000 g for 75 min. The clear supernatant was then collected and BCA protein assay was 
used to determine the concentration of the unbound protein in the supernatant. Lysozyme 
standards were prepared by diluting 5 mg/mL lysozyme stock solution in 2 mM MES 
buffer containing 0.1% of Tween 20. The amount of bound protein was found from the 
difference between the initial and unbound protein concentrations. Each of the 
experiments on determination of binding efficiency was reproduced three times with 
independently synthesized samples.  
4.2.2.5.Enzyme activity assay with bacterial substrate 
Protein-nanoparticle conjugates prepared from the suspension with the initial 25:1 
lysozyme:nanoparticle ratio were used for all enzyme activity assays and for zeta-potential 
measurements. A turbidometric enzyme activity assay was performed by monitoring the 
decrease in optical density of an aqueous suspension of a natural substrate for lysozyme, 
Micrococcus lysodeikticus, in potassium phosphate buffer. Micrococcus lysodeikticus was 
preferred to other Gram-positive species because it is routinely used as a substrate for 
assaying lysozyme activity (Shugar 1952). A 6 mM solution of potassium phosphate was 
prepared by dissolving 0.898 g of potassium dihydrophosphate in 1 L of deionized water. 
The pH of the solution was adjusted to 6.2 using a 0.1 M solution of potassium hydroxide. 
A 0.018 wt. % suspension of Micrococcus lysodeikticus was prepared by suspending 3.75 
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mg of lyophilized cells in 20 mL of 6 mM potassium phosphate buffer solution. Protein-
nanoparticle conjugates were then added to the bacterial suspension; net concentration of 
lysozyme in all final mixtures was adjusted to 8.3 g/mL. Samples were incubated in a 12-
well microplate at room temperature, and the decrease in optical density at 405 nm was 
monitored as a function of time. Initial rates of the reactions were calculated from the 
slopes of the linear initial parts of the kinetic curves. Two independently synthesized 
samples were studied for each type of nanoparticles. Control experiments were performed 
with free lysozyme at the same enzyme concentration as in the samples. All kinetic 
experiments were reproduced in triplicate. 
4.2.2.6. Enzyme activity assay with a low molecular weight substrate 
 Lysozyme activity was also determined colorimetrically using a neutral oligosaccharide 
substrate for lysozyme, p-nitrophenyl penta-N-acetyl-ß-chitopentaoside, PNP-(GlcNAc)5, 
and was based on a coupled reaction with NAHase [262]. A 10 mM solution of PNP-
(GlcNAc)5 at pH 6.2 was prepared by dissolving 1.5mg/mL PNP-(GlcNAc)5 in 6 mM 
potassium phosphate buffer. Lysozyme cleaves the first glycosidic bond of PNP-
(GlcNAc)5, giving the monochitoside, PNP-GlcNAc. NAHase [purchased as a suspension 
in 2.5 M (NH4)2SO4 containing 1.2 mg protein/mL and diluted 1:100 in 6 mM phosphate 
buffer] then catalyzes the release of the chromogen, p-nitrophenol, from the PNP-GlcNAc. 
Addition of 50 mM Na2CO3 stops the reaction and yields a yellow color from the released 
p-nitrophenolate. For activity measurements, 50 L sample aliquots were incubated with 
150 L of PNP-(GlcNAc)5 and 10 µL of NAHase at 37C in a 96 microplate well. Six 
reaction wells were prepared for each sample. Every 30 minutes, 100 µL of a 50 mM 
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Na2CO3 was added to one of the wells, and the absorbance at 405 nm was measured using 
a microplate reader, while the reaction was allowed to continue in the other wells. Six time 
points were taken for each sample. From these points, initial rates were determined and 
used as a measure of enzyme activity. Two independently synthesized samples were 
studied for each type of nanoparticles. Control experiments were performed with free 
lysozyme at the same enzyme concentration as in the samples. All kinetic experiments 
were reproduced in triplicate. 
4.3. Results  
4.3.1. Yield of binding. 
Figure 4.2 shows efficiency of binding of lysozyme to polystyrene latex nanoparticles 
without PEG spacers. In the case of attachment via PEG spacers, binding yields are 
similar to those shown in Fig. 2. Binding yield in the case of aminated particles is in both 
cases lower than that for their negatively charged counterparts. We speculate that this 
difference is primarily due to electrostatic effects. The initial step of covalent attachment 
of lysozyme to nanoparticles involves its physical adsorption (Suen and Morawetz 1985; 
Sarobe et al. 1998; Molina-Bolivar and Galisteo-Gonzales 2005; Giacomelli et. al 2000). 
This adsorption is primarily determined by the interactions of the hydrophobic parts of 
lysozyme molecules with the hydrophobic surface of polystyrene latex. However, it can be 
expected that more positively charged lysozyme molecules (pI=10.6) can be adsorbed to a 
negatively charged surface, than to a positively charged surface. This difference in the 
initial physical adsorption results in different binding efficiency. Notably, a theoretical 
monolayer of lysozyme on a 20 nm spherical particle calculated from the dimensions of 
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the lysozyme molecule (2.5 nm X 3.5 nm X 3.5 nm) should consist of ~120 molecules per 
nanoparticle [263]. 
 
Figure 4.2. Efficiency of covalent attachment of lysozyme to polystyrene latex 
nanoparticles for samples prepared by (A) direct conjugation and (B) conjugation 
via PEG spacers. Black squares correspond to aminated nanoparticles and red 
circles correspond to chloromethylated nanoparticles, respectively. 
At high initial lysozyme concentrations, the number of attached lysozyme 
molecules exceeds the number of chloromethyl groups available for attachment (see Table 
4.1). However, it should be noted that lysozyme tends to form oligomers (dimers and 
tetramers) at pH>4.0 [264]. The degree of oligomerization can also be affected by 
interaction with polystyrene latex particles. The observed excessive conjugation is 
consistent with the attachment of oligomers. Possible presence of physically adsorbed 
lysozyme that cannot be removed by treatment with 0.1% Tween 20 also cannot be 
completely ruled out. It should be noted, however, that according to the literature data 
(Peula et al. 1995), treatment by Tween 20 removes 75 - 85 % of physically adsorbed 
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protein from polystyrene latex microspheres. We observed binding yields of ~80% in the 
case of lysozyme attachment to chloromethylated nanoparticles after treatment with 
Tween 20. It is thus unlikely that non-covalent adsorption of lysozyme plays an important 
role in the observed phenomenon. 
4.3.2. Bacterial turbidometric activity assay 
Protein-nanoparticle conjugates prepared from the suspension with the initial 25:1 
lysozyme: nanoparticle ratio were used for all enzyme activity assays. A bacterial 
turbidometric activity assay was performed by monitoring the decrease in optical density 
of an aqueous suspension of Micrococcus lysodeikticus. Lysozyme cleaves the β (1-4)-
glycosidic bond between N-acetylmuramic acid (MurNAc) and the N-acetyl-D-
glucosamine (GlcNAc) in the polysaccharide that forms the backbone of the bacterial cell 
walls. This cleavage is the first step in the lysis of bacterial cells. The degree of lysis is 
measured as reduction in turbidity of the bacterial suspension (Shugar 1952). We 
monitored the decrease in optical density at 405 nm for two sets of samples: a) samples 
purified by centrifugation and b) samples purified by dialysis. To take into account 
possible precipitation of bacteria from the suspension, the turbidity of the bacterial 




Figure 4.3. Results of bacterial lysis assay. (A) Direct attachment of lysozyme to 
nanoparticles; samples purified by centrifugation, (B) attachment via PEG spacer; 
samples purified by centrifugation, (C) Direct attachment of lysozyme to 
nanoparticles; samples purified by dialysis, and (D) attachment via PEG spacer; 
samples purified by dialysis. Black squares – lysozyme attched to positively 
charged nanoparticles; red circles – lysozyme attached to negatively charged 
nanoparticles, blue triangles – free lysozyme. 
In the first set of samples, the final step of purification of protein-nanoparticle 





lysozyme directly conjugated to nanoparticles to that of free lysozyme. The initial rate of 
the lysis reaction was calculated from the slopes of the linearized kinetic curves. We 
observed significantly faster bacterial degradation for lysozyme conjugated to aminated 
nanoparticles (Table 4.2). Bacterial lysis rates for lysozyme conjugated via PEG spacer 
were not significantly different from those observed for lysozyme directly attached to the 
same type of nanoparticles.  
Sample 
Initial rate from linearized slopes for 
sample purified by 
dialysis centrifugation 
Free lysozyme 4.90.1 · 10
-4 
 




 7.00.1 · 10
-4
 
Lysozyme conjugated to aminated 
nanoparticles via PEG spacer 
9.30.2 · 10
-4
 6.50.1 · 10
-4
 




 2.40.1 · 10
-4
 
Lysozyme conjugated to chloromethylated 
nanoparticles via PEG spacer 
2.40.1 · 10
-4




Table 4.2. Initial rates of the bacterial lysis study for samples purified by dialysis and 
centrifugation 
In an another study, we also studied the effect of controls, positively charged aliphatic 
amine and negatively charged chloromethylated nanoparticles on lytic activity of 
Micrococcus lysodeikticus.. No detectable lytic activity was observed for any of the 
controls. Figure 4.4 compares the rates of bacterial lysis for both types of polystyrene 




Figure 4.4. Results of bacterial lysis assay. Pink circles – Aliphatic amine 
nanoparticles; Light Blue squares – Chloromethyl nanoparticles, Yellow squares – 
Control bacterial cells. 
We also studied the effect of purification method on the activity of the conjugates. 
The unbound protein was separated from protein-nanoparticle conjugates by either 
dialysis or centrifugation. Figure 4.3 (B) shows results of bacterial lysis assay for samples 
purified by centrifugation, and Figure 4.3 (A) shows the data for samples purified by 
dialysis. Table 4.2 summarizes results of bacterial lysis assay. As can be seen from Table 
4.2, dialyzed samples always show slightly higher bacterial lysis rates than those purified 
by centrifuging. A possible explanation of the effect of purification method is higher 
degree of nanoparticle aggregation in the case of centrifugation. As a result of 
aggregation, some lysozyme molecules can be trapped inside the aggregates and blocked 
from the interaction with their substrate. Figure 4.5 compares representative AFM images 
of lysozyme conjugated to aminated nanoparticles and purified by dialysis (Fig. 4.3A) or 
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centrifugation (Fig. 4.3B). As can be seen from Fig.4.5, much larger aggregates are 
observed in the case of samples purified by centrifugation. Since samples purified by 
dialysis showed higher activity than those purified by centrifugation, dialysis has been 
used as the primary purification method in all further experiments. 
 
Figure 4.5. Tapping mode AFM images comparing the degree of aggregation for 
samples purified by dialysis and centrifugation. Scan size is 5 m x 5 m and Z 
scale is 100 nm. (A) Lysozyme conjugated to aliphatic amine nanoparticles after 
purification by dialysis and (B) lysozyme conjugated to aliphatic amine 
nanoparticles after purification by centrifugation. 
4.3.3. Enzyme activity assay with a low molecular weight substrate 
PNP-(GlcNAc)5 is a chromogenic pentachiteoside that serves as an alternative substrate 
for lysozyme [265, 266]. The color is produced by free p-nitrophenol (PNP), liberated 
from PNP-(GlcNAc)5 through a coupled reaction of lysozyme and NAHase. First, 
PNP-(GlcNAc)5 is cleaved by lysozyme at the first glycosidic linkage, releasing 
monochiteoside PNP-GlcNAc [266]. The presence of NAHase is essential for the assay to 




increases the pH of the reaction mixture, stops the reaction and reveals the yellow color of 
PNP.  
 
Figure 4.6. Lysozyme activity assay with low molecular weight substrate 
PNP-(GlnAc)5. (A) Direct attachment and (B) attachment via PEG spacer. Black 
squares – lysozyme attached to positively charged nanoparticles; red circles – 
lysozyme attached to negatively charged nanoparticles, blue triangles – free 
lysozyme. 
Figure 4.6 shows the results of the assay with PNP-(GlcNAc)5. In this case, free 
lysozyme shows higher activity than lysozyme conjugated to both types of nanoparticles. 
The difference between the activities of lysozyme attached to aminated and 
chloromethylated nanoparticles is much less pronounced than in the case of bacterial lysis 
assay. To obtain numerical values of kinetic constants, kinetic curves were empirically 





Sample Initial rate from linearized 
slopes 
Free enzyme 5.10.5 · 10
-3
 
Lysozyme directly conjugated to aminated nanoparticles 4.40.3 · 10 
-3
 










Lysozyme conjugated to chloromethylated nanoparticles 
via PEG spacer 




Table 4.3. Initial rates of enzyme activity with low molecular weight substrate for  all 
samples  
4.3.4. Zeta potential analysis 
Zeta potential studies were performed to characterize electrostatic properties of 
colloidal suspensions used in this study. Table 4.4 shows zeta potential values averaged 
over 4 independent experiments for each of the samples. As expected, Micrococcus 
lysodeikticus in aqueous suspension has highly negative zeta potential. Highly positive 
zeta potentials are observed for aminated nanoparticles; zeta potential values slightly 
decrease upon direct coupling of lysozyme and further decrease upon protein conjugation 
via bis-butyraldehyde spacers.  
It is currently not clear why conjugation of positively charged lysozyme to positively 
charged nanoparticles reduces their zeta-potential. One possible explanation of this fact is 
increase of hydrodynamic resistance of the conjugates. Presence of a “fluffy” lysozyme 
layer may decrease electrophoretic mobility of nanoparticles. Since the absolute value of 
zeta-potential is proportional to the electrophoretic mobility, this will result in the decrease 
of zeta-potential. This explanation is in agreement with the observed higher drop of zeta-
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potential for the case of lysozyme attached to nanoparticles via PEG spacers, in which 
lysozyme has even more spatial freedom. Notably, even in the latter case zeta potential 
remains highly positive and significantly exceeds that of free lysozyme. Stronger 
electrostatic interactions resulting in more effective delivery can thus be expected between 










Table 4.4 - Results of zeta potential measurements.  
Bare chloromethylated nanoparticles have highly negative zeta potential. Its absolute 
value decreases upon direct coupling of lysozyme and further decreases upon coupling of 
lysozyme via PEG spacers, consistent with the hypothesis of decreased electrophoretic 
mobility of the particles upon protein attachment. Yet for all protein conjugates with 
chloromethylated particles zeta potential remains highly negative hindering their 
interactions with the bacteria. 
Sample Zeta potential, 
mV 
Bare aminated nano-particles (control) + 37.3  1.1 
Lysozyme directly conjugated to 
aminated nanoparticles 
+ 31.5  1.7 
Lysozyme conjugated to aminated 
nanoparticles via PEG spacer 
+ 27.2  1.7 
Bare chloromethylated nanoparticles 
(control) 
- 43.3  1.5 
Lysozyme directly conjugated to 
chloromethylated nanoparticles 
- 32.0  1.6 
Lysozyme conjugated to 
chloromethylated nanoparticles via PEG 
spacer 
- 25.0  1.4 
Bacterial substrate - 27.8  1.1 




Electrostatic interactions play an important role in targeting lysozyme to its 
substrate bacteria [267-271]. Lysozyme has pI of 10.6 [271] and therefore bears 
significant positive charge (+8 or +9 per molecule) at neutral pH [272]. Most bacterial cell 
walls, on the other hand, are negatively charged due to the presence of teichoic, 
lipoteichoic, and teichuronic acids in the cell membrane [273, 274].  
Previous results indicate that positive charge is essential for lysozyme‟s 
antibacterial function but not to activity towards low molecular weight substrates. 
Acetylation of all six free lysine residues of lysozyme abolished action towards 
Micrococcus lysodeikticus but did not affect the cleavage of the tetramer of N-
acetylglucosamine, (GlnAc)4, from chitin [275]. T4 bacteriophage lysozyme lost > 90% of 
its native activity in bacterials lysis assay with Micrococcus lysodeikticus when adsorbed 
onto 9 nm silica nanoparticles, which are strongly negatively charged [276]. At the same 
time, lysozyme adsorbed onto similarly negatively charged silica nanoparticles (4, 20, and 
100 nm in diameter) retained ~ 80% of its native activity when assayed with a neutral 
substrate, PNP-(GlnAc)5 [263].  
The results of this study indicate that nanoparticle charge can be used to control 
bacteriolytic activity of lysozyme. Lysozyme attached to positively charged nanoparticles 
shows significantly higher activity in bacterial lysis assay than free lysozyme. The 
observed effect is probably due to the differences in targeting of the enzyme to negatively 
charged bacterial cell walls (Figure 6) because similar activities are observed for lysozyme 
attached to both positively and negatively charged nanoparticles when assayed with a 
neutral low molecular weight substrate, PNP-(GlnAc)5. These activities are somewhat 
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lower than that of free enzyme, consistent with the previous data [276-279] on decreased 
activity of immobilized enzymes due to conformational changes arising from the 
interactions with nanoparticle surface and partial screening of the active site by the 
nanoparticle.   
 
Figure 4.7 shows charge-directed targeting of lysozyme to bacterial cell walls 
The hypothesis of electrostatic contribution to targeting nanoparticles to bacteria is 
confirmed by zeta-potential measurements, which show negative zeta potential for 
Micrococcus lysodeikticus suspension and lysozyme conjugated to negatively-charged 
nanoparticles, but a positive zeta potential for free lysozyme and lysozyme attached to 
positively-charged nanoparticles. Notably, zeta potential for lysozyme attached to 
positively charged nanoparticles is more positive than that of free lysozyme, in good 
agreement with the observed higher activity of the former. On the other hand, electrostatic 
interaction is probably not the only factor that mediates targeting of lysozyme to bacterial 
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cells because lysozyme attached to negatively-charged particles also shows some 
bacteriolytic activity in spite of the fact that these nanoparticles should be electrostatically 
repelled from bacterial cell walls. 
Another important result of this study is the development of a protein attachment 
protocol that minimizes nanoparticle aggregation. Aggregation often has been observed 
previously [280-282]and presents a serious problem for the use of nanoparticles in 
biomedical applications because of the uncontrollable size of the aggregates and 
broadening of the distributions of their functional properties. Here, we observed that 
samples with higher degree of aggregation show decreased enzymatic activity of the 
immobilized protein. The protocol developed in this work uses small amount of surfactant, 
Tween 20, to remove non-covalently bound protein and employs dialysis for purification 
from unbound proteins and small molecules. Optimization of the concentrations of the 
components enabled us to significantly reduce degree of aggregation, as can be seen from 
representative AFM images in Figure 4.5. 
We also studied the effect of attachment via PEG spacers on enzymatic activity of 
lysozyme. No significant difference in activity has been observed for lysozyme attached 
via a spacer compared to lysozyme directly attached to nanoparticle surface. This result 
was somewhat contradictory to our expectations because previous research [170, 260] 
demonstrated a beneficial effect of attachment via spacer on activity of immobilized 
enzymes. This effect was attributed to reduced interaction of the enzyme with the surface 
of its support due to the presence of the spacer. However, lysozyme is known to be a 
“rigid” enzyme [283], which reluctantly changes its structure. In addition, we use Tween 
20, which blocks the hydrophobic polystyrene surface and produces oligoethyleneglycol-
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terminated surface. Thus, interaction of lysozyme with the nanoparticle surface is likely to 
be reduced even in the case of direct conjugation due to the presence of Tween 20. This 
agrees well with the small drop in enzymatic activity of the protein-nanoparticle 
conjugates, as compared to free lysozyme, in the assay with PNP-(GlnAc)5. Therefore, use 
of PEG spacers does not have a considerable effect on enzymatic activity of lysozyme.  
In conclusion, nanoparticle charge has been used to controllably change activity of a 
covalently immobilized protein. Enhanced charge-directed targeting of lysozyme-
nanoparticle conjugates to bacteria was achieved using positively charged aliphatic amine 
nanoparticles as the protein carriers. This result can be useful for development of 


















ANTIBODY-DIRECTED TARGETING OF LYSOSTAPHIN ADSORBED TO 
POLYLACTIDE NANOPARTICLES INCREASES ITS ANTIMICROBIAL 
ACTIVITY AGAINST S.AUREUS IN VITRO 
5.1. Introduction 
Staphylococcus aureus is a versatile and virulent Gram-positive pathogen that is 
frequently found among clinical isolates from patients in the United States. It is capable of 
causing a wide range of infections, being one of the major causes of bacteremia and is 
associated with significant mortality [39]. It produces a variety of virulence factors, with 
both structural and secreted products playing a role in the pathogenesis of infection. The 
rates of infections caused by both community and hospital-acquired strains are increasing 
steadily and treatment of these infections through conventional antibiotic therapy is 
becoming more and more difficult because of the increasing prevalence of multidrug-
resistant strains [44]. The decreased effectiveness of current antibiotic treatments due to 
resistance has spurred the search for alternative approaches to antimicrobial therapy.  
Currently, much attention is paid towards the use of natural antimicrobial proteins 
and peptides as antibacterials to overcome the problems associated with antibiotic 
resistance [284]. Naturally occurring antimicrobial peptides and enzymes are characterized 
by high activity, broad antimicrobial spectrum, and low rates of resistance [285, 286]. 
Lysostaphin is an antimicrobial enzyme produced by Staphylococcus staphylolyticus. It 
belongs to the class of Endopeptidases, which specifically cleave cross-linked 
pentaglycine bridges in the peptidoglycan of S. aureus, thereby hydrolyzing the cell wall 
and lysing the bacteria [287].   
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In spite of the great enthusiasm regarding the prospect of developing antibacterial 
enzymes and peptides as a new generation of antibacterial agents, they are still at an early 
stage of technologic maturation, and many hurdles have yet to be overcome [288]. 
Because of their peptidic nature, they could present the following problems: 1) short half 
life in vivo, 2) loss of activity in physiological conditions (especially at high ionic 
strength, which may interfere with their charge-directed targeting and mechanism of 
action), 3) toxicity and immunogenicity, 4) poor storage stability, and 5) interference with 
normal bacterial flora that may arise when attempts are made to use those peptides as 
antibacterial agents (3). Availability of a technology for targeted delivery of antimicrobial 
peptides could provide a valuable contribution towards addressing most if not all of these 
problems. Most importantly, targeted delivery can improve efficacy and reduce systemic 
toxicity of antimicrobial peptides by reducing their action against non-specific targets.   
Although much work has been done recently on design of drug carriers for site-
specific delivery, studies of targeted drug delivery have been thus far primarily focused on 
anticancer drugs [289] and certain other therapeutics targeting the host cells and tissues 
[290, 291]. Much less attention has been paid up to date to studies of targeted delivery of 
antimicrobial agents. Recently, mannosylated or galactosylated polystyrene latex 
nanoparticles were shown to result in agglutination of mutant strains of E. Coli 
overexpressing mannose and galactose surface receptors, respectively [228, 229]. Targeted 
photothermal lysis of pathogenic bacteria such as Salmonella and Pseudomonas 
aergusinosa has been studied using antibody-conjugated gold nanoparticles and nanorods, 
respectively [292, 293]. Our group has previously studied charge-directed targeting of 
lysozyme conjugated to nanoparticles and demonstrated enhanced antimicrobial activity 
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against Micrococcus lysodeikticus for enzyme conjugated to positively charged 
nanoparticles [250, 294]. Enhanced efficacy against Gram-positive Listeria 
Monocytogenes has also been demonstrated for lysozyme co-immobilized with anti- L. 
Monocytogenes antibody on polystyrene latex NPs [295, 296]. However, a systematic 
study of activity of targeted enzyme-NP conjugates with different enzyme and antibody 
loadings against clinically relevant pathogens has not been performed previously. With 
this in mind, the goal of the present work was a detailed study of antimicrobial activity of 
targeted (lysostaphin-antibody-NPs) and untargeted (lysostaphin-NPs) conjugates against 
S. aureus at different enzyme and antibody ratios. 
5.2. Materials and methods 
Staphylococcus aureus (ATCC 27660) was purchased from American Type Culture 
Collection (Manassas, VA). Lysostaphin (26 kDa) isolated from Staphylococcus 
staphylolyticus was purchased from AMBI products LLC (Lawerence, NY). Poly (DL-
lactide) and Bovine Serum Albumin (BSA) were purchased from Sigma Aldrich (St. 
Louis, MO). Immunogen-specific Rabbit Polyclonal antibody to Staphylococcus aureus 
(ATCC 27660) formulated in a phosphate saline buffer (0.01M, pH 7.2) was purchased 
from ViroStat (Portland, ME). Alexa Fluor 350 and Alexa Fluor 594 Carboxylic acid, 
Succinimidyl ester dyes used for fluorescent labeling were purchased from Invitrogen, 
Molecular Probes (Carlsbad, CA).  Microsep Centrifugal Devices with a modified 
Polyethersulfone membrane (low protein binding; MWCO - 3K and 30K) used for protein 
purification were purchased from Pall Life Sciences (Ann Arbor, MI). Fluorescence and 
turbidimetric activity assays were performed using a Synergy microplate reader (Bio-Tek 
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Instruments, Inc., Winooski, VT). Particle sizing and Zeta potential analysis were done 
using a 90plus Particle Size Analyzer (Brookhaven Instruments Co, Holtsville, NY).  
5.2.1. Preparation of nanoparticles 
Polylactide nanoparticles were prepared using a nanoprecipitation method based on 
solvent diffusion. Briefly, Poly(DL-lactide) (Mw 97,500) was dissolved in 25 ml of 
acetone at a concentration of 8 mg/ml and this solution was then dispersed in an aqueous 
phase (200 ml) containing Pluronic F68 (5 mg/ml) under sonication for 15 min. The 
acetone solution was added into the aqueous phase dropwise at a uniform rate.  The 
resulting suspension containing the nanoparticles was then purified from excess of 
polymer and Pluronic by triple centrifugation followed by redispersion in DI water. 
Centrifugation was performed at 3,000 rcf for 1 hr at 25°C using Allegra™ 64R 
Centrifuge (Beckman Coulter, USA). Nanoparticle suspension in DI water was stored in 
refrigerator at 4°C. Concentration of PLA in the suspension was determined using 
gravimetric analysis. The number of nanoparticles per ml of the suspension was then 
calculated using the size of nanoparticles determined from DLS experiments (see below) 
and assuming PLA density of 1.25 g/cm
3
 [297].  
5.2.2. Fluorescent labeling of proteins 
Alexa Fluor succinimidyl ester dyes (Alexa Fluor 350 and Alexa Fluor 594) were used for 
fluorescent labeling of the antibody and lysostaphin, respectively.  The dyes react with the 
primary amines of proteins at pH 7.5–8.5 yielding stable conjugates [298]. Approximately 
1 μg of Alexa Fluor 350 (ε 19,000) was dissolved in 100 μl of dimethylformamide and 25 
μl of the solution was then added to 2 ml of a 1 mg/ml solution of S. aureus antibody in 10 
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mM PBS (10 mM phosphate; 140 mM NaCl, 3 mM KCl).  A similar procedure was performed 
for labeling of lysostaphin using Alexa Fluor 594 (ε 73,000). The samples were incubated 
at 25°C for 2 h, diluted two fold in 10 mM PBS and then centrifuged at 3,000 rcf for 1 h 
using a Nanosep® membrane centrifugal device (MWCO 3K and 30K for lysostaphin and 
anti-S. aureus antibody, respectively) to remove any unbound dye. As per the 
manufacturer‟s instructions, the molecular weight cutoff (MWCO) of approximately 6 
times less than the molecular weight of the protein to be retained was chosen for 
purification to achieve maximum sample recovery.  
5.2.3. Protein adsorption to PLA nanoparticles  
Adsorption of Alexa 594 labeled lysostaphin with or without Alexa 350 labeled S. 
aureus antibody to PLA nanoparticles was studied at different NP: lysostaphin and NP: 
lysostaphin: antibody ratios. The ratios used for the preparation of lysostaphin-
nanoparticle conjugates corresponded to 1300, 2700 and 5400 lysostaphin molecules per 
nanoparticle. For protein adsorption, 900 μl each of lysostaphin solutions with 
concentrations of 5.68, 11.79 and 23.59 μg/ml were prepared in 1 mM PBS buffer from a 
1.25 mg/mL lysostaphin stock solution and combined with 100 μl of the NP stock solution 
containing 9.8*10
11
 particles per ml.  
The ratios for targeted lysostaphin-antibody-nanoparticle conjugates consisted of 
1300: 450; 2700: 900 and 5400: 1800 lysostaphin and antibody molecules per 
nanoparticle, respectively. Three protein solutions containing both lysostaphin and 
antibody (900 μl each) were prepared in 1 mM PBS buffer from lysostaphin and antibody 
stock solutions. Lysostaphin and antibody concentrations for each of the ratios consisted 
of 5.68 : 10.9 μg/ml for sample 1300: 450; 11.79 : 21.9 μg/ml for sample 2700: 900; and 
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23.59 : 43.8 μg/ml and 87.6 μg/ml antibody for sample 5400: 1800. 100 μl of the 
nanoparticle stock solution (containing 9.8*10
11
 particles per ml) was added to each of the 
protein solutions to make up the final volume of 1 ml.  
All sample mixtures were then incubated for 6 h in a shaker at 150 rpm at 20°C. 
The samples were then centrifuged at 3,000 rcf for 1 h to remove any unbound enzyme 
and antibody. The supernatant was collected and the pellet was resuspended in 1 ml of 10 
mM PBS and stored at 4 °C.  The concentration of unbound enzyme and antibody in each 
of the supernatants was determined from fluorescence measurements. Enzyme and 
antibody solutions with known concentrations were used as the standards. The 
concentrations of bound enzyme and antibody in the resuspended pellets were found from 
the difference between the initial concentration and concentration in the supernatant. The 
signal-to-background ratio was ~ 500: 1 for the fluorescently labeled lysostaphin (with or 
without antibody) and ~ 1000:1 for fluorescently labeled antibody. Protein adsorption 
experiments were reproduced in triplicates.  
A second batch of protein-NP conjugates was also synthesized using newly 
prepared NPs to verify batch-to-batch reproducibility of antibacterial activity. Unlabeled 
proteins were used for the preparation of the second batch; otherwise all synthesis 
procedures were identical to those described above. Particle sizing and zeta potential 
measurements were also performed for the second batch. 
5.2.4. Particle Size Measurements and Zeta potential analysis 
Stock solutions containing nanoparticles or protein-nanoparticle conjugates were diluted 
1:1000 in 10 mM PBS in a disposable cell and particle size was measured using dynamic 
light scattering with a 90Plus particle size /zeta potential analyzer (BrookHaven 
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Instruments Corporation, Holtsville, NY). Before particle sizing, the samples were 
sonicated for 20 min to break up any loosely-held agglomerates. Particle size was 
expressed as a combined mean diameter in nm (+/- SD). For zeta potential analysis, stock 
solutions were diluted 1:100 in 1 mM PBS in a disposable cuvette and zeta potential was 
measured using the 90 Plus analyzer. Zeta potential was expressed in millivolts (mV) as a 
combined mean of (+/- SD).  
5.2.5. Bacterial turbidimetric activity assay 
A cell suspension of S. aureus was prepared by inoculating 10 ml of 30% (w/v) 
tryptic soy with 100 µl of S. aureus culture prepared according to ATCC instructions. The 
procedure used was similar to the one employed by Schindler and Schuhardt [299].  The 
cells were incubated at 37C for 18 - 24 h under gentle shaking to grow to a mid-log 
phase. The cells were then pelleted at 2,000 rpm for 10 min and washed twice with 10 mM 
PBS. The cells were then resuspended in PBS to prepare bacterial suspension with optical 
density (OD600) of 0.56 at 600 nm (1 cm light path).  The turbidity assay was performed 
by adding 100 µl of the diluted sample solution in a 96 well microplate followed by 100µl 
of thus prepared S. aureus cell suspension. Lysostaphin concentration was fixed for all 
samples and consisted of 0.83 g/ml. The decrease in OD600 was monitored at 37°C in 1 
min intervals for a total period of 3 h. These kinetic data were fitted exponentially, in 
assumption of the first order kinetics with respect to bacteria. The mean kinetic constants 
determined from these exponential fits were used as the measure of lysostaphin activity in 
a particular sample. Control experiments were performed with free lysostaphin at the same 
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enzyme concentration. All kinetic experiments were reproduced in triplicate for two 
different batches of samples synthesized independently (n=6).  
5.2.6. Fractional analysis of enzyme activity in leached samples 
To determine whether antibacterial activity of the enzyme-NP conjugates comes 
primarily from adsorbed or leached enzyme, we performed fractional analysis of enzyme 
activity. Two samples corresponding to the highest lysostaphin and antibody coatings 
(1:5400:0 and 1:5400:1800 NP: lysostaphin: antibody ratios) were prepared using the 
procedure described above. The samples were then incubated in PBS buffer at 37C with 
gentle shaking. 100 l of each sample was taken at each of the different time points (1, 6 
and 24 h) and centrifuged at 3,000 rcf for 1 h followed by collection of the supernatants. A 
cell suspension of S. aureus was grown to a mid-log phase similarly to the procedure 
described previously, centrifuged at 2,000 rpm for 10 min, washed twice and resuspended 
in 10 mM PBS. 100 µl of the cell suspension was added to wells of a 96 well plate 
containing either 100 µl of the total sample or 100 µl of the supernatant collected at a 
particular time point (leached aliquot). The samples were incubated with the cell 
suspension at 37ºC under continuous shaking, and the rate of bacterial lysis was monitored 
for 3 h, similarly to the procedure described in the previous section. From these 
experiments kinetic constants for bacterial lysis were determined using the exponential fits 
and used as the measure of leached lysostaphin activity at different time points. All kinetic 
experiments were reproduced in triplicates.  
5.2.7. Statistical analysis 
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Data are presented as means±SD. Paired t-test and one-way analysis of variance 
(ANOVA) was performed for the binding efficiency data of proteins on NPs and kinetics 
constants in the bacterial lysis assay. The null hypothesis was that the means are not 
significantly different. Tukey‟s test was used to compare different samples in the event 
that the ANOVA null hypothesis was not true. Data were analyzed using Origin 6 Data 
Analysis and Graphing Software (OriginLab Corporation, MA, USA). A p value of <0.05 
was considered statistically significant. 
5.3. Results and Discussion 
5.3.1. Characterization of enzyme-NP conjugates 
Lysostaphin and anti S. aureus antibody was adsorbed onto biodegradable PLA 
NPs (Figure 5.1). We found that adsorption was preferred method of immobilization in 
this case because it resulted in strong protein attachment and high activity without the 
need for additional chemical modification steps. Also, adsorption can be carried out in 
milder chemical conditions, generally resulting in better protein stability and is more cost 
effective. Adsorption has been successfully used previously to co-immoblize two proteins 
on PLA NPs for in vivo applications [300]. Leaching studies discussed in detail in the 
following section were performed to demonstrate that major part of antibacterial activity is 
associated with the enzyme conjugated to NPs. Samples with several enzyme : antibody : 
nanoparticle ratios were prepared (Table 5.1). The initial protein concentrations were 
chosen to correspond to approximately 0.5, 1, and 2 monolayers for lysostaphin and 





Figure 5.1. Schematic of the synthesis of protein-NP conjugates. 
The following assumptions were used when calculating amount of a protein 
required for a monolayer coating. The average dimensions of the lysostaphin molecule are 
4.5 nm x 5.5 nm x 8.5 nm [301]. The average surface area occupied by an adsorbed 
lysostaphin molecule based on the smallest dimensions was therefore assumed to be 25 
nm
2
. The size of uncoated PLA NPs measured using dynamic light scattering was found to 
be 145 nm (Table 5.2). A theoretical monolayer of lysostaphin on the surface of a 145 nm 
PLA nanoparticle calculated from the smallest dimensions of the lysostaphin molecule 
should consist of ~2,700 molecules per NP. The average dimensions of an IgG antibody 
molecule reported in the literature vary greatly from 14 nm x 8.5 nm x 4 nm to 23 nm x 23 
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nm x 4.4 nm [302]. We therefore used hydrodynamic radius, Rh, of IgG molecule for 
estimation of its theoretical monolayer coating. Rh can be determined more accurately and 
its value reported for IgG molecule in aqueous solution, Rh=5.3 nm, is consistent in the 
literature [303]. A theoretical monolayer of antibody calculated in the assumption of dense 
hexagonal packing of the spheres with the radius of 5.3 nm would consist of ~900 








Figure 5.2. Binding yield of adsorption on PLA NPs for (A) AlexaFluor 594-labeled 
lysostaphin (Black squares – Plain lysostaphin and Red circles – lysostaphin 
coadsorbed in the presence of antibody (n = 3)), and (B) Alexa Fluor 350 labeled 
anti-S. aureus antibody (n = 3) 
Binding yields for lysostaphin consisted of 40-44% for plain lysostaphin-coated 
samples and 29-38% when lysostaphin was co-adsorbed with the antibody (Table 5.1). 
Binding yield for the antibody consisted of 15-23% for different ratios. Overall, amount of 
adsorbed lysostaphin and the antibody increased linearly with the increase of the 
concentration of the corresponding protein (Figure 5.2 A, B). For lysostaphin adsorption at 
the highest initial enzyme concentrations (which corresponded to two monolayers of 
lysostaphin), coating by the adsorbed enzyme approached theoretically predicted 
monolayer and consisted of 85% and 77 % of a monolayer for plain and antibody-coated 
samples, respectively (Table 5.1). At the same time, antibody coating at its highest initial 
concentration consisted of ~30% of theoretical monolayer. This is an assumption that is 




nanoparticles. However, the actual monolayer coating could be higher as enzymes are 
known to unfold upon conjugation resulting in a slightly higher specific surface area 
occupied by each enzyme molecule.  
 
Table 5.1. Characteristics of samples with different nanoparticle (NP): lysostaphin (LS): 
antibody (Ab) ratios. Binding yield of protein on NPs. Data are presented as meanSD 
(n=3).  
Overall lower binding yields for antibody compared to lysostaphin could be 
attributed to stronger electrostatic interaction between the highly positively charged 
lysostaphin molecules (pI = 10.6) and negatively charged PLA NPs (zeta potential -48 
mV). For comparison, pI of IgG lies in the range 6.4-9.0 and because of the polyclonal 
 




Number of theoretical 
monolayers assuming 












1NP : 1300 LS 0.5 LS 402 LS 201 LS 
1NP : 2700 LS 1 LS 445 LS 455 LS 
1NP : 5400 LS 2 LS 423 LS 856 LS 
1NP :1300 LS : 450 Ab 0.5 LS, 0.5 Ab 293 LS; 234 Ab     151 LS; 122 Ab 
1NP :2700 LS : 900 Ab 1 LS, 1 Ab 383 LS; 177 Ab     391 LS; 177 Ab 
1NP :5400 LS : 1800 
Ab 
2 LS, 2 Ab 392 LS; 151 Ab     763 LS; 302 Ab 
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nature of antibody, molecules with different pIs from this range are expected to be present 
in the solution [304].  
Size was determined by light scattering for bare NPs and protein-NP conjugates 
(Table 5.2). The mean diameter of the enzyme-NP conjugates increased significantly 
(p<0.05) upon adsorption of lysostaphin with or without antibody to the surface of NPs. 
Zeta potentials for all conjugates were highly negative (<-30 mV) indicating that the 
conjugates, similarly to bare NPs, were negatively charged. The mean values from two 
different batches are tabulated in Table 5.2 below.   
 
Table 5.2. Characteristics of samples with different nanoparticle (NP):lysostaphin 











(Mean  SD) 
 
Zeta potential (mV)            
(Mean  SD) 
 
1NP : 1300 LS 0.5 LS 177.4 ± 6.8 -39.7 ± 11.6 
1NP : 2700 LS 1 LS 182.6 ± 6.8 -39.6 ± 13.2 
1NP : 5400 LS 2 LS 187.3 ± 4.7 -42.6 ± 10.3 
1NP :1300 LS : 450 Ab 0.5 LS, 0.5 Ab 182.7 ± 1.8 -45.3 ± 1.9 
1NP :2700 LS : 900 Ab 1 LS, 1 Ab 193.3. ± 7.8  -41.1 ± 4.1 
1NP :5400 LS : 1800 Ab 2 LS, 2 Ab 180.9 ± 9.8 -33. ± 1.4 
Uncoated NPs  148.1 ± 4.1 -49.5 ± 2.1 
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5.3.2. Fractional enzyme activity from leaching study 
It is important to know whether activity of enzyme coated NPs is due to 
immobilized or leached lysostaphin. Fluorescence measurements were found to be not 
sensitive enough to detect enzyme leached from the NPs into the supernatant. Therefore, 
turbidimetric bacterial lysis assay was employed to determine the fraction of total activity 
contributed by leached lysostaphin. This method was found to be more sensitive because 
even extremely small concentrations of lysostaphin can cause significant lysis of bacteria 
in S. aureus suspension.  
Figure 5.3 shows the percent of leached enzyme activity for the aliquots collected 
at different time points compared against total activity for two samples with highest 
lysostaphin loading. These results indicate that less than 10% of enzyme was desorbed 
from the NPs after 24 h incubation in PBS buffer. Shah et al. studied the antimicrobial 
activity of lysostaphin adsorbed on two different
 
plastic surfaces, polystyrene (well plates) 
and fluorinated ethylene-propylene polymer (a Teflon-like
 
material used in Angiocath 
catheters) [240]. Similarly to our findings, they observed that the antibacterial activity was 




Figure 5.3. Fraction of leached lysostaphin activity for aliquots collected at 
different time intervals compared against total enzyme-NP activity for samples 
with highest lysostaphin and antibody coatings.  Black squares – NP: lysostaphin 
(1:5400:0) and red circles - NP: lysostaphin: antibody (1:5400:1800); n=3 
5.3.3. Bacterial lysis assay – Enzyme activity   
Enzyme activity was measured as reduction in turbidity of S. aureus suspension in 
PBS buffer by monitoring the decrease in optical density at 600 nm. Lysostaphin 
concentration was 0.83 µg/ml in all experiments. Enzyme concentration was thus fixed in 
all kinetic experiments; however the number of NPs (and, where applicable, the antibody 
concentration) was different because of different number of lysostaphin molecules 




Table 5.3 - Bacterial turbdimetric assay results for all the samples.  
Figure 5.4 below shows results of the activity assay for two batches of enzyme-NP 
conjugates and free enzyme (n=6).  Note: The high error bars in NP-enzyme samples are 
also indicative of interference of NPs during absorbance reading at 600 nm. Assuming 
first order kinetics with respect to bacteria, the time dependencies were fitted 
exponentially and the mean kinetic constants of the first order reaction were calculated 
from the exponential fits and used as the measure of antimicrobial activity. Table 5.3 
shows results of the analysis of kinetic data obtained from two different batches (n=6; 3 
replicates from each batch). Comparison of the activities for two sets of the samples with 
the lysostaphin loadings (1:1300:0 and 1:1300:450; 1:2700:0 and 1:2700:900) showed no 
significant difference (p>0.05, paired t-test; n=6, see Table 5.3), despite a higher mean rate 






































NP:lyso (1:1300) 0.83 - 
0.007 ± 2E-03 
p < 0.05  
NP:lyso (1:2700) 0.83 - 0.0136 ± 1E-03 p < 0.05  
NP:lyso (1:5400) 0.83 - 0.0147 ± 2E-03 p < 0.05  
NP:lyso:Ab (1:1300:450) 0.83 1.27 0.0088 ± 1E-03 p > 0.05 p > 0.05 
NP:lyso:Ab (1:2700:900) 0.83 0.68 0.0175 ± 6E-03 p < 0.05 p > 0.05 
NP:lyso:Ab (1:5400:1800) 0.83 0.6 0.032 ± 7E-03 p < 0.05 p < 0.05 
Free lysostaphin 0.83 - 0.009 ± 1E-03 -  
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lysostaphin loading that lacked the antibody (1:1300:0) was found to be significantly 
lower than that of the free enzyme (p<0.05, paired t-test; n=6, see Table 5.3). For its 
corresponding analogue that contained the co-adsorbed antibody (1:1300:450), activity 
was not found to be significantly different from that of the free enzyme (p>0.05, paired t-
test; n=6, see Table 5.3).  
However, enhanced activity compared to the free enzyme was observed for both 
enzyme-coated and enzyme-antibody coated nanoparticles for all other ratios (p<0.05, 
paired t-tests; n=6, Figs. 5.4B and 5.4C, Table 5.3).  The rate of bacterial lysis for the 
highest antibody coating was (corresponding to an initial bilayer of molecules to NP) was 
the highest amongst all samples and significantly different compared to its corresponding 
analogue without antibody (Table 5.3).  It had a nearly fourfold faster mean rate of 
bacterial lysis compared to free enzyme at the same concentration. These experiments 
demonstrate the possibility of antibody-directed targeting for samples with the highest 
antibody coating concentration. We hypothesize that co-immobilization of lysostaphin and 
antibody on nanoparticles leads to enhanced binding to bacteria through antibody-antigen 
interactions resulting in higher local concentrations of lysostaphin and therefore leading to 
increased bacterial lysis rates. However, enhanced potency can only be achieved at higher 
antibody and lysostaphin loadings warranting further studies of the mechanism of the 
observed phenomenon. Results of this model study suggest the possibility of regulating 
properties of enzyme-NP conjugates by optimizing the ratio between the functional 
enzyme and the targeting antibody attached to a nanoparticle. Targeting can be enhanced 
by increasing the number of antibody molecules per NP (Figure 5.5B), even though total 
antibody concentration in the assay decreases for samples with higher lysostaphin and 
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antibody loading (Table 5.3). Overall, bacterial lysis rates increased with the increased 
number of antibody molecules per NP (Figure 5.5B). This increase was found significant 
for all samples with different antibody: NP ratios (p<0.05, One way ANOVA).  
An unexpected result was the observation of enhanced activity of lysostaphin-
coated nanoparticles compared to the free enzyme. In spite of the fact that lysostaphin 
concentration in the assay was kept constant, bacterial lysis rates increased with the 
increased number of lysostaphin molecules per NP (Figure 5.5A). This increase was found 
to be statistically significant for all samples with different enzyme:NP ratios (p<0.05, One 
way ANOVA). For two samples with higher lysostaphin loading (1:2700:0 and 1:5400:0), 
activity was significantly higher than that of the free enzyme (p<0.05, paired t-test, n=6), 
while for sample with the lowest lysostaphin loading activity was significantly lower than 




  Figure 5.4. Results of bacterial lysis assay. The data are the means of 
absorbance for six replicates from two batches along with the standard deviations 
for each time point. Blue triangles correspond to untreated bacterial suspension 
(negative control). Black squares – lysostaphin adsorbed on PLA nanoparticles; 
red circles – lysostaphin and antibody co-adsorbed on PLA nanoparticles, and 
green triangles – free lysostaphin. (A) – NPs with low lysostaphin and antibody 
coatings (1:1300:0 and 1:1300:450); (B) – NPs with intermediate lysostaphin and 
antibody coatings (1:2700:0 and 1:2700:900); and (C) – NPs with high lysostaphin 
and antibody coatings (1:5400:0 and 1:5400:1800). High error bars in NP-enzyme 
samples are also indicative of interference of NPs during absorbance reading at 





In general, partial loss of enzymatic activity is expected for surface-immobilized 
enzymes including enzyme-nanoparticle conjugates [263, 277]. In our case, decrease of 
enzymatic activity was only observed for the conjugates with the lowest lysostaphin 
loading, while enhanced activity was observed for the other ratios. We have previously 
observed enhanced enzymatic activity for lysozyme conjugated to positively-charged 
polystyrene latex NPs. This effect was attributed to charge-directed targeting to negatively 
charged bacteria (M. Lysodeikticus).  
We considered the possibility that enhanced activity of lysostaphin-coated NPs 
observed in the present work was also due to charge-directed targeting since lysostaphin is 
positively charged and its attachment to nanoparticles could have lead to the formation of 
positively charged conjugates. However, all conjugates were found to have highly 
negative zeta-potential (Table 5.2). Also of note is that charge-directed targeting reported 
by our group [250] was only observed in an environment with low ionic strength (6 mM 
phosphate buffer, no saline) and was not noticeable at physiologically relevant ionic 
strength (PBS buffer, ~150 mM saline). On the contrary, lysostaphin-coated NPs prepared 
in the present work were robust and showed enhanced activity compared to the free 
enzyme in PBS buffer containing 150 mM saline. Our hypothesis is therefore that 
enhanced activity of lysostaphin-coated NPs in the absence of co-immobilized antibody 
occurs due to multiple-ligand targeting. The mature form of lysostaphin consists of two 
domains, the endopeptidase domain responsible for its catalytic activity, and the C-
terminal cell wall-targeting domain (CWT) [305]. Lysostaphin-NP conjugates studied here 
carry from several hundred to several thousand lysostaphin molecules per nanoparticle 
(Figure 5.5A). Therefore, each particle presents a large number of CWT domains available 
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for binding to bacteria, which can lead to considerably higher binding constant for 
interaction between the NP conjugates and bacteria, compared to that for interaction 







Figure 5.5. (A) Kinetic constant of bacterial lysis plotted as function of adsorbed 
lysostaphin molecules per NP for lysostaphin:NP conjugates lacking the antibody 
(mean±SD; n=6). (B) Kinetic constant of bacterial lysis plotted as function of 
adsorbed antibody molecules per NP (mean±SD; n=6). Note that total antibody 
concentration in the assay decreases with the increase of the number of antibody 
molecules per NP (see Table 5.3). 
Interestingly, enzyme and enzyme/antibody- coated nanoparticles remain 
negatively charged. This finding can have important implications because toxicity of 
many antimicrobial peptides to eukaryotic cells can potentially be reduced by their 
conjugation to negatively charged carriers. High toxicity of antimicrobial peptides remains 
one of the most important concerns in their in vivo applications [306]. Use of negatively 
charged conjugates is expected to reduce non-specific attachment of antimicrobial 
peptides to slightly negatively charged surface of eukaryotic cells therefore reducing their 
toxicity. 
In conclusion, we demonstrated that lysostaphin-coated nanoparticles show 
enhanced antimicrobial activity against S. aureus at physiologically relevant conditions. 
We also showed that co-adsorption of anti-S. aureus antibody to lysostaphin-coated 
nanoparticles leads to further increase of their antimicrobial activity. Results of this study 
indicate that enhanced antimicrobial activity of enzyme-nanoparticle conjugates is due to 








EVALUATION OF ANTIMICROBIAL ACTIVITY OF LYSOSTAPHIN-COATED 
HERNIA REPAIR MESHES 
6.1. Introduction 
The development of an incisional hernia is a common complication after 
abdominal surgery  which results in 90, 000 ventral hernia repair surgeries per year in the 
United States [307]. The implantation of a prosthetic mesh is a well-established procedure 
for reconstructing or reinforcing the abdominal wall and has been shown to decrease the 
rate of hernia recurrence [308-310]. However, one of the most common problems 
associated with the use of prosthetic meshes is bacterial infection. The incidence rate for 
mesh-related infection has been reported to vary between 1% and 18% in different clinical 
studies [311-313]. 
 Mesh infection is associated with significant morbidity and is increased 
considerably in patients with diabetes, immunosuppression, and obesity [314]. Infection 
usually occurs in the early postoperative period and while its incidence can be decreased 
by the use of antibiotics [315], no significant improvement has been made in the reduction 
of mesh infection for more than 20 years. Current conventional therapy has proven to be 
largely unsuccessful due to implantation of a foreign body, wide tissue dissection and the 
development of a number of multi-drug resistant strains. In a study of mesh-related 
infections following incisional herniorrhaphy, 63% of the microorganisms isolated were 
Methicillin-resistant Staphylococcus aureus (MRSA)[313].  
Bacterial adhesion and proliferation to implanted biomaterial surfaces is a key step 
in the pathogenesis of infection [316-318]. Multiple experimental and clinical studies have 
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been focusing on the use of different antimicrobial agents immobilized on the surface or 
released from the bulk of an implant [319].  Increasingly, attention is being paid to surface 
coatings on implants that contain active compounds that may either kill directly on contact 
or via leaching over time. Naturally occurring antimicrobial peptides and enzymes have 
recently attracted much attention because of their high activity, broad antimicrobial 
spectrum, and the low rate of antimicrobial resistance.  
Balaban et.al found that adsorption of an antibacterial peptide, dermaseptin to 
Dacron vascular grafts resulted in increased resistance to bacterial colonization and 
demonstrated its in vivo efficacy in a rat model [239].  Shah et.al demonstrated significant 
antimicrobial activity against S. aureus for intravenous catheters coated by physically 
adsorbed lysostaphin, and observed high efficacy in vitro [240]. Lysostaphin possesses 
extremely high activity against a variety of staphylococcal strains including MRSA [240]. 
Based on literature data lysostaphin has a reported minimum inhibitory concentration at 
which 90% of the strains are inhibited [MIC90] of 0.001 to
 
0.064 µg/ml [320]. This is 
comparatively much lower than MIC90 for most broad spectrum antibiotics and drugs that 
are antimicrobial against S. aureus. For comparison, MIC90 for vancomycin, which is 
currently recommended for treatment of methicillin-resistant S. aureus infections, is 2 
µg/ml [321]. Lysostaphin could therefore be superior to other antibacterial agents in hernia 
repair-related infections given that up to 90% of mesh-related infections result from S. 
aureus. Here, we evaluate the in vitro antimicrobial susceptibility of S. aureus to 
lysostaphin-coated hernia repair polymer meshes and study the effect of enzyme coating 
concentration on antimicrobial activity 
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6.2. Materials and methods 
Staphylococcus aureus (ATCC 32370) was purchased from American Type Culture 
Collection (Manassas, VA). Lysostaphin (25 kDa; LSPN-50) isolated from 
Staphylococcus staphylolyticus was bought from Ambi Products LLC (Lawerence, NY).  
Bovine Serum Albumin (BSA) was bought from Calbiochem (San Diego, CA). Ultrapro 
(Lightweight Polypropylene mesh with Monocryl weave) from Ethicon Inc, Johnson and 
Johnson (Langhorne, PA) and Pariatex
TM
 Composite mesh (Polyester mesh with 
resorbable film) from Covidien (Mansfield, MA) was donated by Carolinas Medical 
Center (Charlotte, NC). Alexa Fluor 594 Carboxylic acid, Succinimidyl ester dyes used 
for fluorescent labeling were purchased from Invitrogen, Molecular Probes (Carlsbad, 
CA).  Microsep Centrifugal Devices with a modified Polyethersulfone membrane (low 
protein binding; MWCO - 3K) used for enzyme purification were purchased from Pall 
Life Sciences (Ann Arbor, MI). All other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA), and used without further purification unless otherwise specified.  Type 1 
Clear Borosilicate glass vial (25 mL) was with attached screw caps was bought from 
VWR (West Chester, PA).   
6.2.1 Fluorescent labeling of lysostaphin 
Alexa Fluor 594 dye was used for fluorescent labeling of lysostaphin due to its enhanced 
resistance to photobleaching [298]. Fluorescent labeling is considered to be an acceptable 
method for monitoring protein concentration, which is assumed to be proportional to the 
fluorescent signal [322]. Labeling of lysostaphin by Alexa Fluor 594 was performed 
according to the manufacturer‟s instructions. Approximately 5 μg of Alexa Fluor 594 (ε 
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73,000) was dissolved in 500 μL of dimethylformamide and 100 μL of this solution was 
added to 2 mL of a 1 mg/mL solution of lysostaphin in 10mM PBS buffer (10 mM 
phosphate; 140 mM NaCl, 3 mM KCl). The enzyme was incubated with dye at 30°C for 2 
h, then diluted two-fold in 10 mM PBS buffer and centrifuged at 3,500 g for 1 h using a 
Microsep membrane centrifugal device (MWCO 3K) to remove any unbound dye 
followed by resuspension of the concentrated labeled enzyme in PBS buffer.  
6.2.2. Measurement of the specific surface area of the mesh samples  
The specific surface area determined for one of the pieces by Brunauer-Emmett-Teller 
(BET) analysis of N2 adsorption at 77 K in a Micromeritics ASAP 2020 (Micromeritics 
Instrument Corporation, Norcross, GA) was found to be 5.5 m
2
/g. Prior to N2 adsorption, 
the mesh samples were degassed overnight at 80 °C. Surface area for each of the mesh 
pieces used in the following experiments was calculated based on the weight of the piece. 
The average weight of a 1 × 1 cm
2
 Ultrapro mesh piece was 6.9±1.0 mg.  
6.2.3. Preparation of lysostaphin-coated meshes  
Ultarpro, Ethicon Inc., mesh (Lightweight Polypropylene mesh with Monocryl weave) 
was cut into ~ 1 × 1 cm pieces in a laminar flow hood under sterile conditions prior to 
physical adsorption of enzyme. Initial enzyme concentrations of 0.01, 0.025, 0.05, 0.1, 
0.25, and 0.5 mg/ml in PBS buffer were prepared from a 1 mg/mL stock solution of Alexa 
Fluor 594-labeled lysostaphin. The initial fluorescence intensities of the enzyme sample 
solutions (1 mL) were measured in a 12 well plate (Nunc Inc.) using a microplate reader 
(Ex 594 nm; Em 625 nm) and then added to 25 mL sterile glass vials. Using a pair of 
sterile tweezers, mesh pieces were gently placed into each of the vials containing the 
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enzyme solutions and incubated overnight at room temperature with gentle shaking (100 
rpm). The enzyme solution over the mesh was then collected and stored for fluorescence 
measurements, and the mesh was gently washed 2 times with 1 mL of PBS buffer. The 
wash solution was also collected and used in determination of enzyme binding yield. In 
order to remove any loosely adsorbed enzyme, 1 mL of 0.1 (v/v %) Tween 20 solution 
(non ionic surfactant) was then added to each of the glass vials followed by incubation for 
3 h. This surfactant solution was also collected and used in the determination of the 
amount of desorbed enzyme and the mesh samples were then washed with copious amount 
of PBS buffer.  
The concentration of unbound enzyme in each of the supernatants and wash 
solutions was determined from fluorescence measurements. Initial enzyme solutions with 
known concentrations were used as the standards. The concentration of the 
unbound/desorbed enzyme at each step was then calculated and subtracted from initial 
concentration of enzyme present in the initial solution. The difference corresponded to the 
bound enzyme concentration on the mesh. Adsorption experiments were reproduced in 
triplicates. Note: Unlabeled lysostaphin was used in all other experiments except binding 
efficiency studies.   
6.2.4. Leaching studies 
Leaching of non-specifically bound lysostaphin from the surface can occur both in 
vitro and in vivo. To model in vivo conditions, we studied enzyme leaching from 
lysostaphin-coated meshes in the presence of BSA. The samples were incubated with 1 
mL of 2 % (w/v) BSA solution in PBS buffer for 24 h at 37C. We found that fluorescence 
measurements lacked sensitivity to determine concentration of leached enzyme in the 
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samples. We therefore estimated enzyme concentration based on its activity. For kinetic 
measurements, 0.1 ml aliquots from each of the samples were taken at different time 
points (5, 15 and 24 h) and added to a 96 well plate. Lysostaphin solutions with known 
enzyme concentrations of 0.0122 – 25 µg/ml were used as standards for each of the 
different time points. A 100 µl cell suspension of S. aureus in PBS buffer with optical 
density (OD600) of 0.3 at 600 nm (1 cm light path) was then added to each of the different 
wells and the rate of bacterial lysis was monitored continuously for 4 h at 37ºC.  
Enzymatic activity for standards and unknown samples was measured simultaneously in 
the same microplate. The initial rate of the reaction for each of the standards and 
unknowns was calculated from the linearized slopes. The standard curve was obtained by 
plotting the initial rate against the enzyme concentration. From the standard curve, the 
unknown enzyme concentrations were determined and the amount of leached enzyme for 
each of the samples was plotted as a function of time. All kinetic experiments were 
reproduced in triplicates. 
6.2.5. Turbidimetric assay  
A cell suspension of S. aureus was prepared by inoculating 10 mL of 30% (w/v) tryptic 
soy with 100 µL of S. aureus culture prepared according to ATCC instructions. The 
procedure used was similar to the one employed by Schindler and Schuhardt [299].  The 
cells were incubated at 37C for 18 - 24 h under gentle shaking to grow to a mid-log 
phase. The cells were then pelleted at 3,000 g for 10 min and washed twice with 10 mM 
PBS. The cells were then resuspended in PBS to prepare bacterial suspension with optical 
density (OD600) of 0.55 at 600 nm (1 cm light path).  1 mL of the suspension containing 
~10
7 
CFU (colony forming units) was added to 25 mL glass vials containing the mesh 
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samples. The samples were incubated with the suspension at 37ºC under continuous 
shaking, and the rate of bacterial lysis was monitored for 5 h by taking 0.2 mL aliquots 
and measuring the OD600 in a 96 well plate at different time intervals. Enzyme activity 
was expressed in units (one unit of lysostaphin activity is defined as a decrease of 0.01 
absorbance units at 600 nm, according to the manufacturer‟s specifications). The vials 
containing the cell suspension were continuously shaken in order to maintain contact with 
the meshes.  All kinetic experiments were reproduced in triplicates. 
6.2.6. Fractional analysis of enzyme activity in leached samples 
To determine whether antibacterial activity of the coated meshes comes primarily from 
immobilized or leached enzyme, we performed fractional analysis of enzyme activity. A 
set of mesh samples with the same initial coating concentrations was prepared in 
duplicates using the procedure as described previously. All the samples were incubated in 
25 ml glass vials containing 0.5 mL of 2 % (w/v) BSA solution in PBS buffer for 24 h at 
37C. From one set of the samples, the meshes were removed at different time intervals 
(1, 4 and 24 h) and a corresponding set containing mesh samples of identical coating 
concentrations were left intact.  
A cell suspension of S. aureus was grown to a mid-log phase similar to the 
procedure described previously, centrifuged at 3,000 g for 10 min, washed twice with 10 
mM PBS and resuspended in PBS to a final optical density (OD600) of ~0.9 at 600 nm. 0.5 
ml of this cell suspension was added to the 25 ml glass vials containing each set of the 
samples and the final OD of this mixture measured was 0.55 at 600 nm. The samples were 
incubated with the cell suspension at 37ºC under continuous shaking, and the rate of 
bacterial lysis was monitored for 2 h by taking 0.2 mL aliquots from the reaction mixture 
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and measuring the OD600 in a 96 well plate at different time intervals.  This procedure was 
done for identical sets of the samples at the different time intervals to compare the enzyme 
activity of the leached sample against total activity of the mesh sample incubated in BSA.  
6.2.7. Colony counting  
The sample meshes were placed in sterile glass vials and challenged with an inoculum of 1 
ml of S. aureus suspension in tryptic soy broth containing 6 x 10
7
 CFU for 24 h at 37 ºC. 
After the incubation, the mesh pieces were retrieved and the broth supernatant was 
collected for subsequent analysis. Each mesh piece was then washed once vigorously with 
1 mL of PBS buffer using a pipette followed by vortex washing for 5 minutes and 
collected for subsequent colony counting analysis. Serial dilutions and spot plating were 
then performed for the broth supernatant (broth count) and the pooled wash (wash count) 
on agar nutrient plates.  The wash count was used to dislodge and quantify the loosely 
attached bacteria. Bacterial counts were quantified as the number of CFU per mL. All 
counts were performed in triplicates and results were calculated as mean log reduction 
±SD.  
6.2.8. In vivo Rat Model 
All in vivo studies were performed by our collaborators, Dr. Yuliya Yurko, Dr. Amy 
Lincourt,   and Dr. Todd Heniford at Carolinas Medical Center along with Dr. John Shipp 
at ViMedrx. A total of 40 male Lewis rats (225-275g, Charles River Laboratories, 
Raleigh, NC) were used. All animal experiments were approved by the Institutional 
Animal Care and Use Committee (CMC) and performed in accordance with NIH 
guidelines.  Rats were randomly assigned to one of the ten groups (n=4 each group) as 
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follows.  Groups A-F had polypropylene mesh implanted as an onlay to the anterior 
abdominal wall fascia.  Group A received mesh with no lysostaphin and no S. aureus 
inoculum. Group B received no lysostaphin and S. aureus inoculum of 5x10
5
 CFU.  Group 
C received mesh-bound lysostaphin (Initial coating concentration - 50 µg/ml) and no S. 
aureus inoculum   Group D received mesh-bound lysostaphin (Initial coating 
concentration – 50 µg/ml) and S. aureus inoculum of 5x10
5
 CFU.  Group E received 
mesh-bound lysostaphin (Initial coating concentration – 100 µg/ml) and no S. aureus 
inoculum.  Group F received mesh-bound lysostaphin (Initial coating concentration – 100 
µg/ml) and S. aureus inoculum of 5x10
5
 CFU.  Groups G-J had polyester mesh implanted 
as an onlay to the anterior abdominal wall fascia. Group G received mesh with no 
Lysostaphin and no S. aureus inoculum. Group H received no Lysostaphin and S. aureus 
inoculum of 5x10
5
 CFU. Group I received mesh-bound Lysostaphin (Initial coating 
concentration – 100 µg/ml) and no S. aureus inoculum.  Group J received mesh-bound 




6.2.9. Surgical Procedures  
Surgical anesthesia was induced and maintained with inhaled isofluorane. The abdominal 
wall was shaved, prepared first with Betadine®, then isopropyl alcohol 70% (v/v), and 
draped in sterile fashion. A 1 cm midline vertical incision was made through dermis and 
subcutaneous pockets was then created bilaterally over the anterior abdominal fascia. A 
3cm x 3cm square piece of sterile polypropylene mesh was placed on the fascia and 
secured with eight stitches of 4-0 Prolene suture (Ethicon Inc.).  For groups assigned to 
receive the bacterial innoculum, a 1 cc suspension of 5 x 10
5
 CFU S. aureus was applied 
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directly on the mesh using a sterile syringe.  The incision was closed using vicryl suture 
and reinforced with skin staples. Topical Bitter Orange (ARC Laboratories, Atlanta, GA) 
was applied over the closure to dissuade wound disruption.  All animals received 
bupranorphine (0.03mg/kg) immediately after surgery and every 12 hours thereafter for 
the next 48 hours.  
Mesh explantation was performed on day 7 after implantation.  General anesthesia 
was induced with isofluorane and the animals were euthanased by intracardiac 
pentobarbitol injection.  The skin around the original incision was prepared in the same 
fashion as above and opened sharply and widely to allow full exposure of the graft 
implant. The entire abdominal wall including the mesh interface was excised in en-block 
fashion. For quantitative bacterial culture analysis the mesh was carefully separated from 
the muscle, agitated and washed five times with sterile phosphate buffer solution. This 
washings were serially diluted up to the final concentration of 10
-8 
and each dilution was 
plated on tryptic soy agar and allowed to incubate overnight at 37º C. Bacterial colonies 
were then counted. 
6.2.10. Statistical analysis 
Data are presented as means±SD. One-way analysis of variance (ANOVA) was performed 
for colony counts from the broth supernatant and wash to compare the samples with 
different initial enzyme concentrations. The null hypothesis was that the means are not 
significantly different. Tukey‟s test was used to compare different samples in the event the 
ANOVA null hypothesis was not true. Data were analyzed using Origin 8 Data Analysis 
and Graphing Software (OriginLab Corporation, MA, USA). A p value of <0.05 was 
considered statistically significant. 
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6.3. Results  
6.3.1. Binding yield of lysostaphin on Ultrapro 
Binding yield was calculated based on the amount of fluorescently labeled enzyme 
adsorbed on mesh and corresponded to the difference in fluorescence intensities of initial 
enzyme and the supernatant solutions as described above. Figure 6.1 shows the binding 
yield for Alexa Fluor-labeled lysostaphin on a 1×1 cm
 
Ultrapro mesh. The amount of 
adsorbed enzyme per unit BET surface area (µg/cm
2
) is plotted as a function of the initial 
enzyme concentration. Based on the above described experimental conditions, 18 to 40% 
of lysostaphin initially present in the solution remained bound to the mesh after treatment 
by Tween 20 solution.  
 
Figure 6.1. Binding yield for Alexa 594 labeled lysostaphin on Ultrapro (1 × 1 cm) 
after overnight adsorption at room temperature (n = 3).  






















Initial lysostaphin concentration (ug/ml)
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The degree of surface coverage on the mesh can be predicted from the binding 
yield of enzyme. Average dimensions of the lysostaphin molecule are 4.5 nm X 5.5 nm X 
8.5 nm. The average surface area occupied by an adsorbed protein molecule based on the 
smallest dimensions is 25.02 nm
2
. The maximum theoretical monolayer of lysostaphin 
adsorbed on a 1×1 cm piece of Ultrapro mesh calculated using the above surface area per 




) consisted of 
1.5x10
15
 molecules. We observed approaching a theoretical 50%, 100%, and 150% 
monolayer coating of adsorbed lysotaphin at initial enzyme concentrations of 100, 250, 
and 500 g/mL, respectively.  Typically, the amount of adsorbed enzyme on a surface 
increases sharply at low initial enzyme concentration, and reaches a plateau at higher 
concentrations, thereby approaching a certain limiting value for adsorption [323]. In our 
case, adsorption did not reach saturation even at the highest coating concentration of 0.5 
mg/mL suggesting the possibility of multilayer adsorption at higher concentrations.  
6.3.2. Lysostaphin leaching 
Enzyme leaching could be a potential problem in the case of non-covalent 
adsorption as the functional protein may be replaced on the surface by more abundant 
nonfunctional ones in vivo.  Also, the Ultrapro mesh is constructed of a monofilament 
lightweight large porous polypropylene with pores larger than 3 mm which could result in 
initial confinement of the enzyme followed by release in vivo [324]. In our study, we 
assessed lysostaphin leaching in the presence of 2 % (w/v) BSA as a model for the most 
abundant protein in the abdominal fluid.  Figure 6.2 shows the standard curve representing 
the rate of lysis for the standards with known enzyme concentrations. From this standard 
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curve, the unknown enzyme concentrations were determined and the amount of leached 
enzyme for each of the samples was plotted as a function of time.   
 
Figure 6.2. Standard curve plotting the mean rate of lysis (OD per min) against 
the different known lysostaphin concentrations (µg/ml) (n=3).  
The samples designated based on their initial lysostaphin concentrations of 
10µg/ml, 25µg/ml, 50 µg/ml, 100µg/ml, 250µg/ml and 500µg/ml were L-10, L-25, L-50, 
L-100, L-250 and L-500 respectively. We observed an overall (0.01- 3) % leaching of 
enzyme based on the initial coating concentration from all the studied samples after 24 h 
incubation in BSA. Bacterial lysis was observed in all mesh samples including those that 
leached very low amounts of lysostaphin at the different time points, suggesting that small 
concentrations of enzyme could be effective in inhibiting growth of cells. In vitro 
antimicrobial activity against S. aureus was evaluated for all of the above samples (L-10 
through L-500) using turbidity assay and colony counting method.  Figure 6.3 below 




Figure 6.3. Leaching of adsorbed lysostaphin as a function of time for mesh 
samples treated by different initial enzyme concentrations. Black squares - 
10µg/ml, Red circles -25µg/ml, Green triangles - 50µg/ml, Blue inverted triangles - 
100µg/ml, Maroon diamonds - 250µg/ml and Pink arrows - 500µg/ml. Leaching 
studies were performed in the presence of 2 % (w/v) BSA in PBS buffer (pH = 7.4) 
at 37C. 
6.3.3.Turbidimetric antibacterial activity assay 
Activity assay provides the most direct measure of an enzyme‟s functionality. Qualitative 
evaluation of lysostaphin activity was done by monitoring the cell lysis of a S. aureus cell 
suspension [325]. The degree of cell lysis is directly proportional to the decrease in OD600 




Figure 6.4. Turbidimetric enzyme activity assay for the different lysostaphin-
coated hernia mesh samples. Black squares - 10µg/ml, Red circles -100µg/ml, 
Blue triangles -  500µg/ml and Green inverted triangles - Unocoated mesh; (n=3); 
p < 0.05 (one way ANOVA; n=3).  
We monitored the decrease in optical density of the bacterial suspension and compared the 
rate of lysis for the samples with different enzyme coatings. Figure 6.4 shows the time 
course of bacterial degradation for three of the samples along with the appropriate 
controls.  The vials containing the cell suspension were continuously shaken in order to 













           
(mean±SD) 
L - 10 10 
2.97 ± 0.8 
L - 25 25 
3.08 ±  0.8 
L - 50 50 3.78 ±  1.1 
L - 100 100  4.02 ±  0.01 
L - 250 250 5.92 ±  0.3 
L - 500 500 6.98 ±  0.3 
P - 100 100 6.98 ±  0.3 
Table 6.1 - Specific enzyme activity of samples with different enzyme coating concentrations 
6.3.4. Leached enzyme activity assay  
It is important to know whether activity of coated meshes is due to immobilized or leached 
enzyme. A turbidity assay that compared the rates of leached sample against that of the 
total activity of enzyme-coated mesh at different time points (incubated in bovine serum 
albumin) was studied to calculate the fraction of activity contributed by lysostaphin 
leaching from the mesh surface into the cell suspension. Enzyme leaching during the first 
5 h (which was the duration of the turbidity assay) never exceeded 1%. However, 
extremely small concentrations of lysostaphin leaching from the mesh can cause 
                                                             
1 Enzyme activity was expressed in units (one unit of lysostaphin activity is defined as a decrease of 0.01 




significant lysis to its natural substrate, i.e. cell walls of S. aureus. Fractional analysis of 
enzyme activity was calculated for the aliquots collected at different time intervals and 
compared against total mesh activity for different coating concentrations for 24 h in 2 % 
BSA. Figure 6.5 below shows the results for all different coating concentrations.  
 
Figure 6.5. Fraction of leached sample activity for the aliquots collected at 
different time intervals compared against total mesh activity for different coating 
concentrations for 24 h in 2 % BSA. Black squares – 10 µg/ml, Red circles -50 
µg/ml, Green triangles – 50 µg/ml, Blue inverted triangles – 100 µg/ml, Light blue 
diamonds - 250µg/ml and Pink arrows – 500 µg/ml 
It was found that lytic activity for these samples is almost entirely due to enzyme 
leaching from the mesh and lysing bacteria in the surrounding supernatant rather than 
adsorbed lysostaphin (data not shown). Interestingly, Shah et al. observed that the 
antimicrobial activity of lysostaphin coated on two different
 
plastic surfaces, polystyrene 
(well plates) and FEP (fluorinated ethylene-propylene) polymer, a Teflon-like
 
material 
used in Angiocath catheters was primarily due to immobilized but not leached enzyme 
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[240]. These authors used a methodology similar to that reported here. One possible 
explanation is difference in materials used in our and Shah‟s studies. Ultrapro, a 
lightweight polypropylene macroporous mesh (with a monocryl weave) containing an 
absorbable component of poliglecaprone is different in density, weave, porosity (3 mm) 
and relative hydrophobicity. It has more „yarn-like‟ properties with its higher specific 
surface area compared to „flat‟ surfaces such as polystyrene well plates and the lumenal 
sides of catheters made up of FEP polymer. Therefore, larger amounts of lysostaphin can 
be adsorbed to and consequently leached from the Ultrapro mesh leading to increased 
fraction of activity coming from the leached enzyme.  
6.3.5. Colony counting  
Log reduction in bacteria is estimated as logarithm of ratio of initial bacterial colonies to 
average final surviving colonies after treatment. This has been used for both broth 
supernatant and wash counts. Table 6.2 shows the log reduction in colonies recovered 
from the broth supernatant and wash counts for all the different initial coating 
concentrations. Broth count is a model for activity against the bacteria present in the 
wound fluid, while the wash count models activity against colonized bacteria present on 
the surface of the mesh, as initial bacterial attachment plays an important role in infection. 
An averaged 1.6 ± 0.4 log reduction in bacterial counts was observed in the case of broth 
supernatant recovered from all the lysostaphin-coated mesh samples after 24 h incubation 







Table 6.2 - Effect of lysostaphin coating concentration on log reduction of colonies for the 
broth supernatant and wash count; (n =3). 
There was no significant difference between samples with different initial 
lysostaphin coating concentrations (p > 0.05; one way ANOVA); however, observed log 
reduction was significantly higher for the all lysostaphin-coated samples when compared 
against uncoated mesh samples (p<0.05; Tukey‟s test). Similarly, an average 1.8 ± 0.36 
log reduction in bacterial counts was observed from the pooled wash count for all the 
samples that were not significantly different from each other (p>0.05; one way ANOVA).  
In contrast, uncoated mesh samples showed hardly any antimicrobial activity and the 
bacteria thrived in their presence as indicated by a comparable surviving bacterial count 






concentration           
(µg/ml) 
Log10 reduction in 
Colonies for Broth 
Supernatant 
(Mean ± SD) 
Log10 reduction in 
Colonies for Wash 
Count 
(Mean ± SD) 
L - 10 10 
1.2 ± 0.2 1.5 ± 0.4 
L - 25 25 
1.3 ± 0.2 2 ± 0.3 
L - 50 50 1.8 ± 0.8 2 ± 0.4 
L - 100 100 1.8 ± 0.6 1.6 ±  0.2 
L - 250 250 2.3 ± 0.5 2  ± 0.3 
L - 500 500 1.6 ± 0.4 1.6 ±  0.2 
P - 100  - 
(Polyester)  
100 1.3 ± 0.6  1.5 ± 0.3  
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infection [326, 327]. A significantly less number of CFU were recovered from the wash 
counts for lysostaphin-coated samples compared to the uncoated samples (p < 0.05). It is 
thus evident from the observed data that lysostaphin-coated meshes are able to both 
efficiently kill bacteria in solution and possibly inhibit surface colonization of bacteria.  
6.3.6. In vivo rat model trial 
All twenty rats survived to the time point of mesh extraction at 7 days.  Groups that did 
not have S. aureus inoculum (Groups A, C, E, G, I) had sterile cultures at the time of 
extraction. None of lysostaphin treated controls had impaired healing.  Two of four rats 
with polyester and no lysostaphin and one of four with polypropylene and no lysostaphin 
had wound complications. All of the rats receiving a S. aureus inoculum and no 
lysostaphin had positive mesh cultures at seven days.  Animals treated with L-50 and 
inoculated with 5 x 10
5
 CFU of S. aureus had positive mesh cultures.  The L-100 group 
with 5 x 10
5




















A Polypropylene None None 7 days 
0/4 
B Polypropylene None 5 x 10
5
 7 days 4/4 
C Polypropylene L-50 None 7 days 0/4 
D Polypropylene L-50 5 x 10
5
  7 days 4/4 
E Polypropylene L-100 None 7 days 0/4 
F Polypropylene L-100 5 x 10
5
 7 days 0/4 
G Polyester None None 7 days 0/4 
H Polyester None 5 x 10
5
 7 days 4/4 
I Polyester L-100 None 7 days 0/4 
J Polyester L-100 5 x 10
5
 7 days 0/4 
Table 3: In vivo rat study results 
6.4. Discussion 
Bacterial infection at the site of implanted medical devices presents a serious and 
ongoing problem in the biomedical arena. Mesh implantation has reduced the rate of 
recurrent hernia but has led to an increased rate of bacterial infections. The incidence is 
reported to be as high as 8% following repair of incisonal hernias [311, 314, 328]. 
Although mesh-related infections occur relatively infrequently compared to other device-
related infections, it can cause significant morbidity resulting in non-wound healing, 
recurrent hernia, and need for reoperation and mesh excision. Considering that nearly one 
million inguinal and incisional hernia repairs are done every year, this is a real and 
significant medical issue.  
In our current study, we evaluate the in vitro antimicrobial susceptibility of S. 
aureus to lysostaphin-coated hernia repair meshes and study the effect of different enzyme 
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coating concentrations on antimicrobial activity. Lysostaphin
 
is a glycylglycine 
endopeptidase isolated from Staphylococcus staphylolyticus which specifically cleaves
 
pentaglycine cross bridges found in the staphylococcal peptidoglycan [329]. It kills S. 
aureus within minutes (MIC
 
at which 90% of the strains are inhibited [MIC90], 0.001 to
 
0.064 µg/ml) [320]. We observed that the antimicrobial activity of the meshes occurs due 
to extremely low concentrations of lysostaphin leaching from the surface into the 
supernatant. These concentrations are higher than its minimum inhibitory concentration 
(MIC) and enzyme release from the mesh into surrounding tissue or fluids can be expected 
to counter any initial elevated infection risk immediately post-surgery or implantation. 
A 6-h post implantation “decisive period” has been identified during which 
prevention of bacterial colonization mediated by adhesion is critical to the long term 
success of an implant [330]. Concentrations of lysostaphin that leached from the mesh in 
the first 5 h incubation in BSA varied from 0.0026 to 0.5 µg/ml depending upon the initial 
coating concentration. This is followed by a sustained release of enzyme at the same 
concentration that could be effective against occurrence of a latent infection. Passive 
coatings that aim to reduce bacterial adhesion are not as effective as “active” coatings that 
are designed to allow release of antibacterial agents immediately following the 
implantation [330]. The antimicrobial activity of the lysostaphin-coated meshes suggests 
that such enzyme releasing surfaces could be efficient at actively resisting bacterial 
adhesion and preventing subsequent colonization of implant.  
From the colony counting data, the antimicrobial activity was not significantly 
concentration dependent in the range of L-25 to L- 500 (25 to 500µg/ml) as all the six 
samples reduced bacterial titers to the same level. This agrees well with the previously 
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reported data [240]. They found that lysostaphin adsorbed onto two different plastic 
surfaces i.e. polystyrene and FEP polymer showed killing that was not concentration 
dependent where all coating concentrations (0.1, 1 and 10 mg/ml) reduced the bacterial 
count to the same level. The overall 1.6 (± 0.421) log reduction in the broth count versus 
1.8 (± 0.36) log reduction in the wash count for the coated meshes emphasized the slightly 
higher activity against adherent bacteria on the mesh surface, possibly due to a higher 
local concentration of lysostaphin near the mesh surface. Bacterial adhesion after 24 h of 
incubation in a 10
7 
CFU/ml of S. aureus suspension is greatly reduced by enzyme-coated 
meshes compared to uncoated sample.  
The results of the in vivo study show that none of the controls had bacterial 
contamination at 7 days.  Treatment with L-50 was insufficient to clear all of bacterial 
innoculum, as evidenced by positive cultures in all rats in Group D.  Interestingly, when 
doubling the treatment concentration to L-100, despite the presence of a foreign body, the 
entire bacterial load was cleared.  Although the colony count data in the in vitro studies 
did not demonstrate significant difference in bacteriocidal activity of lysostaphin at 
different concentrations, the antibacterial efficacy of lysostaphin appears to be dose-
related in vivo. The dramatic antimicrobial activity in L-100 treated group demonstrates 
great potential for lysostaphin in the clinical setting for preventing Staphylococcal related 
prosthesis infections. 
Based on our in vivo findings, we decided to characterize and test the P-100 Polyester 
mesh (Pariatex
TM
) sample with the same set of in vitro experiments as the Ultrapro 
Polypropylene mesh.  
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Our preliminary binding yield study showed a twofold decrease in the total amount 
of adsorbed lysostaphin per mg of a 1 x 1 cm piece of Polyester mesh compared to its 
Polypropylene counterpart with the same dimensions (data not shown).  The P-100 
Polyester mesh sample showed significantly higher leaching (~ 4%) in 24 h compared to 
the L-100 Ultrapro sample which showed negligible leaching. This was further confirmed 
with an activity assay of the P-100 Polyester sample that showed an almost twofold higher 
enzyme activity (7 ± 0.3 units per ml) calculated from the initial rate of the reactions from 
linearized slopes compared to the L-100 Polypropylene sample (Table 1). This can be 
attributed to the difference in rigidity, composition and hydrophobicity between the two 
mesh types. Pariatex
TM
 is a composite mesh made up of multifilament Polyester mesh and 
absorbable hydrophilic film made up of Collagen, Polyethylene Glycol and Glycerol while 
Ultrapro is a lightweight polypropylene mesh (with a monocryl weave) containing an 
absorbable component of poliglecaprone with pores between 0.1 and 3 mm [331].  
Hydrophilicity and low surface tension due to Polyethylene Glycol in the film could result 
in minimizing and weakening enzyme adsorption to Polyester meshes. We observed an 
average of 1.3 ± 0.6 log reduction for broth supernatant and 1. 46 ± 0.3  log reduction in 
the bacterial wash count for the P-100 Polyester sample after 24 h incubation. The L-100 
Polypropylene sample also had a similar (1.56 ± 0.2 log reduction) in the wash count 
despite higher amount of lysostaphin adsorbed to the mesh surface (twofold higher) and 
negligible leaching of enzyme in vitro.  
 In conclusion we have demonstrated the antimicrobial activity of lysostaphin- 
coated hernia repair mesh against S. aureus at different coating concentrations. Our early 
in vivo trial did not show impaired wound healing in the lysostaphin treated groups; 
124 
 
furthermore these data demonstrate that lysostaphin has significant promise in preventing 
prosthetic infection when used at dose of 100 µg/ml. Utilizing such an antibiotic-free 
approach, one can control the release of enzyme locally, in the area of implant infection, 
by using an appropriate coating concentration that would result in lower systemic toxicity 
and higher antibacterial efficacy. Further work is on the way to confirm our findings in the 
clinical arena.  Surface-coatings using antibacterial enzymes could be a ground breaking 
addition to the field of hernia repair and other areas of surgery in which prosthetic 




















APPLICATION OF ENZYMES AS ANTIBACTERIAL COATINGS ON PLAIN 
AND NANOPARTICLE COATED CATHETER SEGMENTS 
7.1. Introduction 
Medical devices such as intravascular and urinary catheters are routinely employed 
in healthcare sector for hemodialysis, drainage of urine, administration of IV fluids, 
medication, oxygen, anesthetic agents and monitoring of blood and intracranial 
pressure[332, 333]. Unfortunately, these catheters are also a major cause of nosocomial 
infections that occur in more than two million hospitalizations in the US annually, with 
major medical remediation costs  Consequently, catheter-related infections are notoriously 
difficult to treat via conventional antibiotic therapy, with associated mortality rates 
ranging from 12% to 25% [334]. Extended hospital stays therefore calls for an active 
intervention on the part of the healthcare personnel, and has driven the estimated annual 
healthcare cost arising from these catheter-related biofilm infections to more than nine 
billion dollars [334].  
Catheters are generally infected by microorganisms that are typically present in the 
surrounding site of insertion, usually as part of natural flora in the skin; contaminate the 
catheter along the outer surface [335]. They can also be contaminated in their lumenal 
compartments through fluid flow from contaminated infusate or from parts of the implant 
that are improperly sterilized [335]. Sometimes, percutaneous devices such as catheters 
sometimes are „marsupialized‟, where basal cells from the epidermis near the edge of the 
wound may migrate down the edge of the dermis to surround the implant forming a pouch 
without any surrounding tissue integration [336]. The space between the implant and the 
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epidermis then becomes filled with cell debris which then is a permanent source for onset 
of infection because of the lack of a natural mechanism for rejuvenation or cleaning [336]. 
In addition, upon insertion in the host, the surface of the catheter becomes „passivated‟ by 
a layer of blood proteins (due to contact with device) that assists attachment of planktonic 
bacteria. Eventually, the final stage in bacterial colonization leads to the formation of 
biofilms on the surface of the device [3, 6, 41, 231, 232]. Various clinical studies have 
been focusing on the use of different antibiotics immobilized on the surface or released 
from the bulk of an implant for prevention of biofilm formation [337, 338]. However, 
treatment with conventional antibiotics frequently fails because bacteria develop multi-
drug resistance and bacteria growing in biofilms are more resistant than planktonic cells. 
Staphylococcus aureus is a Gram-positive, biofilm-forming bacterium that is regarded as a 
leading cause of nosocomial infections and accounting (together with Staphylococcus 
epidermidis) for more than one-half of prosthetic device-associated infections[339].  
Thus, there is an urgent need for development of alternative treatment strategies that 
could overcome the problems associated with the use of conventional antibiotic therapy. 
Increasingly, attention has been paid specifically to enzymes and peptides as surface 
coatings to prevent device-associated infections [106, 109, 240, 340, 341]. For a catheter 
surface, the coating may be retained by either physical adsorption or covalent attachment 
of the enzyme. The use of nanoparticles as enzyme supports since the 80s has thereafter 
sustained a continued interest for its application modern biotechnology [187-190]. Higher 
surface area for enzyme loading, better stability and long term durability are some of the 
expected outcomes of using nanoparticles as coatings on catheter segments for enzyme 
immobilization. Hence we propose to use poly (lactic acid) nanoparticles as „surrogate‟ 
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surface coatings for enzyme adsorption on indwelling medical devices such as Central 
venous catheters (CVCs).  In this preliminary study, we propose to coat DispersinB and 
lysostaphin to the surface of Polyurethane catheter segments at different coating 
concentrations through single adsorption and coadsorption (two enzymes), characterize 
and evaluate the in vitro performance of plain and nanoparticle coated catheter segments.   
7.2. Materials and methods 
Materials: Staphylococcus aureus (ATCC 27660) was purchased from American Type 
Culture Collection (Manassas, VA). Lysostaphin (25 kDa; LSPN-50) isolated from 
Staphylococcus staphylolyticus was bought from Ambi Products LLC (Lawerence, NY).  
DispersinB (41 kDa) produced by Aggregatibacter actinomycetemcomitans was bought 
from Kane Biotech Inc. (Manitoba, Canada). Bovine Serum Albumin (BSA) was bought 
from Calbiochem (San Diego, CA).  Polyurethane Catheter tubing (Single lumen) was 
purchased A.P. Extrusion (Salem, NH). Antibiotic–antimycotic solution, heat inactivated 
fetal bovine serum, Dulbecco‟s modified eagle medium and Alexa Fluor 594 Carboxylic 
acid, Succinimidyl ester dyes used for fluorescent labeling were purchased from 
Invitrogen, Molecular Probes (Carlsbad, CA).  PBS Tablets (#524650) were purchased 
from Cabiochem (La Jolla, CA). BCA and micro BCA reagent kits were purchased from 
Pierce Biotech Inc (Rockford, IL). BBL
TM
 Trypticase Soy Broth was purchased from 
Becto, Dickinson and Company (Sparks, MD). Methylene Blue was obtained from the 
Department of Biological Sciences at Clemson University courtesy of John Abercombie. 
Poly (DL-lactide; average Mw (97500), Pluronic F68 (MW = 8.4 kDa) and 4-nitrophenyl-
N-acetyl- D-glucosaminide (substrate for DispersinB) was purchased from Sigma Aldrich 
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(St. Lous, MO). CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay (MTS) for 
cell viability studies was purchased from Promega Corporation (Madison, WI). Type 1 
Clear Borosilicate glass vial (8 mL) was with attached screw caps was bought from VWR 
(West Chester, PA).  A microsep Centrifugal Devices with a modified Polyethersulfone 
membrane (low protein binding; MWCO - 3K) used for enzyme purification were 
purchased from Pall Life Sciences (Ann Arbor, MI). All other reagents were purchased 
from VWR (West Chester, PA) and Fisher Scientific (Pittsburgh, PA), and used without 
further purification unless otherwise specified.  Binding efficiency, Turbidimetric activity 
and Colorimetric assays were performed using a Synergy microplate reader (Bio-Tek 
Instruments, Inc., Winooski, VT). Particle sizing and Zeta potential analysis of 
nanoparticles (NPs) was done using a 90plus Particle Size Analyzer (Brookhaven 
Instruments Co, Holtsville, NY). Scanning electron microscopy was done at the Electron 
microscopy facility at the Advanced Materials Research Laboratory (Pendleton, SC).  
7.2.1. Preparation of nanoparticles 
Polylactide nanoparticles were prepared using a nanoprecipitation method based on 
solvent diffusion. Briefly, Poly(DL-lactide) (average Mw (97500) was dissolved in 30 ml 
of acetone at a concentration of 8 mg/ml and this solution was then dispersed in an 
aqueous phase (200 ml) containing Pluronic F68 (5 mg/ml) under sonication ((Bransonic 
5510, Branson, MO) for 30 min. The acetone solution was added dropwise at a uniform 
rate into the aqueous phase.  The resulting suspension containing the nanoparticles was 
then purified three times in DI water by ultracentrifugation (Allegra™ 64R Centrifuge, 
Beckman Coulter, USA) at 3000g for 1 hr at 25°C to remove any excess polymer and 
Pluronic. Nanoparticle suspensions in DI water were stored in refrigerator at 4°C.  The 
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number of nanoparticles in the final suspension was then determined using gravimetric 
analysis.  
7.2.2. Particle sizing  
Stock solutions containing nanoparticles were diluted 1:1000 in DI water in a disposable 
cell and particle size was measured using dynamic light scattering with a 90Plus particle 
size /zeta potential analyzer (BrookHaven Instruments Corporation, Holtsville, NY). 
Before particle sizing, the samples were sonicated for 30 min to break up any loosely-held 
agglomerates. Particle size was expressed as a combined mean diameter in nm (+/- SD).  
7.2.3. Preparation of NP coated catheter segments 
Single lumen Polyurethane catheter tubing (Outer diameter (0.125 inches) and Inner 
diameter (0.63 inches) purchased from A.P.Extrusion was used for all the adsorption 
studies. 1 cm segments were cut off from the main tubing in a laminar flow hood under 
sterile conditions and autoclaved at 121 °C. Using a pair of sterile tweezers, the catheter 
segments were gently placed in 8 ml glass vials containing 0.5 ml of the concentrated 
nanoparticle solution and incubated overnight at room temperature with gentle shaking (50 
rpm).  Control catheter segments were placed in glass vials containing 0.5 ml of DI water. 
The samples were then washed gently with DI water three times and air dried at RT for 6 
h before protein adsorption experiments. The average weight of a 1 cm catheter segment 
was 77.5 mg calculated from combined weight of 6 catheter segments weighed together.  




NP coated catheter and uncoated samples were cut longitudinally to 0.2 cm segments and 
gently adhered horizontally to aluminum specimen support stubs using double-sided 
carbon tape. Specimens were then sputter-coated with Platinum and examined using a SU 
6600 field emission SEM equipped with variable pressure. The instrument was operated at 
10 kV accelerating voltage with a 10-12 mm working distance and the images were 
captured digitally.  
7.2.5. Enzyme adsorption on plain and NP coated catheter segments 
Initial enzyme concentrations of 0.025, 0.05, 0.1, 0.25, and 0.5 mg/ml in 1mM PBS buffer 
were each prepared from a 1 mg/mL stock solution for lysostaphin and DispersinB 
respectively. Using a pair of sterile tweezers, catheter segments (plain and NP coated) 
were gently placed into each of the vials containing 0.5 ml of enzyme solutions and 
incubated overnight at room temperature with gentle shaking (100 rpm). The sample 
solutions were removed and the catheter segments were gently flushed with 5 ml of PBS 
buffer five times and air dried for 1 h. The enzyme solution above the catheter segment 
was then collected and stored for binding efficiency measurements. The concentration of 
unbound enzyme in the supernatants was determined using BCA assay. Initial enzyme 
solutions with known concentrations were used as the standards. The concentration of the 
unbound enzyme was calculated and subtracted from initial concentration of enzyme 
present in the initial solution. The difference corresponded to the bound enzyme 
concentration on the catheter segment. Adsorption experiments were reproduced in 
triplicates. 
7.2.6. Enzyme coadsorption on plain and NP coated catheter segments 
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For coadsorption studies, we used fluorescently labeled lysostaphin (AlexaFluor 594) of enzyme 
concentrations - 0.025, 0.05, 0.1, 0.25, and 0.5 mg/ml in 1mM PBS buffer and correspondingly 
mixed with 0.025, 0.05, 0.1, 0.25, and 0.5 mg/ml of DispersinB to make up the final volume of 0.5 
ml. Alexa Fluor 594 dye was used for fluorescent labeling of lysostaphin as described in 
previous sections [298]  . Catheter segments (plain and NP coated) were placed into each of the 
vials containing 0.5 ml of enzyme mixture solutions and incubated overnight at room temperature 
with gentle shaking (100 rpm). The sample solutions were removed and the catheter segments 
were gently flushed with 5 ml of PBS buffer five times and air dried for 1 h. The enzyme solution 
above the catheter segment was similarly collected and stored for binding efficiency 
measurements. The concentration of total unbound enzyme in the supernatants was determined 
using BCA assay. Initial enzyme mixture solutions with known concentrations were used as the 
standards. The concentration of unbound enzyme was calculated and subtracted from initial 
concentration of total enzyme present in the initial mixture solution. The difference corresponded 
to the total bound enzyme concentration on the catheter segment for both lysostaphin and 
DispersinB.  
The concentration of unbound lysostaphin in the supernatant was determined from 
fluorescence measurements. Fluorescence intensities of the supernatant and standards (100 
µl) were measured in a 96 well plate using a microplate reader (Ex 594 nm; Em 625 nm). 
The concentration of unbound lysostaphin was calculated and subtracted from initial 
concentration of enzyme present in the initial solution. The difference corresponded to the 
bound lysostaphin concentration on the catheter segment. The difference of total bound 
concentration of both enzymes (BCA assay) and bound lysostaphin (fluorescence) 
corresponded to the bound concentration of DispersinB on the catheter segment. 
Coadsorption experiments were also reproduced in triplicates. 
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7.2.7. Activity assay for adsorbed enzymes 
Lysostaphin: Turbidity assay was used to assess the activity of lysostaphin adsorbed to 
Polyurethane segments. A cell suspension of S. aureus was prepared by inoculating be 10 
mL of 30% (w/v) tryptic soy with 100 µL of S. aureus culture prepared according to 
ATCC instructions as described previously. The cells were incubated at 37C for 18 - 24 h 
under gentle shaking to grow to a mid-log phase. The cells were centrifuged at 2,000 g for 
10 min and washed twice with 10 mM PBS. The cells were then resuspended in PBS to 
prepare a bacterial suspension with optical density (OD600) of ~ 0.4 at 600 nm (1 cm light 
path).  0.5 mL of the bacterial suspension was be added to 8 mL glass vials containing the 
catheter segments. The samples were be incubated with the suspension at 37ºC under 
continuous shaking, and the rate of bacterial lysis was be monitored for 1 h by taking 0.1 
mL aliquots and measuring the OD600 in a 96 well plate.  The vials containing the cell 
suspension will be continuously shaken in order to maintain contact with the catheter 
segments. All kinetic experiments were reproduced in duplicates. 
DispersinB: Activity of adsorbed DispersinB was measured using a colorimetric assay 
[107]. DispersinB activity was quantitatively assessed using UV-visible (UV-VIS) 
spectroscopy by measuring the absorbance at 400 nm of the p-nitrophenolate reaction 
product resulting from enzymatic hydrolysis of the substrate 4-nitrophenyl-N-acetyl- D-
glucosaminide. 0.5 ml of 5 mM substrate in 50mM Sodium Phosphate buffer was added to 
the vials containing the catheter segments and the enzymatic reaction was carried out for 1 
h at 37°C. After 1 h, the reaction was quenched by adding 50 µl of 10 N NaOH and 100 µl 
aliquots were collected from each sample and the absorbance was measured at 400 nm. 
All experiments were reproduced in duplicates.  
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7.2.8. Enzyme leaching studies 
Lysostaphin: Leaching of non-specifically bound enzymes from the catheter surface can 
occur both in vitro and in vivo. To model in vivo conditions, we studied enzyme leaching 
from enzyme coated catheter segments in the presence of BSA. The samples were 
incubated with 0.5 mL of 2 % (w/v) BSA solution in PBS buffer for 72 h at 37C. We 
found that fluorescence measurements lacked sensitivity to determine concentration of 
leached enzyme in the samples. We therefore estimated enzyme concentration based on its 
activity. For kinetic measurements, 50 µl aliquots from each of the samples were taken at 
different time points (6, 24, 48 and 72 h) and added to a 96 well plate.   
A 125 µl cell suspension of S. aureus in PBS buffer with optical density (OD600) of 
0.4 at 600 nm (1 cm light path) was then added to each of the different wells and the rate 
of bacterial lysis was monitored continuously for 2 h at 37ºC.  Lysostaphin solutions with 
known enzyme concentrations of 0.0071 – 7.14 µg/ml were used as standards for the 
assay. Enzymatic activity for standards and unknown samples was measured 
simultaneously in the same microplate. The initial rate of the reaction for each of the 
standards and unknowns was calculated from the linearized slopes. The standard curve 
was obtained by plotting the initial rate against the enzyme concentration. From the 
standard curve, the unknown enzyme concentrations were determined and the amount of 
leached enzyme for each of the samples was plotted as a function of time. All kinetic 
experiments were reproduced in duplicates.  
DispersinB:  
Similarly, leaching of DispersinB was studied modeling in vivo conditions, in the 
presence of 2 % (w/v) BSA solution in PBS buffer for 72 h at 37C. For kinetic 
134 
 
measurements, 50 µl aliquots from each of the samples were taken at different time points 
(6, 24, 48 and 72 h) and added to a 96 well plate. A 100 µl solution of 4-nitrophenyl-N-
acetyl- D-glucosaminide (5 mM) was added to each of the different wells and the 
absorbance at 400 nm of the p-nitrophenolate reaction product resulting from enzymatic 
hydrolysis of the substrate was monitored continuously for 1 h at 37ºC.   
DispersinB solutions with known enzyme concentrations of 0.083 – 8.3 µg/ml 
were used as standards for the assay. Enzymatic activity for standards and unknown 
samples was measured simultaneously in the same microplate. The initial rate of the 
reaction for each of the standards and unknowns was calculated from the slopes. The 
standard curve was obtained by plotting the initial rate against the enzyme concentration. 
From the standard curve, the unknown enzyme concentrations were determined and the 
amount of leached enzyme for each of the samples was plotted as a function of time. All 
kinetic experiments were reproduced in duplicates.  
The different samples designated based on their initial coating concentrations of 
10µg/ml, 25µg/ml, 50 µg/ml, 100µg/ml, 250µg/ml and 500µg/ml were L-25, L-50, L-100, 
L-250, L-500 for lysostaphin and D-25, D-50, D-100, D-250 and D-500 for DispersinB 
coated on uncoated catheter segments. Similarly, samples were designated as NPL-25, 
NPL-50, NPL-100, NPL-250, NPL-500 and NPD-25, NPD-50, NPD-100, NPD-250, 
NPD-500 for lysostaphin and DispersinB adsorbed on NP coated catheter segments 
respectively.  
7.2.9. Cell viability using MTS assay 
The CellTiter 96
®




inner salt; MTS) and the electron coupling reagent, phenazine methosulfate (PMS). MTS 
is chemically reduced by cells into formazan, which is soluble in tissue culture medium 
[342]. The measurement of the absorbance of the formazan can be carried out using 96 
well microplates at 492nm. The assay measures dehydrogenase enzyme activity found in 
metabolically active cells. Since the production of formazan is proportional to the number 
of living cells, the intensity of the produced color is a good indication of the viability of 
the cells. MTS solutions were prepared according to the manufacturer‟s instructions.  
Using the methods outlined in ISO standard 10993-5 as a guideline, mouse 3T3 
fibroblasts (donated by Cassie Gregory; Department of Bioengineering, Clemson 
University) were previously cultured in Cell culture flasks in DMEM supplemented with 
1% Fetal Bovine Serum (FBS) and 1% antibiotic (Penicillin/Streptomycin). The cells were 
trypsinized, centrifuged for 5 minutes at 1000 rpm with the medium aspirated and the cell 
pellet resuspended in fresh media at a concentration ~10,000 cells/mL.  Aliquots (100 µL) 
were then pipetted into individual wells of a 24-well plate with fresh media.  Cells were 
allowed to grow to confluence for 24 h at 37°C in a humidified 5% CO2 environment.  
Cell viability was checked under a microscope and the media replaced every 12 h.  The 
samples were then cut into 0.3 cm pieces to ensure specimen coverage of approximately 
one-tenth of the cell layer surface (ISO 10993-5).  Samples were then gently placed on the 
cell layer in the center of 24-well plates using a pair of sterile forceps. Subsequently, 
plates were incubated for 48 h at 37°C in a humidified 5% CO2 environment with media 
being changed every 12 h.  Care was taken during mesh placement in the wells to prevent 
unnecessary movement, which can lead to physical trauma to the cells and dislodgement 
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of cells from the mesh. Sterile Latex pieces were used as positive controls for assessment 
of cytotoxicity (ISO 10993-5) while cells in media alone were used as negative controls.  
After 48 h, samples were gently removed using a pair of sterile forceps and 50 µl 
of MTS reagent was added to every well in one of the 24-well plates in a ratio of 1:5 
(MTS reagent : volume of media in the well).  The plate was incubated at 37 °C for 4 h in 
a humidified, 5% CO2 atmosphere.  100 µl from each well was then transferred to wells of 
a 96-well plate and the absorbance was recorded at 490 nm (OD490) and 650 nm (OD650) 
using a plate reader. Raw quantitative data generated by the microplate reader were 
analyzed by first subtracting the difference of OD490 and OD650 reading to remove any 
background interference.  The resultant mean OD readings from each well were calculated 
as an average of two replicates for each sample and expressed as a percentage of the OD 
values observed relative to OD values measured in the negative control wells (negative 
control – cells in media).   
7.2.10 Antibiofilm assay 
Briefly, S. aureus culture was grown overnight in 10 ml of TSB (Bidifico) supplemented 
with 1% D-glucose (Tokyo Kasei, Japan). The overnight bacterial cultures was then 
centrifuged twice, resuspended in TSB and spot plating on Agar was done to determine 
the number of colonies in the active culture. 1 ml containing ~ 10
6
 CFUs in TSB 
supplemented with1% D-glucose was added to wells of a 12-well tissue culture plate 
(Costar Inc., Corning, N.Y.) containing the coated catheter segments. The 12-well plate 
was incubated at 37°C with shaking at 100 rpm for 12 h and then removed from the shaker 
and supplemented with either 200 µl of additional fresh TSB to compensate for medium 
evaporation. These plates were then be incubated at 37°C for an additional 24 h.  
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After ~36 h of growth, the media was removed from various wells, washed thrice 
with phosphate-buffered saline (PBS) to remove any non-adherent bacteria. The assay 
plates were allowed to dry at 37°C for approximately 2 hr. The wells containing the 
segments were then stained with 0.5 ml of 1% Methylene Blue for 30 min and then gently 
washed with PBS three times; air dried for 1 h and destained with 30% acetic acid 
solution. The eluted dye solution was then transferred to wells of a 96 well plate and the 
absorbance was recorded at 660 nm to evaluate the inhibition of S. aureus biofilms.  
7.2.11. Accelerated Shelf life Study 
Accelerated aging testing is performed on packaged medical devices such as 
catheters and implants to ascertain its shelf life and document expiration dates. We 
modeled a study based on long term stability testing of our enzyme coated catheter 
segments by measuring enzyme activity after storage. Initial lysostaphin and DispersinB 
concentration of 0.5 mg/ml in 1mM PBS buffer was each prepared from a 2 mg/mL stock 
solution and using a pair of sterile tweezers, catheter segments (plain) were gently placed 
into vials containing 0.5 ml of enzyme solutions and incubated overnight at room 
temperature with gentle shaking (100 rpm). The sample solutions were removed and the 
catheter segments were gently flushed with 5 ml of PBS buffer five times and air dried for 
1 h. The samples were then incubated in a -80 °C freezer overnight in glass vials sealed 
with parafilm. Samples were then freeze-dried for 24 h in a Freeze Dry System/Freezone 
4.5 from Labconco (Kansas City, MO) courtesy of Dr. Ken Webb (Clemson University). 
Samples were then hermetically sealed using a heat press in special peelable high barrier 
pouches (# TPC-1475B) from Oliver-Tolas Healthcare Packaging (Grand Rapids, MI). 
138 
 
The samples were then incubated at 60 °C for 1 week in an Isotemp Oven; Model 516G 
from Fisher Scientific (Ann Arbor, MI).   
After 1 week, the samples were removed and placed in wells of a 24 well plate.  
For lysostaphin activity, 0.5 mL of a previously purified bacterial suspension with optical 
density (OD600) of ~ 0.38 at 600 nm (1 cm light path) was added to each of the wells 
containing the catheter segments. The samples were incubated with the suspension at 37ºC 
under continuous shaking along with appropriate controls, and the rate of bacterial lysis 
was be monitored for 3 h by taking 0.1 mL aliquots every hour and measuring the OD600 
in a 96 well plate.  The vials containing the cell suspension were continuously shaken in 
order to maintain contact with the catheter segments. Activity of DispersinB adsorbed on 
catheter segments was monitored using the colorimetric assay as described previously by 
measuring the absorbance at 400 nm of the p-nitrophenolate reaction product resulting 
from enzymatic hydrolysis of the substrate 4-nitrophenyl-N-acetyl-D-glucosaminide. 0.5 
ml of 5 mM substrate in 50mM Sodium Phosphate buffer was added to the vials 
containing the catheter segments and the enzymatic reaction was carried out for 1 h at 
37°C. After 1 h, the reaction was quenched by adding 50 µl of 10 N NaOH and 100 µl 
aliquots were collected from each sample and the absorbance was measured at 400 nm. 
All experiments were reproduced in triplicates.  
7.2.12. Statistical analysis 
Data are presented as means±SD. One-way analysis of variance (ANOVA) and Paired„t‟ 
test was performed for comparing coated and uncoated samples with different initial 
enzyme concentrations. The null hypothesis was that the means are not significantly 
different. Data were analyzed using Origin 6.0 and 8.0 Data Analysis and Graphing 
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Software (OriginLab Corporation, MA, USA). A p value of <0.05 was considered 
statistically significant.  
7.3. Results and Discussion 
7.3.1. Enzyme Binding yield  
Based on previous preliminary data, which demonstrated high antibacterial activity 
of enzyme-NP conjugates against planktonic cells (Chapters 4 and 5), we proposed to 
compare the loading of enzymes and enzyme-NP conjugates on catheter segments and 
subsequently evaluate antimicrobial and antibiofilm activity of the catheter segments. We 
decided to adsorb both DispersinB and lysostaphin to the surface of PLA nanoparticles 
either alone or through coadsorption. After synthesis and characterization of enzyme-NP 
conjugates, we incubated them with catheter segments and compared the binding 
efficiency of plain enzyme- and enzyme-NP conjugate-coated catheter segments. 
Higher binding yield, better enzyme stability and long term durability were some 
of the expected outcomes using this approach. However, we observed two- to five-fold 
less amount of DispersinB adsorbed in the case of enzyme-NP conjugate-coated catheter 
segment compared to the plain enzyme-coated catheter segment and thirty-fold less 
amount of DispersinB adsorbed in case of samples coadsorbed with lysostaphin (data not 
shown).  
We hypothesized that coating by enzymes makes NPs more hydrophilic leading to 
decreased NP attachment to the catheters. Thus, we decided to modify our approach to 
achieve better coating by enzyme-NP conjugates. We opted to first coat the surface of the 
catheter segment with PLA nanoparticles and then adsorb enzymes at different initial 
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concentrations either alone or through coadsorption. This approach eliminates possible 
error in determination of enzyme concentration in enzyme-NP conjugates as we are using 
the same initial enzyme concentrations when coating catheters by either plain enzyme or 
enzyme-NP conjugates.  
We made certain theoretical approximations. A greater surface area is expected 
upon coating PLA nanoparticles on the surface of a Polyurethane catheter segment. The 
average diameter of a PLA NP calculated from previous DLS experiments was 181 ± 29 
nm (mean from 3 different batches) depending upon the batch of NPs used for coating 
experiments. Based on the dimensions of a 1 cm PU catheter segment, with ID and OD of 
0.317 cm and 0.158 cm, the theoretical surface area calculated assuming a hollow cylinder 
is 1.614 cm
2
. The number of nanoparticles that could saturate the surface of a 1 cm PU 
catheter segment with a diameter of 180 nm is 1.5 x 10
9
 particles assuming that the surface 
of the catheter segment is smooth and devoid of any topography. The surface area 
occupied by each spherical NP adsorbed on the surface is 4πr
2
.  Theoretically, an enzyme 
molecule that has an average hydrodynamic radius of „r‟ occupying the surface of the 
catheter segment will have a surface area of r
2
.  However, if it were to adsorb on the 
surface of a catheter segment that is completely saturated with a monolayer of NPs, it 
could theoretically occupy a surface area of 4 πr
2
 per NP on the catheter (Figure 7.1). This 
increase in surface area and high surface energy of a nanoparticle could contribute to 
better adsorption and subsequently higher effective loading based on the same initial 
coating concentration of enzyme for NP coated catheter segments. Previously, Crisante et 
al investigated the antibiotic release of nano-structured polymer systems in carboxylated 
polyurethane [343]. They hypothesized that since nanoparticles are characterized by a high 
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surface/volume ratio; their presence in the polymer could result in a greater surface area 
available for the antibiotic adsorption.  
 
 
Figure 7.1. An illustration for a model single lumen catheter segment before and 
after coating with nanoparticles.  
Binding yield was calculated based on the total amount of enzyme adsorbed per 
mg of plain or PLA NP coated PU catheter segment. Figure 7.2 shows the binding yield 
for lysostaphin and DispersinB on plain or NP coated 1 cm
 
PU catheter segment at 
different initial enzyme coating concentrations. Figure 7.2A and 7.2B specifically 
corresponds to enzyme adsorption for lysostaphin and DispersinB individually and Figure 
7.2C and 7.2D correspond to adsorption of each enzyme in the presence of the other 
(coadsorption). The amount of adsorbed enzyme (µg) per mg of catheter segment is 













Figure 7.2 A). Binding yield for lysostaphin on plain and NP coated PU catheter 
segment; B). Binding yield for DispersinB on NP coated PU catheter segment C). 
Binding yield for lysostaphin on plain and NP coated PU catheter segment when 
coadsorbed with DispersinB at the same coating concentration. D). Binding yield 
for DispersinB on plain and NP coated PU catheter segment when coadsorbed 
with lysostaphin at the same coating concentration; (Mean ± SD; n = 3). Black 






Based on the above described experimental conditions, ~11 to 23% of lysostaphin 
initially present in the solution remained bound to the catheter segment for plain catheter 
samples and ~ 8 to 29% was bound to NP coated catheter segments depending upon the 
initial coating concentration. Similarly, ~12 to 30% and ~ 20 to 35 % of DispersinB 
initially present in the solution remained bound to the catheter segment for plain and NP 
coated catheter segments respectively. Generally, the amount of enzyme bound to catheter 
segment increased linearly on increasing the enzyme coating concentration for plain and 
NP coated catheter segments (Figure 7.2A and 7.2B). Plain coated catheter segments 
showed a slightly higher adsorbed lysostaphin concentration per weight than NP coated 
catheter segments for the samples, while the amount of DispersinB bound to catheter 
segment was not significantly different for both types of catheter segments (p > 0.05).  
In case of the coadsorption study, both lysostaphin and DispersinB were 
simultaneously adsorbed at different initial concentrations and the amount of each enzyme 
was calculated using both BCA analysis and fluorescence. As described in the methods 
section, the amount of bound lysostaphin was calculated via fluorescence labeling and the 
difference between the total protein content (BCA analysis) and bound lysostaphin was 
used to calculate amount of DispersinB bound on the catheter segment. Binding yields for 
lysostaphin consisted of ~2 to 10% and ~8 to 13 % per total weight of the protein mixture 
in the initial solution for plain and NP coated catheter segments respectively.  Similarly, 
the binding yield for DispersinB corresponded to ~0.1 to 68% and ~1.5 to 42% per total 
protein weight for plain and NP coated catheter segments respectively when co-adsorbed 
with the lysostaphin (Figure 7.2C and 7.2D).  
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We expected a higher surface area for enzyme adsorption for NP coated catheter 
segments after precoating plain Polyurethane catheter segments with PLA nanoparticles. 
BET specific surface analysis study comparing both plain and NP coated Polyurethane 
segments was inconclusive for all sets of samples because specific surface area for all 
samples was below BET detection limit (data not shown).  Figure 7.3A-H below shows a 
cross section of the outer surface of plain and NP coated Polyurethane catheter segments 
taken at different magnifications taken on SU-6600 field emission SEM equipped with 
variable pressure. These images clearly show that the sample catheter segments did not 
have a monolayer of nanoparticle coating on the surface as expected. There was still a 
large portion of the catheter segment that was bare and devoid of any nanoparticles. 
Lysostaphin and DispersinB molecules probably bound more on the bare portion rather 
than NP coated part of the polyurethane catheter segment just to due to higher available 





Figure 7.3. SEM images of plain (A, C, E, G) and PLA NP (B, D, F, H) coated 
Polyurethane catheter segments at different magnifications taken on SU-6600 








The degree of surface coverage on the catheter segment can be predicted from the 
binding yield of each either of the enzymes when adsorbed alone or in the presence of the 
other.  Average dimensions of the lysostaphin molecule are 4.5 nm X 5.5 nm X 8.5 nm 
[301]. The average surface area occupied by an adsorbed protein molecule based on the 
smallest dimensions is 25.02 nm
2
.  Similarly, the average dimensions of DispersinB 
molecule are 4.1 nm X 8.6 X 18.1 nm [344]. The average surface area occupied by 
adsorbed DispersinB molecule based on smallest dimensions is 35.26 nm
2
.  The maximum 
theoretical monolayer of lysostaphin adsorbed on a 1 cm catheter segment calculated 
using the above surface area per molecule and the theoretical surface area of catheter 
segment of 1.614 cm
2
 consisted of 6.5 X 10
12
 molecules. Similarly, for DispersinB, the 
number of molecules that could occupy the surface of the catheter segment for a 
theoretical monolayer is 4.6 X 10
12
.  Based on these theoretical considerations, the binding 
yield data for lysostaphin and DispersinB adsorbed alone or through coadsorption on plain 
and NP coated catheter segments suggests multilayer protein adsorption, from ten to 
several hundred layers of molecules, depending upon the coating concentration.  
Multilayer adsorption on polymer surfaces has been observed with different 
proteins interacting with a variety of surfaces [344-347]. The proteins in direct physical 
contact with the adsorbing surface or the layer of water molecules present around the 
surface will be strongly affected by surface properties [348, 349]. These surface properties 
include wetability, topography, chemical composition etc. Due to these surface 
characteristics, the interaction between a protein molecule and the surface can induce 
conformational changes on the protein, resulting in a different surface that would 
influence interaction with the surrounding protein molecules in the bulk solution and so 
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on. The adsorption isotherms (Figure 7.2A and 7.2B) from a single protein solution do not 
reach saturation upon increasing the protein concentration providing additional argument 
in favor of multilayer adsorption hypothesis. 
Another possible explanation is that adsorbed proteins actually form a monolayer 
but real specific surface area of the catheter segment is significantly higher than that 
estimated from purely geometric considerations. In fact, BET using Kr adsorption 




) of the surface: 
Thus, even if the catheter‟s actual specific surface area exceeds that calculated from 
geometric dimensions by the factor of 200-300, it would still be undetectable using BET 
method. Of note, alternative BET approach that uses N2 instead of Kr is even less sensitive 
and requires 0.5-1 m
2
 of the surface at the lower detection limit.  
Protein adsorption studies from solutions containing a mixture of proteins imply 
some competitive adsorption, where different proteins with different characteristics will 
compete with each other for the available surface area for adsorption [241]. Aside from 
the size, isoelectric point, molecular weights, secondary structures of the protein etc 
surfaces features also influences interactions between different proteins. We observed a 
decrease in amount of each of individually adsorbed protein (lysostaphin and DispersinB) 
when adsorption occurs from a mixture of protein solutions. At the same time, the total 
amount of bound protein from a mixture of proteins is significantly higher (p < 0.05) than 
total protein adsorbing from a single solution for both plain and NP coated catheter 
segments.  
7.3.2. Adsorbed enzyme activity assay  
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Activity of adsorbed lysostaphin on plain and NP coated catheter segments was 
done by monitoring the cell lysis of a S. aureus cell suspension [325] as described 
previously. We monitored the decrease in optical density of the bacterial suspension and 
compared the rate of lysis for the samples with the highest and lowest initial enzyme 
coating concentration (25µg/ml and 500µg/ml). Figure 7.4A shows the mean rate 
constants of bacterial lysis and standard deviations for these samples (n=2) for both plain 
and NP coated catheter samples.  
 
Figure 7.4. Activity assay data shown as bar graphs comparing the kinetic 
constant of bacterial lysis against the highest and lowest lysostaphin coating 
concentrations for plain and NP coated catheter segments. Black bar – NPL-25 
represnts NP coated catheter segment with initial lysostaphin concentration of 25 
µg/ml, Red bar – NPL-500 represents NP coated catheter segment with initial 
lysostaphin concentration 500 µg/ml; Green bar – L-25 represents plain catheter 




represents plain catheter segment with initial lysostaphin concentration 500 µg/ml; 
(Mean ± SD; n= 2; * - p > 0.05)  
We found that the initial rate of cell wall lysis was not significantly concentration 
dependent for the two sets of initial concentrations (p>0.05 –„Paired t test‟) and not 
significantly different for all samples of plain and NP coated catheter segments (p>0.05 – 
One way ANOVA).  A similar trend in adsorbed lysostaphin activity was also seen in 
samples coadsorbed with DispersinB at the same coating concentrations (data not shown). 
It is well known that lysostaphin is active against S. aureus at extrememly low 
concentrations [320]. The results obtained here are in strong agreement with data obtained 
by Shah et al, who also evaluated lysostaphin activity after physical adsorption to catheter 
segments [240]. They also found that the antibacterial activity of lysostaphin was not 
dependent upon coating concentrations as they found all three concentrations used (0.1, 1 
and 10 mg/ml) showed the same antistaphylococcal activity by inhibiting bacterial growth 
to the same level.  This is in contrast to our experiments with lysostaphin-coated hernia 
repair meshes (Polypropylene weave – Ultrapro) where we observed a correlation between 
lysostaphin coating concentration and lytic activity of all the samples. This can again be 
attributed to differences in material composition and porosity of the two types of samples 
as mentioned previously.  
We used a colorimetric assay to test activity of DispersinB adsorbed to catheter 
segments with a synthetic substrate, 4-nitrophenyl-N-acetyl-β-glucosaminide in a 
procedure similar to the one used by Donelli et.al [107]. We monitored the optical density 
(OD400) of p-nitrophenolate reaction product resulting from the enzymatic hydrolysis of 
the substrate by comparing the rates of enzymatic hydrolysis for the samples with the 
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highest and lowest initial enzyme coating concentration (25 µg/ml and 500 µg/ml).  It is 
well known that most biofilm-producing staphylococcal strains produce a linear PNAG 
and it has been demonstrated previously that DispersinB is able to degrade N- 
acetylglucosamine-containing polysaccharides [107, 350, 351]. Figure 7.5 shows the mean 
rate constants of hydrolysis and standard deviations for these samples (n=2) for both plain 
and NP coated catheter samples. We found the rate of hydrolysis of substrate was 
significantly concentration dependent for the two sets of initial concentrations (p<0.05 –
„Paired t test‟) for both plain and NP coated catheter segments. However, we did not see a 
significant difference between plain and NP coated catheter segments (p > 0.05; one way 
ANOVA).  A similar trend in adsorbed DispersinB activity was also seen in samples 
coadsorbed with lysostaphin at the same coating concentrations (data not shown).  
 
Figure 7.5. Activity assay data shown as bar graphs comparing the kinetic 
constant of substrate hydrolysis via colorimetric assay against the highest and 
lowest DispersinB coating concentrations for plain and NP coated catheter 





DispersinB concentration of 25 µg/ml, Red bar – NPD-500 represents NP coated 
catheter segment with initial DispersinB concentration 500 µg/ml; Green bar – D-
25 represents plain catheter segment with initial DispersinB concentration of 25 
µg/ml and Pink bar – D-500 represents plain catheter segment with initial 
DispersinB concentration 500 µg/ml; (Mean ± SD; n= 2; ¥ - p < 0.05; * - p > 0.05;)  
7.3.3. Enzyme leaching results 
We assessed lysostaphin and DispersinB leaching in the presence of 2 % (w/v) 
BSA, as a model for the most abundant protein in blood plasma.  Figure 7.6 shows 
leaching for all samples with different coating concentrations for lysostaphin and 
DispersinB adsorbed to plain and NP coated catheter segments. We chose to quantify 
leaching using activity assays for the individual enzymes rather than BCA analysis or 
fluorescent labeling owing to low sensitivity of the two latter techniques. The unknown 
enzyme concentrations for each of the samples were determined from a standard curve 
that plotted rate of the reaction (enzymatic lysis for lysostaphin and enzymatic hydrolysis 
for DispersinB) against a series of known enzyme concentrations and the amount of 








Figure 7.6. Leaching of enzyme as a function of time for plain and NP coated 
catheter segments treated by different initial enzyme concentrations. A.) 
Lysostaphin leaching from plain catheter segment B). Lysostaphin leaching from 
NP coated catheter segment C). DispersinB leaching from plain catheter segment 
and D). DispersinB leaching from NP coated catheter segment. Black squares – 
25 µg/ml, Red circles -50 µg/ml, Green triangles – 100 µg/ml, Blue inverted 




performed in the presence of 2 % (w/v) BSA in PBS buffer (pH = 7.4) at 37C. 
(Mean ± SD; n= 2).  
We observed an overall < 0.2 % enzyme leaching from all the studied samples 
after 72 h incubation in BSA (Figure 7.6 A-D).  In case of coadsorption of lysostaphin and 
DispersinB on plain and NP coated catheter segments, we observed an almost identical 
trend of < 0.2% leaching of enzyme for all the samples (data not shown). Again, the data 
obtained in our leaching study reflected a similar trend in the results obtained by authors at 
Biosynexus Inc [240]. They observed almost negligible leaching after coating lysostaphin 
on a Teflon-like FEP polymer used in angiocath catheter segments and Polystyrene well 
plates.   
7.3.4. Cell viability study 
Of particular importance in assessing cellular response and biocompatibility is 
quantifying the prospective biomaterial‟s inherent cytotoxicity, or its ability to induce cell 
death [352]. In vitro models may provide answers regarding several aspects, including cell 
viability (cytotoxicity of implant material or extractables), proinflammatory effects and 
alteration of cellular response to different signaling molecules like cytokines [353].  
Fibroblasts were chosen as an appropriate cell model as they play a crucial role in the 
inflammatory response [354]. This study aimed to evaluate the cellular response to 
enzyme coated catheter segments using an in vitro approach and methods in accordance 
with the International Organization for Standardization‟s (ISO) standard number 10993-5.  
In particular, it is important to evaluate the cytotoxic effects of the two adsorbed enzymes, 
lysostaphin and DispersinB. Both enzymes are produced by different bacterial species. 
Lysostaphin is isolated from culture filtrates of S. Staphylolyticus and DispersinB is 
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isolated from A. actinomycetemcomitans and could show potential cytotoxcity, especially 
if small amounts of enzyme leached from the catheter surface during in vivo trials.  
 The results of cytotoxicity tests on extracts by MTS assay are shown in Fig.7.7. 
Raw quantitative data generated by the microplate reader were analyzed by first 
subtracting the difference of OD490 and OD650 reading to remove any background 
interference.  The resultant mean OD readings from each well were calculated as an 
average of two replicates for each sample and expressed as a percentage of the OD values 
observed relative to OD values measured in the negative control wells (negative control – 
cells in media). 
 
Figure  7.7. Direct cytotoxicity results of MTT assay that shows the percentage of 
cell viability after 48 h of all the catheter samples coated with the highest coating 
concentration that were placed in contact with 3T3 fibroblasts (n=2). Coating 
concentration for all samples was 500µg/ml. Black Bar –   L-500, Red bar – D-
500, Yellow bar – LD-500, Wine Red – NPL-500, Grey Bar –NPD-500, Dark Blue 
bar – NPLD-500, Pink Bar – Uncoated cathter segment, Green Bar – PLA NP 
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coated catheter segment, Light Blue Bar – Negative control (Untreated 
Fibroblasts) and Orange Bar - Positve control (Latex samples) 
The metabolic activity of the fibroblasts is directly proportional to the cell 
viability. Overall, the cell viability in the negative controls (Plain cells in media) did not 
differ significantly from any of the test samples including uncoated or coated either by 
lysostaphin coated or DispersinB or via coadsorption of two enzymes (p > 0.05; p = 
0.31718, One way ANOVA). There was also no significant difference between coated 
plain and NP coated catheter segments (p > 0.05; p = 0.14232, Paired‟t‟ test). Again, we 
did not see a significant difference between plain and NP coated segments. The positive 
control (Latex fragments) was shown expectedly to be highly cytotoxic showing ~ 14 % 
cell viability post 48 h incubation with the cells. These results demonstrated that the 
enzyme coated catheter segments were not cytotoxic in vitro in chosen experimental 
conditions.  
7.3.5. Antibiofilm assay 
DispersinB combined with various antimicrobials has been shown to work 
synergistically to inhibit the growth and proliferation of biofilm-embedded bacteria such 
as Staphylococcus epidermis and Staphylococcus aureus [107, 109, 110]. Figure 7.8 
shows the percentage of biomass for the samples coated with the highest enzyme 
concentration – 0.5 mg/ml. We tested the in vitro antibiofilm activity of samples coated 
with DispersinB or lysostaphin alone or as a combination for both plain and NP coated 
catheter segments. We wanted to test synergy between lysostaphin (antibacterial) and 
DispersinB (antibiofilm) and study if we could completely inhibit adhesion and growth for 




Figure  7.8. Biofilm inhibition assay of catheter samples done by Methylene Blue 
staining for catheter samples coated with highest enzyme concentration. Black 
Bar –   NPL-500, Red bar – NPD-500, Blue bar – NPLD-500, Green Bar – L-500, 
Brown Bar –D-500, Light brown bar –LD-500 and Dark Blue Bar – Uncoated 
catheter segment; (Mean ± SD ; n=3).  
We chose methylene blue as our dye for biofilm staining over crystal violet 
because in our preliminarily studies we observed significant non-specific binding of 
crystal violet to Polyurethane catheter segments. Percentage of biomass on the catheter 
segment was calculated from the following formula – ((Absorbance (660) of sample) / 
(Absorbance (660) of control))*100 
We observed an average of 26 ± 13 % biomass on NP coated catheter segments adsorbed 
with lysostaphin compared to plain lysostaphin samples that showed an average of 13 ± 1 
% biomass and this was not significantly different (p>0.05; Paired „t‟ test) compared to 
samples coated with DispersinB for plain (12 ± 4)% and NP coated catheter samples (15 ± 
4)% biomass.  At coating concentrations of 0.5 mg/ml, it seems like both DispersinB and 
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lysostaphin inhibit biofilm formation on catheter surfaces and there was no significant 
difference in amount of biomass on catheters even after coadsorption of the two enzymes 
(p> 0.05; One way ANOVA).  
Polysaccharide intercellular adhesin (PIA), composed of poly-β-1,6-linked-N-
acetylglucosamine, a sticky extracellular polysaccharide, is the main constituent of S. 
aureus  and S. epidermis biofilm matrix [40]. PIA is produced by the intercellular 
adhesion (ica) operon present in nearly all S. aureus strains. DispersinB specifically 
hydrolyses the glycosidic linkages of poly-β-1,6-N-acetylglucosamine without inhibiting 
the growth of bacteria [108]. It is a stable glycoside hydrolase that functions in a narrow 
pH range and effective against both Gram positive and Gram negative bacteria.  
DispersinB can only inhibit or disperse Staphylococci biofilms without affecting their 
growth, so it would be necessary to combine it with lysostaphin in order to inhibit the 
growth and cause lysis of biofilm-embedded bacteria. Previously, authors at Kane Biotech 
have shown synergy and in vitro and in vivo efficacy of DispersinB® and Triclosan 
combination against S.aureus and S.epidermis biofilms [109].  
However, lysostaphin by itself is known to have some biofilm inhibiting activity. 
Kokai-Kun et al have previously shown inhibition of S. aureus biofilms by lysostaphin in 
vitro on artificial surfaces and in vivo using a catheterized mouse model [341]. The 
authors have also observed that lysostaphin not only killed the staphylococci in the 
biofilm, but also appeared to prevent formation of the EPS matrix needed for biofilm 
formation on the artificial surfaces.  The exact mechanism by which lysosytaphin disrupts 
biofilm formation remains unclear but the authors suggest that disruption occurs through 
the rapid lysis of the sessile staphylococci, which may be sufficient to destabilize the 
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entire biofilm matrix in a manner that allows cell detachment from surfaces [162]. We also 
similarly observed inhibition of S. aureus biofilm after coating lysostaphin on plain and 
NP coated catheter segments. We hypothesize that the planktonic bacteria in the media 
(during growth of biofilm) are directly interacting with the enzyme coating on our catheter 
segment. Our preliminary binding yield study suggests the possibility of multiple layers of 
enzyme coating on the catheter surface. These layers of lysosyaphin molecules are either 
directly interacting with planktonic bacterial cells or lysostaphin molecules slowly leach 
into the surrounding environment and lyse the bacteria thereby preventing subsequent 
attachment and biofilm formation. The latter however seems unlikely since data from the 
leaching study shows lysostaphin leaching (Fig 7.6) to be less than 1 % after 72 h of 
incubation in BSA.  
 
Figure 7.9.  Images taken on a digital camera courstey department of 
Bioengineering; A). Control – Uncoated catheter PU segment. B). Lysostaphin 
and DispersinB coated PU catheter segment.  




Biomedical devices and implants coated with antimicrobial enzymes in storage may 
change as they age, but they are considered to be stable as long as they retain specific 
activity as per manufacturer's specifications. The number of days that the product remains 
stable at the recommended storage conditions is referred to as the shelf life. Shelf life is 
commonly estimated using two types of stability testing: real-time stability tests and 
accelerated stability tests [355-357] In the former, a product is stored at recommended 
storage conditions and its shelf life is monitored while in the latter, a product is stored at 
elevated stress conditions using temperature, humidity, pH or a combination. In practice, 
evaluators use both real-time stability tests and accelerated stability tests. However, real-
time stability testing can take a longer time to complete and so accelerated tests are often 
used as temporary measures to expedite processes in product development [356].  
Temperature is the most common acceleration factor used for chemicals, pharmaceuticals, 
and biological products and accelerated aging testing is based on a thermodynamic 
temperature coefficient formulated by Von't Hof stating that for every 10 C degree rise in 
temperature, the rate of chemical reaction will at least double [358]. According to FDA 
regulations and package testing industry, this is useful in defining and justifying 
accelerated aging testing services [355].  An appropriate temperature for the accelerated 
shelf life testing must be chosen to avoid failure conditions such as deformation due to 
polymer melting. In our chosen study, the catheter segments are made up of Polyurethane 
which has a melting temperature of 240 C.  
 Based on the shelf life testing of lysostaphin coated hernia-repair meshes performed by 
Sriram Sankar in collaboration with CMC (data not shown), we decided to choose a 
testing temperature of 60 C and a time period of 1 week for storage which is equivalent to 
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4 months of shelf life at room temperature. Before studying long term enzyme stability on 
catheter segments, it is necessary to lyophilize the enzyme to improve its stability. 
Lyophilization gives the opportunity to help avoid enzyme denaturation caused by 
heating, by maintaining the samples frozen throughout the drying process. The first step in 
the lyophilization process is to freeze all the water molecules present in the sample and 
then it is placed in a lyophilizer and gradually heated in vacuum where all the water 
sublimates as vapor.  The samples were frozen overnight at -80 C,  lyophilized for 24 h 
and then sealed in air tight pouches (blasted with nitrogen) to prevent entry of air and 
moisture. 
We studied accelerated shelf life testing for plain and NP coated catheter samples 
adsorbed with the highest coating concentration of 0.5 mg/ml of lysostaphin and 
DispersinB using activity assays as described preciously. Turbidity assay was used to 
quantify the activity of lysostaphin and colorimetric assay was used to test activity of 
DispersinB. We also tested activity of lysostaphin samples coadsorbed with DispersinB at 
the same coating concentration and vice versa.  Figure 7.10 below shows the kinetic 
constant for bacterial hydrolysis for lysostaphin coated samples for plain and NP coated 




Figure 7.10. – Comparing the mean rate constants of bacterial lysis for both plain 
and NP coated catheter samples after 1 day and post 1 week at 60C (equivalent 
4 months at RT). Red bar – NPL-500 represents NP coated catheter segment with 
initial lysostaphin concentration 500 µg/ml; Green bar – L-500 represents plain 
catheter segment with initial lysostaphin concentration of 500 µg/ml; (Mean ± SD; 
n= 2; * - p > 0.05)  
We found that the initial rate of bacterial lysis for all the samples was almost equal to the 
lytic activity assayed before shelf life testing (p>0.05 – One way ANOVA) for plain and 
NP coated samples at coating concentration of 0.5 mg/ml. Again, no significant difference 
between samples coated only with lysostaphin and coadsorbed with DispersinB (data not 
shown). These results seem to suggest that lysostaphin retained all of its activity after 1 
week at 60 C (equivalent of 4 months at RT). We had also quantified lysotaphin activity 
before storage at 60 C, after a lyophilization time period of ~ 24 h and found there was no 




the process of freeze drying the catheter samples could affect enzyme activity before 
checking its stability for accelerated shelf life testing.  
 
Figure 7.11. Comparing the mean rate constants of enzymatic hydrolysis for both 
plain and NP coated catheter samples after 1 day, post lyophilization (1 day) and 
post 1 week at 60C (equivalent 4 months at RT). Red bar – NPD-500 represents 
NP coated catheter segment with initial DispersinB concentration 500 µg/ml; 
Green bar – D-500 represents plain catheter segment with initial DispersinB 
concentration of 500 µg/ml; (Mean ± SD; n= 2 for 1st two sets and n = 3 for 
accelerated aging study )  
In case of samples coated with DispersinB, we found that the rate of hydrolysis for 
uncoated catheter segment was not significantly different (p>0.05; n =3; One way 
ANOVA) for both plain and NP coated catheter segments indicating that DispersinB 
possibly lost its activity during the accelerated testing study (Figure 7.11).  But, we did 
observe ~ 90% percentage drop in DispersinB activity on catheter segments (compared to 
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its activity before freeze-drying) via the colorimetric assay after a 24 h lyophilization 
period suggesting that DispersinB  (unlike lysostaphin) did not retain its hydrolytic 
activity after the freeze-drying step. During lyophilization process, stresses associated 
with freezing and drying cycle can sometimes lead to aggregation of the protein molecules 
with a consequent loss in enzyme activity. This happens because solutes (including salts in 
solution) may reach concentrations as high as 50 times their initial concentration due to 
separation of ice, leading to increased molecular interactions in the freeze-dried state [359, 
360]. In order to prevent loss of enzyme activity during lyophilization, enzymes may be 
modified chemically or stabilizers may be added to the buffer solution [342, 344, 361, 
362]. For, e.g. addition of cryoprotectants or stabilizers like Sucrose might help prevent 
denaturation of the functional enzymes such as DispersinB during the lyophilization 
process [363].  
7.4. Conclusion 
In conclusion, adsorbed enzyme activity for both lysostaphin and DispersinB, 
enzyme leaching, cytotoxicity and antibiofilm activity were not significantly different for 
plain and NP coated catheter segments. Our study showed that coating of nanoparticles on 
catheters overall did not significantly improve performance of enzymes on the catheters 
when adsorbed alone or through coadsorption. This is in part, possibly due to lack of a 
significantly higher surface area available for enzyme binding due to presence of 
nanoparticles, as it appears that enzymes were bound to the bare part of the catheter 
segment. We were unable to achieve good coating of PLA NPs on catheter surface, 
despite using excess of the NPs (based on theoretical surface area of catheter) in the initial 
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NP suspension. Furthermore, expected improvement in stability has not been achieved, 
again likely because most of the enzyme was present as adsorbed not on nanoparticles but 
on the bare part of the catheter segment. 
Our accelerated shelf life testing showed lysostaphin retaining all of its activity 
after freeze-drying cycle and shelf life study, while DispersinB lost most of its activity 
during the lyophilization process and all of its activity after the shelf life study. Further 
work involving addition of stabilizers or cryoprotectant to preserve enzyme activity, 
especially for a temperature sensitive enzyme such as DispersinB may be performed. 
However, based on the overall similar antibiofilm activity of the segments coated by 
lysostaphin, we conclude that use of lysostaphin may be preferable instead of DispersinB 
















CONCLUSIONS AND FUTURE RECOMMENDATIONS 
8.1 Conclusions  
One of the most serious complications in the use of prosthetic devices such as Central 
venous catheters is device-associated infections and S.aureus is most frequently 
encountered nosocomial pathogen in this setting. However, the emergence of antibiotic 
resistant strains such as MRSA, has spurred the need for alternative sources of treatment. 
Coatings of devices and implants using antibacterial enzymes and peptides have numerous 
advantages including low rates of resistance, broad spectrum of action, short treatment 
time and synergism (between peptides). Our study proposed to use nanoparticles as 
coatings on biomedical devices for higher enzyme loading, low leaching and long term 
durability.  Based on the results from this study, the following conclusions can be drawn 
regarding the application of nanotechnology for targeted delivery of antibacterial enzymes 
to planktonic cell suspensions and as potential „surrogate surfaces‟ for enzyme adsorption 
on devices to prevent bacterial colonization and subsequent biofilm formation:  
 Intrinsic properties of nanoparticles such as charge and surface charge density can 
be used to improve targeting of enzymes to bacterial cell walls. Lysozyme 
covalently conjugated to positively charged nanoparticles (modified with amine 
groups) shows better lytic activity to Micrococcus lysodeikticus than free enzyme 
and lysozyme conjugated to negatively charged nanoparticles (modified with 
chloromethyl and sulfate groups) through charge directed targeting to negatively 
charged bacterial cell walls.  
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 High surface to volume ratio enables attachment of multiple ligands on the surface 
of nanoparticles including a specific antibody along with the corresponding 
antibacterial enzyme to improve targeting to bacterial pathogens. Lysostaphin 
adsorbed to Poly (lactic) acid nanoparticles in the presence and absence of a S. 
aureus antibody showed significantly better activity due to multiple-ligand 
targeting and antibody-directed targeting compared to free enzyme against 
S.aureus.  
 Coating of antibacterial enzymes (lysostaphin) to synthetic hernia-repair meshes 
through physical adsorption can prevent bacterial colonization and implant 
associated infection. Our data specifically showed that enzyme leaching surfaces 
could be effective in inhibiting bacterial growth and is significantly dependent 
upon coating concentration in vivo.  
 We did not observe a significant difference in enzyme loading, leaching, 
cytotoxicity, antibiofilm activity and long term durability for enzymes (lysostaphin 
and DispersinB) coated on plain and PLA nanoparticle coated Polyurethane 
catheter segments. This was in part due to the absence of a significant monolayer 
of nanoparticle coating on the surface of the catheter segment.  
8.2 Future recommendations  
Our studies aimed at using nanotechnology for targeted delivery of antibacterial enzymes 
and as surface coatings for enzyme-based coatings on catheter segments. However, while 
we showed that nanoparticles can be used to improve targeted delivery of antibacterial 
enzymes to bacterial cells, we were not able to significantly improve characteristics of 
enzyme coated catheters after precoating catheters with nanoparticles. PLA nanoparticles 
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did not strongly bind to the surface of Polyurethane catheter segment despite using several 
fold excess of nanoparticles in the initial NP suspension, suggesting that nonspecific 
adsorption might not be an appropriate method and PLA not the most appropriate material 
for surface coating on Polyurethane. Stability of DispersinB could be improved during the 
lyophilization process by addition of cryoprotectants although the theory behind coating 
multiple enzymes including lysostaphin and DispersinB to achieve a synergistic 
interaction seems a little unlikely. Lysostaphin, by itself seems to have antibiofilm activity 
against S.  aureus specifically and is more stable as an enzyme; hence coating of catheters 
with lysostaphin alone could probably be just as effective. However, DispersinB could be 
used in combination with other antimicrobials in inhibition of growth and biofilm 
formation for other slime producing bacterial strains other than S. aureus.  Addition of 
cryoprotectants or stabilizers could prevent loss of activity during the lyophilization 
process [363]. Before choosing an appropriate stabilizer, it is important that it does not 

























































































































Digital camera images showing reduction of turbidity of S. aureus cell suspension 
(clearing) through bacterial lysis by ultrapro samples coated with lysostaphin at 




















Tapping mode AFM images showing topography and height of a polyurethane 
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